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INTRODUCTION
GENERIC TOOLS FOR OPERATIONAL
RESEARCH ON HIV
1. Rationale

2. Description of the Generic Tools
project

The combined efforts of countries and international partners have
resulted in substantial advances in HIV treatment and prevention.
Nonetheless, access to key HIV services remains low in many
settings around the world, and there are still major research
gaps about the best way to expand HIV testing, prevention and
treatment, especially in resource-limited settings. The World
Health Organization (WHO) has endorsed the “learning by
doing” approach, which advocates that public health strategies to
scale up HIV treatment and prevention services be continuously
reviewed, evaluated and revised, so that the results of research
can inform programmes as quickly as possible (WHO 2006).
Along with monitoring and evaluation, operational research is a
central component of the process of gathering and analysing data
to inform HIV programmes and policies.

The Generic Tools project is part of WHO’s broader efforts to
facilitate operational research on HIV testing, treatment and
prevention. To identify the information needed to improve HIV
programmes, the HIV Department of WHO held international
meetings, multi-stakeholder consultations and local workshops,
and reviewed the evidence and the availability of data collection
tools. These activities highlighted a number of research questions
that were amenable to operational research, had relevance in
diverse settings, and had the potential to improve programmes
and strengthen the evidence base for policies. These research
questions are grouped under the following four broad topics, which
correspond to the four substantive chapters in this volume:
1. The utilization of HIV testing and counselling. In particular,
what are the barriers and facilitators to the uptake of HIV
testing and counselling? How do different service provision
models influence the uptake and quality of services? And, what
are the ethical implications of practices related to consent,
confidentiality and counselling?

There are many different definitions of operational research
(WHO and the Global Fund 2008), and here, we use a pragmatic
definition of operational research as “the science of better” or, more
specifically, as research designed to improve the performance of
programmes and policies. This volume focuses on health services
and is, therefore, addressed to programme managers and
researchers with an interest in conducting operational research
to inform HIV policies, programmes and services.

2. HIV stigma and discrimination. What are the consequences
of disclosure, including patterns and levels of HIV stigma
and discrimination? To what extent are HIV stigma and
discrimination associated with the utilization of health
services?

While numerous instruments have been developed for operational
research on HIV, there have been few efforts to review what is
known about existing data collection tools or to help researchers
select among the many tools that are available. The multiplicity
of tools and approaches hinders efforts to track progress in
providing services for testing, treatment and prevention. The
lack of standardized approaches to data collection also hampers
comparisons across settings, limiting the potential to draw lessons
about how different models of service provision function in the
field. To address this gap, in 2006, the World Health Organization’s
HIV Department initiated a project to develop generic tools for
operational research on HIV. These tools are designed for data
collection on HIV testing, treatment and prevention programmes
in multiple settings. They are called generic because, while they
are standardized, they lend themselves to adaptation to particular
country situations.

3. Adherence to antiretroviral therapy. Specifically, how can
researchers measure adherence and the factors that influence
adherence? What are levels and patterns of adherence
in different settings? And, how can programmes support
adherence?
4. HIV prevention in the context of scaled-up access to HIV
treatment. What are the levels and patterns of high-risk
behaviours among patients receiving HIV treatment? Does
access to antiretroviral therapy influence risk behaviour and
perceptions of the risks of HIV?
These research questions represent a first phase of work in
this area, to be complemented by others as resources become
available.
1
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3. Definitions and terminology

5. How this volume was put together

Because the words “topics”, “questions” and “tools” have
multiple meanings that can lead to confusion, we propose to use
these terms as follows. Topics refer to the four topics identified
by the chapter titles, noted above. Questions may refer to either
research questions or to items in a questionnaire that respondents
are asked during an interview (survey questions). Throughout
this volume, we have tried to use specific wording to distinguish
between the two. The survey questions are clustered together to
form modules, and the modules combine into two main research
instruments: a Client Instrument and a Provider Instrument.
The word “tools” refers to the complete set of literature reviews,
research questions, methodological recommendations, variables
and instruments provided in this volume for each of the four
selected topics.

The Generic Tools volume is the result of the collective efforts of
many individuals. During the first phase of the work, a team of
researchers reviewed the published and unpublished literature
on each selected topic, summarized the evidence, compiled
available instruments, took stock of existing data collection
approaches and identified the essential information needed for
operational research on HIV. In parallel with this process, the
WHO held several international consultations with researchers,
managers and country representatives to discuss research
priorities in the field of HIV. Subsequently, a group of experts
drafted chapters summarizing the evidence on the four selected
topics. These chapters formulated priority operational research
questions, recommended preferred approaches to data collection
and included draft research instruments for data collection. The
Population Council collaborated closely with WHO on this phase
of the work. After the four chapters were drafted, they were
extensively revised to produce the consolidated set of tools and
instruments included in this volume.

4. Approach and methodology
The research questions formulated in this volume can be
investigated through various study designs, but the volume
focuses primarily on health facility-based, cross-sectional survey
research. When information at more than one point in time is
desirable, researchers can conduct repeated cross-sectional
surveys or use the instruments with longitudinal study designs. In
most cases, the study populations for data collection envisioned
by these chapters include clients and providers at health facilities;
however, the chapters suggest ways to include study populations
outside the clinic, such as non-users of services, when such
comparisons are needed. Researchers who would like more
detailed suggestions for designing operational research projects
on HIV may find it helpful to consult the publication entitled,
Designing HIV/AIDS intervention studies: an operations research
handbook, published by the Population Council (Fisher et al
2002).

While the organization of the four chapters varies, they all share
a common core structure, as follows:
1. A background section that spells out the rationale for
conducting operational research on the selected topic, based
on a review of the literature;
2. A summary of the literature concerning what is known about
the factors that influence the key outcome;
3. A section that formulates the operational research questions
to be addressed;
4. A methodology section about study populations and study
design;
5. A discussion of variables and survey questions/questionnaire
items.
This volume also includes two data collection instruments that
address the research questions developed in the four chapters.
The first instrument is designed to be used with clients at
health facilities, while the second instrument is designed for
use among health care providers. Each instrument includes at
least one module that corresponds to each of the four chapters.
As a result, the full instruments are very long, and it is clearly
neither feasible nor desirable to administer them in full. To
help researchers select the sections that are most relevant to
a given research project, the instruments are organized into
modules that correspond to different chapters. Much effort was
invested to maximize consistency, minimize redundancies, and
simplify skip patterns in order to enable researchers to keep
only those sections that are most pertinent to their project. Even
within individual modules, however, researchers may need to
identify which sections to include and which to omit. A detailed
description or “map” of the Client Instrument is provided at the
end of this introduction to help researchers select the appropriate
sections. Electronic versions of the instrument are also provided
on the WHO website.

While simple survey designs facilitate the conduct of research, it
is often desirable to triangulate multiple sources of information
and to combine different approaches to data collection. For
example, qualitative methods provide an important complement
to quantitative surveys, and it is recommended that they be
included in the design of operational research whenever possible.
Qualitative methods can elicit respondents’ perspectives on
key topics and provide broad insights into the situations that
are investigated. In this volume, the qualitative component is
limited to some open-ended questions in the Client and Provider
Instruments. Further use of qualitative methods is encouraged,
however, including semi-structured key informant interviews,
observations at health facilities, in-depth interviews, focus groups
and textual analyses of important documents, such as guidelines
or media reports. For more guidance, we recommend: Qualitative
research methods: a data collector’s field guide, published by
Family Health International (Mack et al. 2005).
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Although the full instruments in this volume have not been
subjected to a formal validation process, they are based on a
number of recognized instruments that have been validated
or at least field-tested. For example, previous versions of the
Testing and Counselling Client and Provider Modules were
used in the Multi-country African Testing and Counselling
(MATCH) study, coordinated by WHO in four African countries.
The Disclosure, Support and Stigma Modules in the Client and
Provider Instruments are based on validated instruments in the
literature, the field testing experience of the Horizons Program/
Population Council, and recommendations of the USAIDconvened Interagency Stigma and Discrimination Indicators
Working Group. The Adherence Module includes survey items
that were part of several research projects recently conducted
by the French National Agency for Research on AIDS (ANRS,
Agence Nationale de Recherche sur le Sida), including the VESPA
survey on HIV-positive individuals in France, the EVAL survey on
access to antiretroviral therapy in Cameroon and the MANIF2000
cohort of drug users in France. The Prevention Module is based
on well recognized instruments that have been widely used
for population-based HIV surveys, including those conducted
by the Centers for Disease Control and Prevention and by the
Demographic and Health Surveys. While the instruments in this
volume are expected to perform well in the field, it is important
for researchers to pilot and pre-test them, in order to assess
whether they are appropriate to the context in which they will
be used. Improved versions are planned on the basis of further
use in the field.

Fund 2008). In addition, WHO encourages researchers to use
a multi-stakeholder process that involves researchers, national
programme managers, those who support research and those
who may use the results. Researchers can find advice about this
phase of work in the brochure entitled, Conducting operational
research: strategic and managerial guide for applicants (WHO
2007). Other preparatory tasks may include the following:

4 Conduct a situation analysis or rapid assessment to summarize
what is known about the selected topic in the country. This
will be the basis for formulating the research questions to
be addressed through operational research, discussing the
feasibility and trade-offs of different study designs and deciding
how to design sampling plans and field procedures.

4 Develop a multi-stakeholder process to commission the
situation analysis, discuss the results, and foster a common
approach to the project.

4 Conduct formative research in order to gain information about
the context and gather locally appropriate terminology.

4 Adapt, translate, field-test and revise the instruments. Include
country-specific information in the instruments as needed, by
revising the survey questions and the response categories.

4 Combine these tasks with training members of the research
team.

4 Secure ethical clearance for the research and adapt
the informed consent sections of the instruments (see the
WHO Research Ethics website for guidance and useful
documents on ethical clearance at www.who.int/rpc/research_
ethics/en/.)

6. How to use the chapters and
instruments
Researchers should engage in a careful preparatory phase of
work before using the operational research tools presented
in this volume. They will need to assess the situation being
investigated, identify the specific problem to be addressed,
refine the research questions, select the most appropriate study
design, define the study population(s), design a sampling plan,
develop field procedures and anticipate how they will analyse
their data. The chapters in this volume can serve as a basis for
such discussions, but they are not fully formed research protocols
or simple recipes to be applied. Other steps, both technical and
strategic are necessary. Regarding technical content, researchers
may find it useful to consult the publication entitled, Framework
for operations and implementation research in health and
disease control programs, a document designed for Global
Fund-supported operational research programmes (The Global

The instruments presented in this volume have been extensively
revised, but they would benefit from further improvements based
on additional field experiences in different settings. WHO is
planning to disseminate these tools and encourage their use in
countries around the world, with the goal of regularly updating,
improving and possibly expanding them to address other topics
on which further evidence is needed.
The operational research section of the WHO HIV Department
website includes electronic versions of the chapters and
instruments, information about operational research activities, as
well as links to instruments and email addresses. Researchers who
use these tools in the field are urged to share their experiences
and suggestions by going to the following link: http://www.who.
int/hiv/topics/operational/generic.
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DETAILED CONTENTS (OR “MAP”) OF THE CLIENT INSTRUMENT

module and sub-section

sub-sample

never tested

tested, with

question

or declined

negative or

and willing

numbers

to say

unknown status

to disclose

2.1–2.15

4

4

4

4

tested positive

Sociodemographic Module
Sociodemographics

All respondents

Testing and Counselling Module
HIV testing: filter questions

All respondents

3.1–3.3

4

4

First HIV test

Tested more than once

3.4–3.10

4

4

Most recent test

Have tested, ever

3.11–3.23

4

4

Pre-test services and experience

Have tested, ever

3.24–3.28

4

4

Consent

Have tested, ever

3.29–3.37

4

4

Results of HIV test

Have tested, ever

3.38–3.41

4

4

Post-test services

Received results

3.42–3.47

4

4

Confidentiality

Received results

3.48–3.49

4

4

HIV status

Received results

3.50–3.51

4

4

HIV-negative or indeterminate results

Results negative or indeterminate

3.52–3.54

4

HIV-positive results

HIV+

3.55–3.56

Follow-up care and support

HIV+

3.57–3.63

Non-user, attitudes and knowledge

Never tested

3.64–3.83

4

General knowledge and attitudes about testing

All respondents

3.84–3.94

4

4

4

4

4
4

Disclosure, Support and Stigma Module
Disclosure

All respondents

4.1–4.6

4

4

Stigma — negative judgements, fear of contact and enacted stigma

HIV- and status unknown

4.7–4.14

4

4

Disclosure to others, HIV-positive

HIV+

4.15–4.23

4

Reactions to the disclosure of HIV-positive status

HIV+ who disclosed to others

4.24–4.31

4

Experience with stigma and discrimination

HIV+

4.32–4.42

4

Support

HIV+

4.43–4.51

4

5.1–5.6

4

Adherence Module

Antiretroviral therapy

Receiving ART

Social support

Receiving ART

5.7–5.18

4

Access

Receiving ART

5.19–5.22

4

Food security

Receiving ART

5.23–5.24

4

Health status

Receiving ART

5.25–5.26

4

Perceived side-effects

Receiving ART

5.27–5.34

4

Antiretroviral therapy regimen (prescribed doses)

Receiving ART

5.35

4

Adherence over the past three days

Receiving ART

5.36–5.37

4

Adhering on weekends

Receiving ART

5.38–5.39

4

Adherence over the past one month

Receiving ART

5.40–5.46

4

Treatment interruption

Receiving ART

5.47–5.49

4

Changes in adherence over time

Receiving ART

5.50–5.54

4

Prevention Module

Time since diagnosis and ART initiation

All HIV+ respondents

6.1–6.3

4

Sexual activity and partners

All HIV+ respondents

6.4–6.8

4

Regular partner relationships

Sexually active HIV+

6.9–6.17

4

Non-regular partner relationships

Sexually active HIV+

6.18–6.24

4

Commercial sex

Sexually active HIV+ males

6.25–6.29

4

MSM

Sexually active HIV+ males

6.30–6.38

4

Concurrency

Sexually active HIV+

6.39

4

Fertility intentions and family planning methods

HIV+ with regular partner

6.40–6.44

4

Knowledge and attitudes related to HIV and ART

All HIV+ respondents

6.45–6.49

4

Knowledge of people infected with HIV

All HIV+ respondents

6.50–6.52

4

Treatment optimism

All HIV+ respondents

6.53

4

Alcohol and Drug Module

Alcohol use

All HIV+ respondents

7.1–7.2

4

Drug use

All HIV+ respondents

7.3–7.12

4
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CHAPTER 1
THE UTILIZATION OF HIV TESTING AND
COUNSELLING
1. BACKGROUND

the proportion of the population who know their HIV status is
generally low. In 23 countries that conducted Demographic and
Health Surveys between 2005 and 2007, the proportion of adult
women who reported having ever been tested and received their
results ranged from a low of 2% in Niger to a high of 45% in
Ukraine; the median was about 11% for women and 10% for
men, and the figures were slightly lower for countries of subSaharan Africa (9% of women and 8% of men) (WHO 2008).
Even in more developed countries, such as the United States of
America, an estimated 20% to 30% of HIV-positive individuals
are unaware of their serostatus (Glynn and Rhodes 2005). Such
low utilization of testing and counselling indicates that obstacles
are considerable, and programmes need a better understanding
of how to overcome them.

1.1 Rationale: Why operational research is needed on the
utilization of HIV testing and counselling
While there is consensus that knowledge of HIV status should be
universal and that rapid scale-up of testing is needed at the global
level, there are debates about the best way to expand testing
and counselling for HIV. Before treatment became available, the
possibility that routine testing might lead to adverse consequences
for individuals seemed to outweigh the public health benefits of
people knowing their status; consequently, there was little support
to expand testing other than through client-initiated testing
(commonly known as Voluntary Counselling and Testing). With
the availability of treatment, however, the debate has shifted. The
exceptionalism that characterized public health responses to HIV
— whereby measures such as routine testing and notification,
widely practiced for other diseases, were not acceptable for HIV
— came to be less defensible (Bayer 1991).

In recent years, numerous projects have tried to expand access
to both client- and provider-initiated testing, through routine
testing in prenatal care programmes, home-based testing, freestanding testing and counselling centres, and national campaigns
to encourage key populations at higher risk to be tested. The
diversity of testing models underscores the need for comparative
analyses of how different policies and programmes operate, how
they affect the uptake of testing, whether uptake is accelerated
when treatment becomes available, to what extent stigma acts
as a barrier to testing and, conversely, whether expanded testing
increases awareness and reduces stigma.

Scaled-up testing has been increasingly advocated both as a
gateway to treatment and prevention and as a way to “normalize”
and destigmatize HIV (De Cock and Johnson 1998; De Cock et
al. 2006; Koo et al. 2006). Research showing that screening for
HIV is cost-effective (Bozzette 2005) bolstered the position of
those in favour of expanding testing programmes, and there have
been calls to incorporate HIV testing and counselling into health
services such as prenatal care, care for sexually transmitted
infections (STIs), hospitalization and even general primary care.
Mathematical models suggest that universal testing followed
by immediate antiretroviral therapy for all individuals who test
positive could, in theory, reduce new HIV cases by 95% within
10 years (Granich et al. 2008). This analysis has re-energized the
debate about the desirability and feasibility of rapidly scaling up
testing. It has also highlighted the important research gaps that
remain about the best way to expand testing and counselling.
The need for operational research is especially acute in resourcelimited settings where health systems are weak, in low-prevalence
epidemics where key populations at higher risk are hard to
reach and in settings where there are particular concerns about
protecting individual rights as testing becomes routinized.

Changes in the provision of testing and counselling in resourcelimited settings
Operational research is also needed to examine how different
models of testing and counselling affect quality of care, health
outcomes and patient rights. There are wide variations in the
quality and acceptability of different models of testing and
counselling around the world. Differences in the availability and
organization of human and financial resources affect the quality
of counselling. In resource-limited settings, staffing constraints,
overloaded facilities and ambivalence among providers often
result in insufficient counselling. And in many settings, questions
have been asked about the usefulness of pre-test counselling at
health facilities, with some observers recommending that it be
omitted altogether (Koo et al. 2006). It is unclear whether the
omission of pre-test counselling facilitates testing by eliminating a
possibly cumbersome practice or whether it diminishes the quality
of testing services because clients do not receive needed advice

Barriers and facilitators to uptake of testing and counselling
One important research gap is the need to understand more
about the barriers to the uptake of testing. Around the world,
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or information. Understanding the issues surrounding counselling
represents a major challenge for the utilization of testing, and
more evidence is needed to inform guidelines regarding pre- and
post-test counselling, and to tailor requirements to the particular
type of testing, whether client- or provider-initiated.

discrimination are generally thought to be higher in settings where
HIV is concentrated among marginalized populations such as
injecting drug users, sex workers or men who have sex with men.
Systematic evidence is, however, scant. One comparative study in
low (Viet Nam) and high prevalence settings (Ethiopia, the United
Republic of Tanzania and Zambia) found more commonalities
than differences in the forms and levels of HIV stigma and
discrimination (Ogden and Nyblade 2005). This underscores the
need for better documentation of the links between measures of
stigma and contextual factors.

Another research gap is the effect of different models of HIV
testing and counselling services on sexual risk behaviour, because
results of studies have not been consistent. On the one hand,
studies from Kenya, Trinidad and Tobago and the United Republic
of Tanzania suggested that testing and counselling could have
a beneficial effect on prevention behaviour among couples who
were counselled together (The Voluntary HIV-1 Counseling and
Testing Efficacy Study Group 2000). A meta-analysis of seven
studies from developing countries published between 2000 and
2005 found that testing and counselling was associated with a
significant but moderate decline in unprotected sex (Denison et al.
2008). Recent research from Uganda suggests that appropriate
provision of testing and counselling can lead to adopting safer
behaviour among HIV-positive individuals (Bunnell et al. 2006).
On the other hand, the meta-analysis mentioned above did not
find a decline in the number of sex partners among HIV-positive
individuals or serodiscordant couples, and studies from the
United States and Zimbabwe have reported that high-risk sex
increased following rapid HIV testing among men who tested
negative (Metcalf et al. 2005; Corbett et al. 2007). Thus, the
evidence supports both caution and optimism about the effect of
HIV testing on sexual risk behaviour, and more research is needed
to determine what type of service delivery or package of services
maximizes the preventive effects of testing and counselling while
minimizing any potential negative consequences.

1.2 Definitions and terms for different types of testing and
counselling
The terminology regarding testing has evolved in response to
changes in policies and in the debates surrounding HIV testing,
treatment and prevention. In 2007, the World Health Organization
(WHO) and the Joint United Nations Programme on HIV/AIDS
(UNAIDS) issued a publication entitled, Guidance for ProviderInitiated Testing and Counselling in Health Facilities, which
built on earlier consultations and policy statements (WHO and
UNAIDS 2007). Just under a year earlier, the Centers for Disease
Control and Prevention (CDC) had called for routinely testing
people aged 13 to 64 years and for simplifying the process of
obtaining consent (CDC 2006). In a number of countries around
the world, policies have also shifted towards increasing access
to HIV testing. The 2007 WHO-UNAIDS guidance recommends
that health care providers advise patients to take an HIV test as a
standard part of medical care in the following situations: for any
patients exhibiting signs that may be related to HIV infection; for
all patients attending health facilities in settings with generalized
HIV epidemics; and, in settings with low HIV prevalence, for
patients who are seen at certain types of health facilities, such
as those providing services for tuberculosis or STIs.

Ethical dimensions of testing and counselling
Last but not least, operational research is needed to address
the ethical dimensions of HIV testing and counselling practices.
Recommendations to expand testing raise numerous questions
about how to protect public health while safeguarding individual
rights and minimizing the potential stigma, discrimination and
violence that may follow disclosure of HIV-positive status (Maher
et al. 2000; UNAIDS Reference Group on HIV/AIDS and Human
Rights 2005; Rennie and Behets 2006). These questions are
especially important in settings where HIV is found predominantly
among marginalized groups, such as sex workers, men who have
sex with men or injecting drug users. Different models of testing
may require different strategies to ensure informed consent and
confidentiality. Research is needed to examine the circumstances
under which consent is obtained, the extent to which health
services protect confidentiality in different settings, and whether
referral, treatment and prevention services are provided after
clients receive their test results.

The WHO-UNAIDS guidance document seeks to avoid the
potential confusion of earlier terminology about “opt-in” and “optout” testing in medical settings. It also aims to prevent possible
misunderstandings about the word “routine”, which can mean
offering testing to all patients, but has sometimes been used to
refer to “routinely” testing without informing patients or seeking
their consent. The new formulation distinguishes between two
types of HIV testing, both voluntary:

4 Client-initiated HIV testing and counselling (commonly known as
Voluntary Counselling and Testing or VCT) involves individuals
actively seeking HIV testing and counselling. Client-initiated
HIV testing and counselling is conducted in a wide variety of
settings including health facilities, stand-alone facilities outside
health institutions, mobile services, community-based settings
and even people’s homes.

4 Provider-initiated HIV testing and counselling refers to HIV

Special attention needs to be directed to fear of stigma and
discrimination, reportedly one of the main obstacles to the
use of HIV services. Comparisons across settings can help
contribute to a better understanding of how stigma varies from
setting to setting. One important hypothesis to examine relates
to the influence of the epidemiological context. Stigma and

testing and counselling recommended by health care providers
to patients attending health care facilities. Providers are to
recommend testing as a standard component of medical
care when patients exhibit clinical manifestations that might
result from underlying HIV infection, at health facilities that
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serve populations where the risks of exposure to HIV infection
are thought to be considerable and to all patients in high
prevalence settings. While this type of testing can be routine
under certain conditions, it should never be mandatory or
compulsory.

studies also showed that a substantial proportion of individuals
who were tested did not receive their results. In some settings
where the percentage of the population tested reached 80% to
90%, the percentage who returned for results hovered around
60% (Cartoux et al. 1998; Coovadia 2000). Such discrepancies
have been documented in populations as diverse as clients at STI
clinics in the United States, male factory workers in Zimbabwe
and women receiving antenatal care services in Côte d’Ivoire,
Kenya, South Africa and Zambia (Obermeyer and Osborn 2007).
Rapid tests, testing at convenient locations and times, as well as
home-based testing have the potential to reduce these obstacles
(Wolff et al. 2005), and operational research can document how
different models for providing testing and counselling may or may
not increase access and uptake.

2. FACTORS AND PROGRAMME STRATEGIES
The socio-behavioural factors that influence HIV testing and
counselling can be assessed by gathering information about
users, providers, their interactions and the context of those
interactions. These factors can be grouped as follows:

4 those related to the demand for testing and counselling,
Reluctance to acknowledge risk
An important barrier to testing is the reluctance of individuals to
acknowledge that they are at risk, as documented in a recent
literature review (Obermeyer and Osborn 2007). In settings
as diverse as Brazil, Canada, Ethiopia, Thailand, the United
Kingdom, the United Republic of Tanzania and the United States,
individuals’ behaviours and risk perceptions are frequently at
odds with objective measures of risk and with professional
recommendations (Moatti and Souteyrand 2000; Obermeyer
2005). The reasons for this discrepancy are complex. Risk
perceptions are shaped by social and psychological factors; the
meaning of HIV tests is not simply a matter of information about
serostatus; and the decision to be tested is tied to relationships,
emotions and the resources that individuals have for dealing with
the diagnosis (Antelman et al. 2001; Klitzman and Bayer 2003).
Research can contribute to uncovering how these complicated
social factors play out in particular contexts.

including access to services and expectations regarding
care, risk perceptions, attitudes and behaviours regarding
disclosure, stigma and gender;

4 those related to the provision and quality of testing and
counselling services, including providers’ abilities and
attitudes, institutional support for providers, the resources
available in health facilities and interactions around testing
and counselling;

4 the ethical dimensions of testing and counselling, including
practices around consent and confidentiality that affect
patients’ rights, and clients’ attitudes towards consent,
confidentiality and counselling.
The way in which these factors influence the uptake and quality
of testing services depends on the type of epidemic. For example,
in low prevalence settings, obstacles such as access and stigma
may disproportionately affect key populations at higher risk, such
as sex workers, men who have sex with men and injecting drug
users. (While earlier formulations referred to “risk groups”, more
recent literature refers to “most-at-risk-populations” (MARPs)
or key populations at higher risk.) Concerns about scaling up
HIV testing are heightened in settings where such groups are
marginalized from a legal, economic or social point of view.
The next chapter in this volume identifies some key operational
research questions related to HIV stigma and discrimination
and proposes a tool to collect the data needed to address those
questions. These materials can be adapted to address the issues
that are most relevant to the particular populations at higher risk
in a given setting.

Fear of stigma, discrimination and violence
Often the explanation for why people do not take HIV tests or return
for results is fear. People may fear the life-threatening nature of
HIV infection, as well as the negative social consequences that
may accompany a diagnosis, such as rejection by loved ones, loss
of a job or housing, discrimination and even physical violence.
Fear of stigma and discrimination is reported to be a major barrier
to testing in countries as diverse as Botswana, Ethiopia, Ghana,
India, Indonesia, South Africa, Thailand, Uganda, the United
Republic of Tanzania, the United States and Zimbabwe (ICRW
2002; Day et al. 2003; Herek et al. 2003; Hutchinson et al. 2004;
Kalichman and Simbayi 2003; Weiser et al. 2006). In view of
such fears, some studies suggest that clients’ perceptions of how
confidentiality is handled in a health facility may also influence
their willingness to be tested (Fylkesnes and Siziya 2004).

2.1 Factors that influence the demand for HIV testing and
counselling

Fear of stigma, discrimination and violence also affects the
decision to disclose HIV status (Yoshioka and Schustack 2001;
Medley et al. 2004). Rates of partner disclosure by those living
with HIV vary widely from study to study, but they are generally
low, typically ranging from one fifth to slightly more than one-half
(Heyward et al. 1993; Kalichman and Nachimson 1999; Nebie et
al. 2001; Maman et al. 2003). Solid evidence about the adverse
consequences of HIV disclosure is still limited; however some
studies have documented negative reactions from family, friends,

Barriers to access
Studies of health care utilization repeatedly document the
importance of barriers to access, including distance to a facility,
cost of services, transportation and time constraints. That these
factors may influence the decision to seek HIV testing as well as
the decision to return for results is suggested by global statistics
showing low use of testing services, especially in resource-limited
settings. Before rapid tests became widely available, a number of
8
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2.2 Factors that influence the uptake and quality of testing
and counselling services

employers and the community in 3% to 15% of cases (Gielen
et al. 2000; Medley et al. 2004; Passin et al. 2006). Evidence
suggests that discrimination is also a problem in health care
settings, and some observers have noted that health workers
may discourage testing if they discriminate against HIV-positive
patients by treating them differently, using excessive precautions
or withholding appropriate care (Bishop et al. 2000; Foreman et
al. 2003; Paxton et al. 2005).

How testing and counselling are provided: different models
New approaches to the delivery of testing services are showing
some success. Rapid tests at convenient times (such as nighttime) and locations (such as homes, workplaces, health facilities
and mobile clinics) have increased the numbers of people who
have been tested as well as the proportion of clients who receive
their results (Day et al. 2004; Mahto and Higgins 2004; Mermin et
al. 2005; Corbett et al. 2006; Rotheram-Borus et al. 2006). Homebased testing and counselling in four Ugandan villages increased
acceptance of testing from 10% to 46%, eliminated differences
in acceptance between women and men and appeared to be
an effective way to reach family members (Wolff et al. 2005).
Interviews and focus group discussions suggested that home
testing avoided some of the inconvenience, fears and costs of
facility-based tests. National level data from Uganda confirmed
the high acceptability of giving blood and receiving results in the
course of a household survey; and a qualitative study conducted
in parallel with that Demographic and Health Survey did not
uncover major problems of understanding or coercion (Yoder
et al. 2006). The vast majority of respondents consented to give
blood samples for HIV tests and to receive the results at home. A
Cochrane review confirms that home-based testing does increase
uptake (Bateganya et al 2007).

Few studies have explored the effect of stigma on HIV testing
using quantifiable measures, and most of these consist of
cognitive measures (e.g. what percentage of a given population
hold particular negative beliefs about people living with HIV)
rather than measures of actual attitudes or behaviours (Parker
and Aggleton 2003; Deacon et al. 2005; Nyblade 2006). In order
to have a better understanding of the role of stigma and fear of
discrimination as a deterrent against testing and as an adverse
consequence for those who disclose their HIV status, there is a
need for well designed measures of stigmatizing attitudes and
behaviours and for better evidence about the extent of stigma
and discrimination in health facilities and in the broader society.
To that end, the next chapter in this volume summarizes the
evidence on HIV stigma and discrimination, formulates possible
operational research questions and suggests approaches to
measurement in different settings.
Gender
Gender is another factor that powerfully shapes motivations to
test and the consequences of testing. Evidence suggests that
women and men experience different barriers to access, perceive
risks differently and fear different sorts of discrimination. In some
settings, men tend to underestimate their risk for HIV infection
more frequently than do women, despite reporting more highrisk behaviours (Riess et al. 2001). Women often have more
fears about testing than men (Sahlu et al. 1999; Stein and
Nyamathi 2000). The negative consequences of disclosure are
more frequently documented for women, and several studies
show that it is among pregnant women that fears of abuse as
a possible consequence of testing positive for HIV are most
manifest (Temmerman et al. 1995; Coulibaly et al. 1998; Gielen
et al. 2000; Gielen et al. 2001; Maman et al. 2001a; Maman et
al. 2001b; Manzi et al. 2005).

Integrating provider-initiated testing in clinical settings appears
to overcome many of the barriers that hindered earlier efforts
and has been found to have unexpectedly high acceptability.
In settings around the world, utilization increases rapidly when
testing is routinely offered during antenatal care (Simpson et al.
1998; Etiebet et al. 2004). Pregnant women are often inclined
to be tested if they think it can benefit their baby (Simpson et al.
1998; Jha et al. 2003; Etiebet et al. 2004; Perez et al. 2006).
Routine provider-initiated (“opt-out”) testing seems to be more
acceptable and to cause less anxiety for women than “opt-in
testing”, perhaps because this approach is ostensibly done for the
benefit of the baby, does not make assumptions about women’s
behaviours and hence does not threaten women’s sense of moral
worth (Sobo 1994; Boyd et al. 1999; Etiebet et al. 2004).

Women’s decisions about testing may be complicated by their
plans to have children, their husbands’ opinions and considerations
such as breastfeeding (Aka-Dago-Akribi et al. 1999; Sahlu et al.
1999; de Paoli et al. 2004). A recent comparative study in four
Asian countries (India, Indonesia, the Philippines and Thailand)
found that men were more likely than women to be tested
because they had HIV-related symptoms, whereas women were
more likely to test because their partner tested positive (Paxton et
al. 2005). In these and other settings, women may become aware
of risks only once their partner is ill, and they may not suspect that
they were exposed until then (Obermeyer et al. Forthcoming). For
all these reasons it is important for operational research studies
to conduct gender analyses of behaviours and attitudes related
to HIV testing.

Similar positive attitudes towards provider-initiated HIV testing
have been observed outside of prenatal care as well. When
hospitalized patients in the United States were asked how they
would feel about provider-initiated HIV testing, most responded
positively (Greenwald 2006). More than two thirds of clients
at a tuberculosis clinic in Kinshasa, the Democratic Republic
of the Congo, preferred provider-initiated (“opt-out”) testing
(whereby the test would be performed unless they declined),
notwithstanding common perceptions that it would be difficult to
decline the test (Corneli et al. 2008). The acceptance of testing
increased considerably after providers began to recommend
the test routinely in postpartum wards in Botswana (Thior et
al. 2007), paediatric wards in Uganda (Nawavvu et al. 2006)
and Zambia (Kankasa et al. 2006), maternity wards in Uganda
(Homsy et al. 2006) and STI clinics in Uganda (Semafumu and
Ngabirano 2006).
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Such results are encouraging, and they highlight the different
factors that can facilitate the uptake of HIV testing. Operational
research is needed to examine whether they will be replicated
as expansion continues (Glick 2005) and to establish whether
the successes observed in well-resourced projects can also be
achieved in resource-limited settings.

a test based on subjective criteria such as their assumptions
about which clients can handle bad news (Gibney et al. 1999).
Operational research can help identify those dysfunctions that
may be amenable to improvements.
Until recently, pre- and post-test counselling have always been
considered integral and essential parts of HIV testing. Pre-test
counselling is typically designed to give information and obtain
consent, while post-test counselling may address additional
information, encourage preventive behaviours and include
referrals to care depending on the test results. What exactly is
conducted under the heading of “counselling” varies a great deal,
however, and evidence is needed about the effect of different
approaches on the uptake of testing and access to follow-up care.
Resource constraints and a lack of evidence about usefulness
have eroded support for pre-test counselling in some settings, in
favour of concentrating those resources on post-test counselling
(Koo et al. 2006). The implications of this type of change are
unclear, and operational research is needed to explore the
consequences of different approaches to counselling.

Communication strategies and provider-client interactions
Research on programmes provides useful insights into the types
of communication strategies that may increase the uptake of
HIV testing at the individual and community levels. Operational
research can also help to evaluate the messages that accompany
the offer of an HIV test and the communication of results.
When providers personalize information about the risks of HIV
and frame messages in terms of personal gains and losses,
clients are more likely to decide to be tested, consistent with
research showing that individuals need to translate abstract
notions of risk into personal terms (Kalichman and Coley 1995;
Apanovitch et al. 2003; Tambashe et al. 2003). Because of
the implications of a positive diagnosis, health workers need to
take great care when communicating about the test, in order to
avoid misunderstandings and to convey the seriousness of the
diagnosis without leading the patient to despair.

Providers and the institutional support they receive
In recent years, attention has increasingly been drawn to the
implications of the serious human resource crisis in many settings
for HIV service provision (WHO 2006). It is important to distinguish
different types of providers in terms of their background and
training, including whether they are specialists or laypersons who
received training, for example as counsellors. When it comes to
HIV testing, much is expected of providers “on the front lines”,
but little is known about how they cope. In addition to practical
difficulties, resource constraints and the emotional dimension
of their work on HIV, providers may have justifiable concerns
about occupational exposure to HIV, particularly where protective
measures are inadequate or are difficult to implement. There
are also considerable variations in the availability and quality
of the services that health providers can access for their own
needs. For example, some research suggests that providers
need access to self-testing for HIV or other special services to
encourage them to learn their own HIV status in a confidential
and non-stigmatizing way (Bongololo et al. 2007). In terms of
the quality of HIV services, while some health care providers are
effective, others may feel ambivalent about testing or may have
doubts about their ability to provide care (Brouwer et al. 2000;
Sherr et al. 2001; Sliep et al. 2001; de Paoli et al. 2002; Chi et
al. 2004). Operational research is needed to gain insights into
testing and counselling from the perspective of providers and to
understand the training, time, resources and institutional support
that providers need. The question of how to support providers so
that they gain clients’ trust is an important one, and answers are
likely to refer to both the capacity of the providers themselves and
the functioning of the health system in which they operate.

Other aspects of the provider-client interactions influence clients’
decision to have an HIV test and to comply with recommendations.
These include providers’ background characteristics (such
as gender or ethnic group), attitudes, perseverance and the
extent to which providers are able to gain clients’ trust and
build good rapport (Marelich et al. 2002; Worthington and
Myers 2003; Anderson et al. 2005; Passin et al. 2006; Zimba
et al. 2006). Operational research can evaluate the extent to
which strategies effectively communicate key messages about
HIV test results, treatment and prevention. At the community
level, media campaigns have been effective in increasing the
uptake of testing in some settings. For example, Burkina Faso
documented a relatively high rate of testing (at a time when
treatment availability was limited), thanks in large part to yearly
national campaigns designed to reach the general population
as well as key populations at higher risk (Some 2003; PAMAC
2004). Comparisons of different approaches can help identify
the elements that contribute to improved communication
strategies.
Health care facility resources and the role of counselling
Although numerous guidelines have been formulated to improve
testing and counselling, there are great variations in the quality
of these services around the world. When health systems are
weak and resources are stretched too thin, providers may have
insufficient training, time or space to provide high quality testing or
counselling. Studies from both developed and developing country
settings have found widespread problems such as insufficient
time for counselling (Ruiz et al. 2002), inadequate information
and poor quality counselling for clients from less-privileged
segments of society (Brown 1993). Even when a facility has a
policy of routinely recommending HIV testing and counselling,
providers may not consistently follow the policy (Coovadia 2000).
In some settings, providers decide to whom to recommend

2.3 Factors that influence the ethical dimensions of
testing and counselling
Attitudes, practices and policies regarding consent
The expansion of testing has heightened awareness of the
ethical dimensions of testing and counselling and the need to
10
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protect the rights of those who are tested (Rennie and Behets
2006); however, evidence about the magnitude of the problem
of testing without consent is limited. There are indications that
nearly everywhere, clients are sometimes tested without their
knowledge; this was documented a decade ago in Europe,
where an estimated 10% to 20% of respondents had been tested
without their knowledge (McCann and Wadsworth 1991; McCann
1992; Schrooten et al. 2001). Similarly, India’s private hospitals
are said to conduct mandatory testing on prospective surgical
patients, and some studies have documented that many Indian
patients are tested without consent (Elamon 2005; Sheikh et al.
2005). More information is needed about the extent to which
guidelines about consent are in fact implemented. Even when
given a choice, clients or survey respondents do not always feel
free to decline the offer of an HIV test. They may accept an HIV
test because they are used to agreeing to health professionals’
requests, because they think that agreeing to a test will improve
the care they receive, because they do not think they can decline,
or because they have a diffuse sense that refusing would have
adverse consequences (Williams et al. 1997; Abdool Karim et al.
1998; Leach et al. 1999; Mitchell et al. 2002; Yoder and Konate
2002; Weiser et al. 2006). It is important to document problems
related to obtaining consent in different settings, to assess the
extent to which client perceptions and expectations influence
their willingness to be tested, and to explore which forms of
consent are appropriate in different settings.

More information is needed about how changes in the provision
of testing and counselling and in the process of securing consent
and ensuring confidentiality will affect utilization, quality of care,
and the protection of clients. Empirical evidence on practices
and attitudes in multiple settings can be drawn from reports by
clients of their experiences, providers’ views and reports of what
happens at health facilities, as well as observations of the process
of testing and counselling at health facilities. This evidence can
help identify innovative ways to expand testing while protecting
patient rights.

3. RESEARCH OBJECTIVES AND QUESTIONS
It may be useful to organize the many operational research
questions that can be formulated regarding HIV testing and
counselling into three groups: those dealing with users of services,
those dealing with providers and those related to practices around
testing (see box on next page).
Other operational research questions may also be relevant in
different settings. For example, researchers may want to explore
whether the use of testing and counselling influences preventive
behaviour, such as levels of unprotected sex, and questions
may be formulated to examine the links between HIV testing
and high- or low-risk behaviours. Researchers may also need
to refine their research questions depending on the nature of
the epidemic in a given setting. For example, in concentrated
epidemics, researchers may need to focus on lines of enquiry
most relevant for understanding the implications of scaling up
testing and counselling for key populations at higher risk, such
as sex workers or men who have sex with men.

Attitudes, practices and policies regarding confidentiality
Confidentiality is another important ethical dimension of testing
and counselling that has implications both for patients’ rights and
for the public health objective of increasing utilization of testing,
since perceptions of how confidentiality is handled may influence
clients’ willingness to be tested (Fylkesnes and Siziya 2004). Laws,
governmental policies, institutional policies, available resources
and prevailing attitudes are all factors that influence the extent
to which health workers protect the confidentiality of medical
information in health care settings. Policies differ considerably
across settings and are rapidly changing. In Singapore, for
example, the Health Ministry made it mandatory to inform the
spouses of HIV patients several years ago (Anon. 2005); and the
possibility of allowing health workers to disclose patients’ status
to their partners has been discussed in some African countries,
where it has been referred to as “beneficial disclosure” (National
AIDS and STD Control Programme of Kenya 2004; Jack 2005).

4. METHODS
4.1 Study populations and study design
In this volume, we have opted for simple study designs that make
it possible to investigate these research questions mostly by
gathering cross-sectional data at health facilities. The instruments
presented in this volume combine quantifiable, closed-ended
questions with open-ended questions to elicit information about
attitudes, perceptions and experiences. Information is to be
collected in the following ways:

Evidence suggests that lack of confidentiality can be a serious
problem in many settings. In a comparative study in India,
Indonesia, the Philippines and Thailand, 34% of HIV-positive
respondents reported that health care workers had revealed their
HIV status to someone else without their consent (Paxton et al.
2005). In some settings, health workers do not have a positive
view of patient confidentiality and may even see confidentiality as
a way to protect irresponsible individuals (Seidel 1996). Patient
confidentiality is often compromised by established practices in
health services and by differential regard for clients’ rights (Brown
1993; Sherr et al. 2001).

4 conducting surveys to interview users and non-users of testing
services to compare the factors that influence the uptake of
testing (e.g. gender and stigma) and to find out about the
conditions of testing and the consequences of disclosure;
and

4 interviewing providers and key informants to obtain information
about policies, programmes and services related to testing,
counselling, confidentiality and consent.
The two core instruments presented in this volume are: a
Client Instrument that can be administered at health facilities
and a Provider Instrument, to be used with health personnel
11
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operational research questions about testing and counselling (t&c)

1. Understand motivations, behaviours and experiences related to testing and disclosure:
n How do users and non-users of T&C services compare in terms of sociodemographic variables such as residence, gender,
socioeconomic status and profession?
n To what extent are knowledge of HIV, attitudes about risks, access to services and other social factors associated with testing
behaviour?
n What experiences have clients had with regard to different models of testing?
n What factors are associated with clients’ perceptions, motivations and behaviours related to T&C and obtaining results?
n What are patterns and levels of disclosure? What factors influence disclosure?
n How do users and non-users of T&C services compare in terms of attitudes about and fear of stigma and discrimination?
n To what extent is the availability of testing, counselling and treatment associated with stigma and discrimination?
n Using a gender analysis, how and to what degree does gender influence the T&C experience, disclosure behaviours and consequences?
How and to what degree does gender influence attitudes about, fear of, and actual experiences of stigma and discrimination?
2. Analyse the provision of appropriate services around testing and counselling:
n How are T&C services delivered in different facilities and settings, and how do these different models vary in terms of uptake, clients’
responses to the offer of testing and disclosure behaviours?
n What are providers’ experiences with T&C in relation to their own life trajectories, training, work conditions, perceptions, motivations
and satisfaction?
n To what extent do health workers fear exposure to HIV in the course of their work, what protective measures do they have access to, and
what is their experience with accidental exposure?
n What interactions and communication patterns occur between providers and clients in the context of T&C? To what degree are providers
able to gain the trust of clients?
n How do different service delivery models link clients to needed care, treatment and support services after testing?
3. Investigate the ethical dimensions of testing and counselling:
n What are practices related to informed consent and confidentiality in different facilities and settings?
n Which practices related to informed consent and confidentiality result in better outcomes regarding clients’ satisfaction with their
decision and the protection of their privacy?
n What constraints and challenges do providers face in relation to informed consent and confidentiality?
n What are the experiences, attitudes, priorities and concerns of clients with regard to consent and confidentiality; and how do these
attitudes and beliefs influence their choices with respect to testing, counselling and disclosure?
n To what degree do ethical practices (or perceptions about the ethical practices in a given facility) influence clients’ responses to T&C
services?

and counsellors at health facilities. We recommend collecting
additional qualitative data through in-depth interviews with people
living with HIV, focus group discussions with individuals who
have not been tested and key informants who are knowledgeable
about programmes and health facilities, and by developing an
observation checklist to be used at health facilities.

data to address the research questions identified in this chapter,
including the following:

5. VARIABLES AND SURVEY QUESTIONS

4 the Testing and Counselling Module, which gathers data on

4 the Sociodemographic Module, which collects data on variables
such as gender, socioeconomic status, ethnicity, residence
(etc.) that are clearly important for understanding uptake and
other dimensions of testing;

variables related to service provision and factors that influence
the uptake, quality and ethics of testing and counselling;
and

The Testing and Counselling Modules of the Client and Provider
Instruments in this volume were originally developed as part of
the MATCH (Multi-site African Testing and Counselling for HIV)
study that addressed some of the research questions formulated
in this chapter. Earlier versions of the instruments were used in
Burkina Faso, Kenya, Malawi and Uganda, and they were revised
prior to being included here.

4 the Disclosure, Support and Stigma Module, which collects
data on levels of stigma, patterns of disclosure and reactions
of friends, family and community members.
Even though the Disclosure, Support and Stigma Module of
the Client Instrument is formatted as a separate module, it
was designed to be used together with the Testing and
Counselling Module to ensure that operational research on

5.1 Variables and survey questions to ask among clients
Several modules of the Client Instrument in this volume gather
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testing and counselling consider the consequences of disclosure.
Researchers who wish to study the effects of testing and
counselling (or a combination of testing and other services) on
sexual behaviour may want to use the Testing and Counselling
Module in combination with the Prevention Module to compare
those who have been tested with those who have not. This would
require some adaptation of the questionnaire, however, since
the Prevention Module was designed for respondents who have
already tested positive for HIV.

questionnaire items and deleting others. Types of questions that
may be explored in relation to home testing include:

4 whether respondents were informed about providers coming
to their home in advance; how they were informed and what
they were told about testing;
4 who and how many health workers came to the home to offer
and conduct testing and counselling;
4 whether other household members were offered testing and
whether they accepted;
4 whether respondents discussed the test with other household
members before and after the test;
4 whether respondents were influenced by other household
members;
4 the extent to which respondents perceived that providers
who came to the home were able to protect their privacy and
confidentiality; and
4 what respondents think about being offering HIV testing and
counselling in the home.

The particular survey questions that respondents are asked in
the Client Instrument will depend on whether or not respondents
have had an HIV test, and if so, whether they have tested positive
for HIV and are willing to disclose their status to the interviewer.
The instrument is designed with skip patterns to accommodate
these different possibilities, and the table below lists key variables
or topics included in the Client Instrument.
The Testing and Counselling Modules of the Client and Provider
Instruments in this volume were designed to consider the
possibility that some HIV testing may occur outside a health
facility, in settings such as people’s homes and workplaces.
Researchers who are specifically interested in testing in such
settings may want to adapt the questionnaire by adding some

An instrument to be used during an HIV testing campaign would
likely have to be considerably shortened to make it possible to
recruit participants. In that case, it may be necessary to omit all
the open-ended questions and to add a few questions to ask

variables and topics related to testing and counselling, disclosure,
support and stigma in the client instrument
disclosure, support and stigma module

testing and counselling module

For respondents who have never been tested:
n Knowledge and attitudes about HIV
n Knowledge of anyone who has been tested, of someone living
with HIV
n Knowledge of testing facilities
n Access to testing facility
n Attitudes towards HIV testing, confidentiality of results and
disclosure
n Ever experienced an offer of a test
n Reasons for not having/refusing a test

For respondents who are HIV-negative, do not know their status
or decline to reveal their status to an interviewer:
n Stigmatizing attitudes
n Personal knowledge of people who have experienced HIV stigma,
discrimination or violence
n Knowledge of support groups for people with HIV
For respondents who disclose their HIV-positive status to an
interviewer:
n Disclosure behaviours and motivations
n Reactions to disclosure by family and friends
n Experiences of stigma and discrimination by others
n Negative self-perception and behaviours (internalized stigma)
n Discrimination in health care settings
n Participation in support groups, social services or other
assistance programmes
n Perceptions about negative and positive consequences of
learning HIV status

For all respondents who have been tested, regardless of HIV
status:
n HIV test (first and most recent), circumstances and reasons for
testing
n Experience of testing, counselling and consent
n Attitudes about consent, confidentiality and disclosure
n Obtaining results and post-test care: experience and attitudes
For respondents who inform interviewer that they are HIV
negative:
n Reaction to test results
For all respondents who inform interviewer about their HIVpositive status:
n Follow-up received, including medication and care
n Reaction to test results
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clients and providers how testing during a campaign compares
to testing at other times, in terms of the factors that encourage
or hinder people from testing.

variables relevant to testing
and counselling in the provider
instrument

5.2 Variables and survey questions in the Provider
Instrument

n
n

Similar to the Client Instrument, there are several modules in the
Provider Instrument that are important for operational research
on Testing and Counselling, including the Sociodemographic and
Work Module, the Testing and Counselling Module, the Fear of
Infection and Work Safety Module, and the Disclosure, Support
and Stigma Module. The box to the right presents an overview
of key variables addressed in these modules of the Provider
Instrument.

n

n
n
n
n
n
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Demographics
Work background (work history, job function, education,
training and work routine)
Practices, perspectives and attitudes related to:
• Testing
• Pre-test counselling
• Consent
• Privacy and confidentiality
• Post-test counselling
• Follow-up care and support
• Disclosure
Fear of infection
Practices related to implemention of universal precautions
Accidental exposure and action taken
Observation of discrimination at health facilities
Stigma
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CHAPTER 2
HIV STIGMA AND DISCRIMINATION
1. BACKGROUND

While many studies have suggested that stigma and discrimination
are obstacles to HIV prevention, testing and treatment, their precise
role is poorly understood. As noted in the previous chapter, there
are particular research gaps about the role of stigma that have
important implications for testing and counselling policies. For
example, proponents of provider-initiated testing and counselling
argue that these policies may decrease levels of HIV stigma by
normalizing testing and increasing access to treatment (Weiser et
al. 2006; Wynia 2006). On the other hand, many opponents fear
that provider-initiated testing may jeopardize the confidentiality
and voluntariness of testing, with negative consequences for
vulnerable populations (Kippax 2006; Wynia 2006). Future
research has the potential to clarify some of these questions as
well as to indicate whether stigma may become less pervasive
in a society once health-preserving treatments are accessible to
most people living with HIV (Castro and Farmer 2005).

1.1 Rationale: why operational research is needed on HIV
stigma and discrimination
Since the early days of the AIDS epidemic, stigma and discrimination
have been recognized as obstacles to HIV prevention, treatment
and support (UNAIDS 2007). The classic definition of stigma
refers to “an attribute that is deeply discrediting”, which results
in the reduction of a person or group “from a whole and usual
person to a tainted, discounted one” (Goffman 1963). It has been
argued that stigma may also reflect and reinforce existing power
structures, social control, mistreatment and marginalization of
disenfranchised groups (Parker et al. 2002; Parker and Aggleton
2003; Link and Phelan 2006). HIV discrimination may include
behaviour that is harmful, intolerant, underrating or prejudicial
against people living with HIV and their families and is often called
“enacted stigma” to underscore the idea that discrimination can
be considered a manifestation of stigma, or at least, an end result
(Jacoby 1994; Nyblade and MacQuarrie 2006).

In the remainder of this chapter, we summarize information on the
manifestations and correlates of HIV stigma and discrimination,
the implications for HIV prevention, testing and treatment, and the
measures and methods used to study stigma and discrimination.
The chapter also formulates a number of operational research
questions and proposes a set of easily administered measures
of stigma.

Operational research is needed to address a number of key
research gaps regarding HIV stigma and discrimination. First,
there is a need for better definitions and quantitative measures.
Such measures could be used to gather comparable data about
patterns and levels across different geographic, sociodemographic
and cultural settings. Standardized, reliable measures could also
facilitate baseline data collection for programmes designed
to reduce stigma and discrimination. There is also a need for
qualitative research to explore the experiences and perspectives
of those living with HIV and to assess the extent to which they
encounter stigma and discrimination on the one hand, and
support, tolerance and compassion on the other.

1.2 Manifestations and patterns of HIV stigma and
discrimination
The precise nature of HIV stigma and discrimination varies
depending on the setting; the local context influences which
attitudes and behaviours are most salient and the extent to which
certain groups are stigmatized, such as female sex workers,
men who have sex with men, injecting drug users or migrant
populations. However, evidence suggests that stigma has some
broadly similar manifestations around the world, across a wide
range of cultural, environmental and sociodemographic settings
(Aggleton et al. 2005; Nyblade and MacQuarrie 2006). The
following are commonly documented expressions of stigma:

Quantitative and qualitative research can be used to help
programme managers and policy-makers formulate more
effective interventions to improve the health, wellbeing and
quality of life of individuals living with HIV in various cultural and
demographic contexts. Measuring stigma can also help alert
programme implementers to negative unintended consequences
of interventions. For example, highlighting certain risk behaviours
as ‘bad’ may exacerbate stigma against those who engage in
those behaviours; and tailoring HIV prevention messages for
populations that are already marginalized — such as sex workers
or men who have sex with men — may increase discrimination
against those groups (Nyblade and MacQuarrie 2006).

4 Fear of casual transmission and refusal of contact. In
some settings, HIV stigma manifests as an exaggerated or
unreasonable fear of contracting HIV through casual or noninvasive contact (Nyblade et al. 2005). This can lead to a
desire to avoid casual or social contact with those living with
HIV in schools, marketplaces, workplaces and health care
settings.
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4 Negative judgements about people living with HIV. Value

their HIV status because they think others may suspect
them of being homosexual (in the case of men) or accuse
them of being promiscuous or sex workers (in the case of
women) (Parker et al. 2002). In concentrated epidemics,
marginalized groups at higher risk of HIV may come to be
seen as responsible for the spread of HIV, and members of the
‘general’ public may be less likely to perceive themselves to
be at risk, even when they engage in high-risk behaviours.

judgements about the moral conduct or the worth of people
living with HIV may express blame, accusation and moral
condemnation (Policy Project 2003; Ogden and Nyblade
2005; Pulerwitz et al. 2008).

4Internalized stigma, also called self-stigma. Internalized stigma
is a frequently described experience of individuals living with
HIV and may include feelings of shame, hopelessness and
guilt, social withdrawal and a tendency not to use existing
treatment or support services (Thomas et al. 2005; Brouard
and Wills 2006; Simbayi et al. 2007a). Evidence suggests that
internalized stigma may aggravate psychiatric morbidity among
people living with HIV (Van Brakel 2006).

2. FACTORS AND PROGRAMME STRATEGIES
Stigma can be considered both a determinant of health-related
outcomes and an outcome in itself. For programmes that aim
to achieve other health behaviours or outcomes, operational
research may explore stigma as a factor that may influence the
programme’s intended key outcomes. For example, a study
may investigate the influence of stigma on uptake of testing and
counselling or adherence to treatment. In other cases, operational
research may focus on stigma reduction as a central programme
objective. For example, a programme might aim to increase HIVrelated knowledge as a means of reducing unreasonable fear
of contagion and the resulting avoidance of people living with
HIV. This section summarizes what is known about the extent to
which stigma and discrimination influence HIV testing, treatment
and disclosure, the key factors that are correlated with stigma
and the main programme strategies that have been developed
to address stigma.

4 Discrimination (‘enacted stigma’) in family or community
settings. Enacted stigma may include a broad range of harmful
actions against individuals who are known or suspected of
having HIV or AIDS (and/or their families), including rejection,
exclusion from social or ritual events, gossip, ridicule, verbal
harassment, abandonment, divorce, expulsion from their
homes, removal of economic support, denial of property and,
in some cases, physical violence (Aggleton et al. 2005; VarasDiaz et al. 2005; Maman et al. 2006).

4 Discrimination (‘enacted stigma’) in institutional settings.
Enacted stigma may occur within institutions such as
workplaces, health-care services, prisons and schools.
Increased attention to the possibility of stigma in medical
settings has resulted in studies documenting discrimination
against people living with or suspected of having HIV in
health care settings in a variety of contexts (Bharat et al.
2001; Mahendra et al. 2007; Oanh et al. 2008), including
withholding medical care, providing inadequate care and
implementing discriminatory policies regarding patient consent
and confidentiality (Aggleton et al. 2005).

2.1 The influence of stigma on HIV testing, treatment,
disclosure and prevention
Utilization of HIV testing and counselling
As noted in the previous chapter, numerous qualitative and
quantitative studies from around the world have found that stigma
and fear of discrimination are associated with a reluctance to
seek HIV testing and counselling or with client anxiety at testing
sites (Fortenberry et al. 2002; Herek et al. 2003; Kalichman et al.
2005; Hutchinson and Mahlalela 2006; Iyaniwura 2006; Weiser
et al. 2006; Obermeyer and Osborn 2007). For example, studies
from South Africa and Botswana found that individuals who had
not been tested for HIV reported significantly higher levels of
stigmatizing attitudes than those who had been tested (Kalichman
and Simbayi 2003; Hutchinson and Mahlalela 2006; Weiser et
al. 2006). A study of truck drivers in Brazil found that the odds of
having had an HIV test decreased by 4% for every unit increase
on a 15-item scale measuring stigmatizing attitudes (Pulerwitz et
al. 2008). And, fear of the negative consequences of a positive
test result, such as social rejection, abandonment and violence,
has been reported as an impediment to testing in settings around
the world — particularly by women (Maher et al. 2000; Maman
et al. 2001; UNAIDS 2007; Sambisa 2008).

4 Discriminatory laws and policies. In many countries, legal
systems have limited the rights of HIV-positive individuals,
either explicitly or by failing to enforce the laws or protect
human rights. For example, in some settings, laws or policies
have restricted the right of people living with HIV to travel
or migrate internationally, to receive comprehensive care,
to consent freely to testing or even to engage in certain
professions (Aggleton et al. 2005). In other settings, laws are
not enforced, and legal systems do not protect the rights of
people living with HIV.

4 Compounded or “layered” stigma. Compounded stigma refers
to HIV-related stigma that mutually reinforces and legitimates
pre-existing stigma and discrimination against marginalized
groups such as sex workers, injecting drug users or men who
have sex with men (Parker et al. 2002). Increased levels of
stigma and discrimination may also be directed against HIVpositive individuals who contribute relatively few economic or
social resources to their communities (Reidpath et al. 2005).
When HIV comes to be associated with certain marginalized
groups, individuals living with HIV may be afraid to disclose

Care and treatment-seeking
Research has documented that fear of stigma and discrimination
represents an important barrier to treatment and care (Heijnders
and van der Meij 2006). Fear of stigma and discrimination
has been identified as a barrier to adherence to antiretroviral
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therapy in research from settings such as China, South Africa
and the United States (Nachega et al. 2006; Peretti-Watel et al.
2006; Rintamaki et al. 2006; Weiser et al. 2003). For example,
respondents receiving HIV treatment in urban areas of the United
States reported skipping doses because they were afraid that
their status would become known to family or friends (Rao et
al. 2007). In South Africa, adherence was considerably lower
among respondents who reported fear of being stigmatized by
their sexual partner (Nachega et al. 2004; Rintamaki et al. 2006).
This evidence suggests that studies on adherence to antiretroviral
therapy should include variables related to fear of stigma and
should ask respondents whether they feel a need to take their
medications in secret. Questions on these factors are, therefore,
included in the Adherence Module of the Client Instrument in
this volume.

health workers was correlated with higher levels of stigmatizing
attitudes and discriminatory behaviours; researchers suggested
that job seniority may have allowed highly educated senior
doctors to avoid caring for HIV-positive patients by delegating
these tasks to junior level staff (Deacon and Boulle 2007). Thus,
operational research should be mindful of the complex links
between knowledge and stigma.
Sociodemographic characteristics such as gender, ethnicity,
class, profession and identification with a marginalized group (e.g.
sex workers, injecting drug users, men who have sex with men or
mobile populations) also influence stigma (Parker et al. 2002). In
many settings, women’s lower socioeconomic status appears to
increase their vulnerability to discrimination following a positive
HIV test. In locations as diverse as Ethiopia, India, Mozambique,
the United Republic of Tanzania, Viet Nam and Zambia, studies
have found that women experience more HIV-related stigma than
men (ICRW 2006). A study from the United Republic of Tanzania
found that nearly two thirds of women with HIV reported stigma
in the past year, compared with less than half of men. Women
may also be more vulnerable than men to extreme consequences
such as physical violence by intimate partners (UNAIDS 2007).
Qualitative research in settings such as Côte d’Ivoire found that
women’s reluctance to be tested or to disclose their HIV status
was closely related to their perceived socioeconomic vulnerability
(Coulibaly et al. 1998).

HIV status disclosure and prevention
Evidence suggests that stigma and fear of discrimination may
represent an important barrier to certain types of harm-reduction
behaviours (Chen et al. 2005; Liu et al. 2006) and may decrease
willingness to disclose HIV status (Clark et al. 2003; Ford et al.
2004; Dias et al. 2006; Liu et al. 2006; Simbayi et al. 2007b;
Pulerwitz et al. 2008). Stigma and fear of discrimination have
frequently been studied as factors that influence levels of HIV
disclosure. In fact, disclosure has often been considered a proxy
measure for stigma, as people living with HIV are more likely to
disclose their status to those around them in low-stigma contexts,
where they expect fewer negative consequences (Nyblade and
MacQuarrie 2006). As noted in the previous chapter, rates of
partner disclosure by people who know that they are HIV-positive
vary widely, but these rates are often low (Heyward et al. 1993;
Kalichman and Nachimson 1999; Nebie et al. 2001; Maman et
al. 2003). For example, a review of 15 studies from sub-Saharan
Africa and Asia found that rates of partner disclosure by women
who tested positive for HIV ranged from 17% to 80%, with the
lowest rates reported by women tested in prenatal care settings
(Medley et al. 2004). Lowering fears of stigma, discrimination and
violence might reduce barriers to HIV disclosure and contribute
to better HIV prevention.

At the community or societal level, HIV stigma and discrimination
may be influenced by factors such as the prevalence and
patterns of HIV in the area, the degree of competition and conflict
over scarce resources, the availability of testing and treatment
services, the extent of programmatic activity that has taken
place and the levels of pre-existing stigma against marginalized
groups (Parker et al. 2002; Parker and Aggleton 2003; Castro
and Farmer 2005; Deacon et al. 2005; Reidpath et al. 2005). For
example, as mentioned earlier, it is possible that compounded
stigma may be especially prevalent in settings where the epidemic
is concentrated among marginalized groups.
Laws and policies are other institutional or societal level factors
that can influence levels of discrimination against those living
with HIV, including policies that restrict their right to travel, to opt
out of testing, to give consent before partner notification and to
obtain certain kinds of medical treatment (Parker et al. 2002).
An analysis of HIV stigma and discrimination in Latin American
health care settings concluded that institutional policies have
discriminated against people living with HIV indirectly by failing
to ensure that staff are adequately trained to diagnose and treat
HIV and AIDS and directly through policies that explicitly refuse
care for AIDS patients (Foreman et al. 2003). A study from
Beijing, China, found that hospital and government policies were
the major source of discriminatory interactions between health
workers and people living with HIV (Yang et al. 2005).

2.2 Factors that influence levels and patterns of HIV
stigma and discrimination
Studies from diverse settings have found a number of factors
to be correlated with levels and patterns of HIV stigma and
discrimination at the individual, community and societal level.
At the individual level, research has often explored the link
between HIV knowledge and stigma, including understanding
the modes of transmission or personally knowing someone with
HIV. Evidence suggests that personal contact with individuals
living with HIV is associated with fewer stigmatizing beliefs
(Bermingham and Kippax 1998; Schiff et al. 2003). Some
studies have found evidence that lower knowledge about HIV
transmission is correlated with greater stigmatizing attitudes
against people living with HIV (Dias et al. 2006; Kalichman
et al. 2006); however, other evidence suggests that a better
understanding of HIV transmission alone does not necessarily
reduce the fear of casual contact (Herek et al. 2002). One study
found that higher levels of medical knowledge about HIV among

2.3 Programme strategies to reduce stigma and
discrimination
Many programmes have aimed to reduce HIV stigma and
discrimination and to increase support for people living with
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HIV (Aggleton et al. 2005). The following section summarizes
some common strategies drawn from reviews of published and
unpublished programme evaluations (Brown et al. 2001; Brown
et al. 2003; Heijnders and van der Meij 2006), including a 2005
UNAID review of “successful” programmes (Aggleton et al.
2005). Except where noted, many of these strategies have not
been rigorously evaluated, so while some show promise, more
research is needed before we can say which approaches are
effective in different settings.

Antidiscrimination measures within institutions
Institutional initiatives have included efforts to reduce HIV stigma
and discrimination within health facilities, workplaces, schools,
prisons, etc. (Aggleton et al. 2005). For example, health sector
initiatives have included efforts to increase access to integrated,
comprehensive HIV care, antidiscrimination health care policies,
and sensitizing and training health workers to change attitudes
and reduce discriminatory behaviour within health care facilities
(Aggleton et al. 2005).

Counselling and peer support groups
Counselling has been used to resolve issues with family and
community members and to teach coping skills. Interventions
studies suggest that counselling may reduce anxiety and distress,
reduce negative consequences of disclosure and improve attitudes
towards people living with HIV (Brown et al. 2003). Counselling
and “mediated disclosure” can be used to help clients who test
positive for HIV consider how to disclose their status to partners
and others in a way that reduces risks to their physical safety and
emotional wellbeing (Maman et al. 2006). Peer support groups
have also been shown to benefit people living with HIV in terms
of self-esteem, coping skills and social integration (Heijnders and
van der Meij 2006).

Human rights, legal and policy Interventions
There have been many efforts to address HIV discrimination by
promoting and protecting the human (and legal) rights of people
living with HIV, including the rights to freedom of movement,
property, employment, education, consent, confidentiality and
access to services. Specific strategies have included mobilizing
communities to demand respect for the rights of those living
with HIV, advocating for legal and policy reforms (e.g. at the
government level) and efforts to enforce laws or seek redress in
the courts when rights are violated (Parker and Aggleton 2003;
Aggleton et al. 2005; Heijnders and van der Meij 2006).

3. RESEARCH QUESTIONS

Mobilizing care and support among family and community
members
Numerous initiatives have included efforts to recruit, mobilize,
support and/or train family members, local volunteers, traditional
healers, religious leaders and other community members to
support and care for HIV-positive individuals and their families
(Aggleton et al. 2005). In addition to improving health outcomes,
these initiatives generally aim to increase emotional and material
support for HIV-positive individuals, to improve their quality of life,
to reduce stigma and discrimination and, in some cases, to improve
adherence to HIV treatment. A qualitative evaluation from Haiti
suggests that recruiting community members as peer supporters
(accompagnateurs) to provide psychosocial support has lowered
the levels of social isolation and stigma experienced by individuals
living with HIV (Behforouz et al. 2004; Mukherjee et al. 2006).

The box on the following page presents selected operational
research questions that are likely to be relevant in multiple
settings. The first, third and fifth questions are descriptive,
designed to assess the extent and manifestations of stigma
among different study populations. Two questions concern the
association between stigma and health behaviours, including
HIV testing and disclosure. Questions six and seven explore the
factors that influence health workers’ fears about HIV exposure.
The final research question addresses the effectiveness of
strategies to reduce stigma, though it may require instruments
and study designs such as comparison groups that go beyond
the materials provided in this volume.

4. METHODS

Education, awareness raising and advocacy
Many initiatives have aimed to raise awareness, dispel
misconceptions and reduce negative attitudes about people
living with HIV at the national level, the community level or
among key populations at higher risk for HIV. Strategies include
mass media, participatory education, mobilizing community
leaders and empowering individuals living with HIV to lead
advocacy or awareness activities. Some initiatives focus narrowly
on HIV or AIDS, while others address broader issues such as
pre-existing stigma against marginalized populations at higher
risk, issues related to sexuality or tolerance and compassion
towards those affected by HIV (Aggleton et al. 2005). Informationbased strategies seem to be most effective at reducing stigma
when combined with other approaches (Brown et al. 2001);
for example, simply increasing knowledge about transmission
has not always reduced concern about contracting HIV through
casual contact (Herek et al. 2002).

4.1 Study populations and study design
This chapter highlights three key populations (listed below) for
the operational research on stigma and discrimination proposed
in this volume. Triangulating data by including more than one of
these populations as participants in a study is a way to get a more
complete picture of stigma from multiple perspectives.

4 People living with HIV. Research among people living with
HIV can provide insights into the patterns and levels of HIV
stigma and discrimination, the patterns and consequences
of disclosure and the ways in which experiences and fears
of stigma and discrimination influence testing, treatment,
adherence, disclosure and prevention.

4 Health care workers. Research among health care workers can
give an indication of the forms of stigma and discrimination
and barriers to appropriate care that people living HIV may
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operational research questions about hiv stigma and discrimination

1. To what extent do people living with HIV experience different forms of stigma, discrimination and (conversely) support in different
contexts (family, community and health facilities)?
2. To what degree are levels of stigma or fear of discrimination associated with HIV disclosure?
3 What are the forms and levels of HIV stigma and discrimination as reported or observed by the general population (specific populations
to be determined by the research project)?
4. To what extent does stigma or fear of discrimination influence service utilization, including HIV testing and treatment; and to what
extent do the availability and utilization of HIV testing and treatment influence levels of stigma in a community?
If data on stigma and on testing can be collected at more than one point in time, then the question may also be formulated as follows:
To what extent does the normalization or routinization of HIV testing and treatment decrease the extent of stigma towards people living
with HIV?
5. What are the levels and patterns of stigma and discrimination in health care settings as reported or observed by health care workers?
6. To what extent do health care workers fear occupational exposure to HIV through invasive procedures (e.g. needle sticks) on the one
hand, and through casual or non-invasive contact on the other?
7 To what extent are health workers fears of transmission associated with the levels of protective measures in the facility?
8. For interventions research studies: What combination of interventions leads to reduced levels of stigma and discrimination on the one
hand, and increased support for people living with HIV on the other?

face within the health care system, as well as the challenges
that health care workers face as they carry out their work and
try to help patients protect their health and wellbeing.

must take special care not to stigmatize these populations further
by drawing attention to their particular HIV-related vulnerability.
Studies that explore discrimination and violence against
individuals living with HIV should also consider the ethical
guidelines developed by WHO for researching violence against
women (Watts et al. 2001). While these guidelines were not
developed for research on HIV stigma, they are relevant for
research that asks women direct questions about physical or
emotional violence, as the Client Instrument does in this volume.
In particular, researchers should ensure that:

4 ‘General’ populations and key populations at higher risk of HIV.
The Client Instrument in this volume is designed to collect
information on HIV stigma and discrimination among general
users of health facilities (specifically, those who have not
been tested for HIV, those who do not wish to reveal their HIV
status and those who have tested negative). With adaptation,
this portion of the instrument can be used to gather data on
levels of stigma among a general population of adults living in
a particular community.

4 Field procedures should ensure privacy during interviews and
the confidentiality of respondents’ answers.
4 All interviewers who ask respondents about violence should
receive training in HIV stigma and violence against women.
Interviewers gathering this type of data among marginalized,
most-at-risk populations, such as sex workers or men who
have sex with men, may also need training about the nature
and patterns of pre-existing stigma and discrimination against
those groups.
4 Researchers should choose a study design that minimizes
distress for respondents as a result of participating in the
research. One important strategy is to offer respondents
information about local sources of violence-related services
and support at the end of each interview, if any such resources
are available.
4 In settings where these resources do not exist, researchers
should consider developing some short-term support
mechanisms by collaborating with local health care or social
services organizations.

Depending on the local epidemiology of HIV, portions of the
instrument can also be adapted for use among key populations
at higher risk of HIV (e.g. sex workers, men who have sex with
men or injecting drug users).
When designing HIV studies and programmes, several issues
related to sampling methodology and ethics should be considered.
First, HIV-positive individuals who are particularly at risk of stigma
and discrimination may be marginalized and hard-to-reach. The
sampling strategy for studies among people living with HIV may
need to go beyond members of organizations such as support
groups, in order to avoid sampling only those people who are
well integrated into known social networks (UNAIDS 2005). To
reach individuals who are not easily accessible, special data
collection strategies can be used, such as Respondent Driven
Sampling, a variant of “snow-ball” sampling (Abdul-Quader et
al. 2006; Johnston et al. 2008). However, it should be noted that
programmes that are designed for key populations at higher risk
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4. 2 Measuring HIV stigma and discrimination

Most items presented in this chapter are designed to be used
with Likert-style response categories. Studies using these
items generally used 3- or 5-point response categories. Fivepoint response categories may include: strongly agree, agree,
undecided/unsure, disagree and strongly disagree. Using five
options enhances the variability of responses and permits greater
understanding of the nuances of stigma. However, five options can
be difficult to respond to, particularly for respondents with limited
literacy skills. A 3-point scale — including: agree, undecided/
unsure and disagree — permits more variability and nuance than
a simple yes/no response; it is more intuitive for respondents and
easier to administer than the 5-point option.

Nyblade and MacQuarrie (2006) and other have synthesized
what is known about how to operationalize various “domains”
or dimensions of stigma and discrimination for different study
populations. The box below lists examples of ways to measure
stigma among people living with HIV, health workers and the
general population.
If the study design requires a summary measure of stigma,
multiple survey items can be combined into an index whereby
responses for each item are summed together to form a stigma
score. Using a greater number of items is generally preferable,
since each item may capture important nuances in attitudes and
behaviours. Alternatively, the items can be analysed individually to
explore specific elements of stigma (Berger et al. 2001). It should
be noted, however, that while most survey items presented in this
chapter are framed negatively (e.g. “HIV is a punishment for bad
behaviour”), items can be framed positively (e.g. “clients who are
sex workers deserve to receive the same level and quality of care
as other clients”). During the creation of an index, researchers
need to code items in the same direction, so that both negatively
and positively framed items have higher scores for more highly
stigmatizing responses.

Finally, this chapter focuses on quantitative measures of stigma
and discrimination that may have the potential to provide
comparable data on across different cultural and epidemiological
contexts. However, purely quantitative studies can miss rich
and nuanced information that can be tapped using qualitative
methods. Triangulating quantitative and qualitative data can
provide a more complete picture of stigma in a particular setting,
as well as explain behaviours or detect unintended consequences
of programmes. Both the Client and the Provider Instruments
in this volume contain open-ended questions. In particular, the
Client Instrument contains a detailed set of open-ended questions
about disclosure behaviours and outcomes. Researchers may
want to administer these questions to a subset of respondents,
depending on the study objectives and resources available.

As noted earlier, the manifestations of stigma and discrimination
are often very context specific, and it is essential to pre-test
instruments in order to ensure that selected items are appropriate
and relevant for the local context. Comparative research across
different contexts can also help identify core quantitative measures
that can be used across diverse settings.

The types of research questions that can be answered through
qualitative research are different from those that are typically
answered using quantitative methods. Rather than measuring

ways to operationalize the extent of stigma for different study populations

Extent of stigma and discrimination feared or experienced by HIV-positive individuals
What proportion of people living with HIV:
n report internalized stigma such as feelings of shame because of their HIV-positive status;
n report experiencing stigma, discrimination or violence;
n express fear of stigma and discrimination if their HIV status were suspected or known, including fear of being seen using HIV services;
fear of disclosing their status or fear of having their status disclosed by others;
n (or conversely) report support, compassion or tolerance from family members, members of social network, health care workers,
community at large, etc.; or
n express fear of stigma or discrimination because they belong to a marginalized group (compounded stigma).
Extent of fears, discriminatory behaviours or negative attitudes expressed or observed by health workers
What proportion of health workers:
n express fear of contracting HIV in the course of their work through casual contact;
n express negative judgements against those living with HIV;
n report discrimination against HIV-positive patients at health facilities; or
n express negative judgements about key marginalized populations at higher risk of HIV (compounded stigma).
Extent of stigma and discrimination among general populations
What proportion of the general population:
n have adequate knowledge about HIV transmission and treatment;
n fear contagion through casual contact with people living with HIV;
n report knowing an HIV-positive individual who has experienced stigma or discrimination;
n (or conversely) report instances of support or tolerance towards people living with HIV; or
n express negative judgements about key marginalized populations at higher risk of HIV (compounded stigma).
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the extent of stigma or testing hypotheses about the amount
of change associated with a programme strategy, qualitative
methods are well suited to gather contextual information, to
explore the expressions of stigma that occur in a community and
to investigate the reasons why certain quantitative results were
found. To answer these questions, a study might use an array
of methods such as observation, life stories, in-depth interviews
and document reviews, in addition to more common qualitative
methods such as focus groups or key informant interviews.

and experiences related to HIV disclosure, including whether
individuals living with HIV have revealed their status and the role
of health workers in that process (Medley et al. 2004; Maman
et al. 2006).
b. Fear of contagion through casual contact
Fear of HIV transmission through casual contact has been
measured in many quantitative and qualitative studies. Survey
items gauging this dimension of stigma typically measure the
percentage of respondents who express fear of contracting HIV
from casual contact with HIV-positive individuals or a desire to
avoid casual contact. One way to formulate this type of question
is: “Would you rather not touch someone with HIV (or AIDS)
because you are scared of infection?” Frequently recommended
questionnaire items for surveys among the general population
have included:

5. VARIABLES AND SURVEY QUESTIONS
This section describes variables and survey questions that can be
included in research instruments on stigma and discrimination.
It is based on a review of the literature, the comments of experts
on drafts of this document, and the recommendations and fieldtesting experience of the Interagency Stigma and Discrimination
Indicators Working Group convened by the United States Agency
for International Development (USAID) (Nyblade et al. 2005;
Nyblade and MacQuarrie 2006; Nyblade 2006). The items
recommended here have been chosen in part because they are
believed to be least context-specific. Additional ways to formulate
survey items to measure different dimensions of stigma can be
found in the references cited in this chapter.

Would you fear getting HIV from any of the following:
4 hugging a person with HIV or AIDS?
4 working next to a person with HIV or AIDS?
4 sitting next to a person with HIV or AIDS?
4 caring for a person with HIV or AIDS?
4 buying fresh vegetables or meat from a shopkeeper
with HIV or AIDS?
Among individuals living with HIV, survey questions can be used
to explore their personal perceptions of inappropriate fears of
contagion among the people with whom they interact, as in the
following:

Some but not all survey items discussed in this chapter are
included in the Client or Provider Instruments in this volume —
where multiple items were available, we have selected the most
frequently recommended and/or the least context-specific. Most
stigma-related items in the Client Instrument can be found in
the Disclosure, Support and Stigma Module, but some appear
in the Testing and Counselling Module (such as those related
to forced testing). Similarly in the Provider Instrument, stigmarelated items may appear in the Disclosure, Support and Stigma
Module, but some appear in the Fear of Infection and Work Safety
Module. As a result, researchers who want to investigate HIV
stigma without using the full Testing and Counselling Module of
the Client Instrument may need to extract some of the stigmarelated questions from the Testing and Counselling Module for
that purpose.

Please indicate whether you agree or disagree with each of
the following statements:
4 Some people are afraid to touch me once they know I
have HIV.
4 Some people have physically backed away from me
once they learned I have HIV.
c. Fear of contagion through occupational exposure (for health
workers)
In some situations, a research goal may be to understand the
prevalence of reasonable fears of HIV transmission by health
workers as compared with inappropriate fears of contagion
through non-invasive contact. For example, items exploring this
issue may include:

key variables related to stigma and
discrimination

a. Attitudes and behaviours related to disclosure
b. Fear of contagion through casual contact
c. Fear of contagion through occupational exposure (for
health workers)
d. Negative judgements about people living with HIV/
Internalized stigma
e. Discrimination and violence (’enacted stigma’)
f. Compounded/layered stigma
g. Community norms
h. Attitudes about human rights (e.g. forced testing)

How concerned would you feel about getting HIV if you had
to do any of the following. Would you feel very concerned,
somewhat concerned or not at all concerned if you had to:
4 take the blood pressure of a person with HIV or AIDS?
4 change the bed linens of a person with HIV or AIDS?
4 change the clothes of a person with HIV or AIDS?
4 give an injection to a person with HIV or AIDS?
4 dress the wound of a person with HIV or AIDS?
Researchers can assess health workers’ access to and use of
protective measures and the proportion of health workers who
express fear of contracting HIV because of inadequate safeguards
in the facility. The Provider Instrument in this volume contains

a. Attitudes about and patterns of HIV disclosure
Many studies (along with the instruments in this volume) have
included survey questions to explore attitudes, behaviours
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detailed questions about these topics. The extent of institutional
safeguards available to health workers may be measured by
determining what proportion of health workers report access to
universal precautions, cases of accidental exposure to HIV in their
workplace and access to HIV post exposure prophylaxis in cases
of accidental exposure.

can use the following recommended items for measuring
discrimination:
Do you personally know someone who has had the following
happen to him/her in the past 12 months because they had
HIV or AIDS? Someone you know was:
4 excluded from social events?
4 abandoned by a spouse or partner?
4 abandoned by other family members?
4 verbally abused or ridiculed?
4 physically assaulted?
4 fired from work or lost their job?
4 expelled from their home?
4 had property taken away?
4 denied health services?

d. Negative judgements about people with HIV/internalized
stigma
Many quantitative studies have measured the percentage
of a population who express negative judgements or blame
towards people living with HIV. This dimension has been less
frequently measured than the fear of casual contact (Nyblade
and MacQuarrie 2006), but a variety of survey items have been
developed for use among the general population, health care
workers and individuals living with HIV. These measures focus
on whether respondents view HIV infection as a punishment,
whether respondents believe that individuals living with HIV
deserve blame for getting infected, and whether respondents
believe that HIV infection brings shame upon those living with
HIV or those associated with them.

For research among people living with HIV, personal experiences
of discrimination can be measured using the same sub-items,
prefaced with the question: “In the last 12 months, has any of
the following happened to you when you thought it was because
of your HIV status?”
For research among health workers, survey questions can ask
whether respondents have observed colleagues treating patients
with HIV differently than other patients. Because of concerns about
social desirability bias and reporting personal discrimination, it
is preferable to ask providers about observed discrimination
among colleagues rather than their own discriminatory behaviour.
Examples of items measuring discrimination in health care
settings include:

negative judgements about people living with hiv:
examples of survey items
For measuring attitudes among the general population
Indicate your agreement or disagreement with each statement:
4 AIDS is a punishment for bad behaviour.
4 People with AIDS deserve blame for getting the disease.
4 People with AIDS should be ashamed of themselves.
For measuring experiences of negative judgements by individuals living
with HIV
Indicate your agreement or disagreement with each statement:
4 Some people act as though it is my fault I have HIV.
4 People say I deserve it for things that I have done.
4 People seem uncomfortable being around me once they learn I
have HIV.

In the past 12 months, have you seen or observed the
following happen in this health facility because a client was
known to have or was suspected of having HIV or AIDS?
4 Staff seemed uncomfortable with a client because of
his or her HIV status?
4 Health worker gossiped about a client’s status?
4 Client was ignored or received less care than other
clients?
4 Client was denied care that he or she should have
received?
4 Staff used excessive precautions with clients
suspected of having HIV or AIDS (e.g. used latex gloves
for non-invasive procedures)?
4 Client was treated with disrespect or abused?

For measuring self-directed negative judgement by individuals living
with HIV (internalized stigma)
Indicate your agreement or disagreement with each statement:
4 I sometimes feel worthless because I am HIV positive.
4 I feel guilty because I have HIV.
In the past 12 months, have you ever found yourself avoiding or
isolating yourself from friends or family because of your HIV status?

e. Discrimination and violence (enacted stigma)
Among the general population, discrimination can be measured
by gathering data on the proportion of respondents who personally
know someone who has experienced HIV-related discrimination.
To minimize under-reporting, discrimination is usually measured
by asking respondents to report ‘observed’ stigma rather their
own discriminatory behaviours. To reduce the possibility that
respondents might refer to the same incidents reported by the
media or well-known throughout a community, it is recommended
that survey items ask about whether the respondent personally
knows anyone who has experienced HIV-related discrimination.
The reference period should be relatively long (most commonly
12 months), since observable acts of discrimination may not
occur with great frequency. Surveys of the general population

When measuring discrimination in health care settings, it can
be difficult to determine whether discrimination results from
institutional policies or from personal attitudes and choices on
the part of individuals, but this is an important factor to consider.
Qualitative methods are useful for investigating the institutional
policy environment in which discrimination takes place.
f. Compounded or layered Stigma
Compounded stigma is complex and difficult to measure
accurately through survey questions. Examples of traditional
survey items that have been used to gain a preliminary sense of
layered stigma include:
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Indicate your agreement or disagreement with each
statement (specific most-at-risk-populations can be
substituted depending on local contexts):
4 Female sex workers are to blame for spreading HIV.
4 Clients who are sex workers deserve to receive the
same level and quality of care as other clients when
they need health care.
4 Homosexuality is the cause of HIV.
4 Injecting drug users are to blame for spreading HIV in
this community.
4 Men who have sex with other men are to blame for
spreading HIV in this community.

extent to which hypothetical questions are useful may depend on
the context and study objectives. Anticipated reactions to people
living with HIV can be measured by whether respondents agree
or disagree that:
In my community (to be defined):
4 A man who has HIV would be abandoned by his partner.
4 A woman who has HIV would be abandoned by her
partner.
4 A person living with HIV would be neglected.
4 A person living with HIV would be avoided.
4 A person living with HIV would be verbally abused or
teased.
4 A person living with HIV would not be allowed to go to
work/school.

One challenge, however, is that in concentrated epidemics,
the belief that HIV prevalence is highest among a particular
marginalized group may be a component of compounded stigma
as well as an accurate reflection of the epidemiology of HIV in
that setting. There are no well-established quantitative measures
of compounded stigma, but some researchers have suggested
that a factorial design can be used to disentangle different layers
of stigma. For example, researchers can ask the same question
about men and women living with HIV, or about different groups
such as sex workers on the one hand and injecting drug users on
the other (Reidpath and Chan 2005; Chan et al. 2007). Properly
disentangling compounded or layered stigma may require
detailed instruments and analyses across different variables that
are beyond the scope of the instruments in this volume. Whether
it is worth investing in such research depends on the particular
context. Qualitative research can also be used to explore these
connections and may yield useful insights.

Another variable that has been used to measure stigma is the
percentage of people reporting willingness to care for or to help
people living with HIV or AIDS. The survey questions can be
phrased as: “Imagine that you find out that one of your friends is
HIV-positive. Would you still be friends with him or her?” Another
possible survey question is: “If a member of your family became
sick with AIDS, would you be willing to care for her or him?”
h. Attitudes about the rights of individuals living with HIV
Some studies have sought to explore opinions among the general
population or among health workers about human rights issues
that affect people living with HIV. For example, this dimension
can be gauged by asking respondents about their support for
specific rights of people living with HIV such as:

g. Measures of social norms and anticipated reactions
A number of studies of stigma include questions about what
attitudes and behaviours respondents would expect from others
(usually other people in their community), but these have not
been included in the Client Instrument in this volume. Some
researchers think that such questions provide a measure of social
norms and of inclinations to stigmatize, while others are sceptical
of hypothetical questions about undefined “communities”. The

Indicate your agreement or disagreement with each
statement:
4 I think patients with AIDS do not have the right to the
same quality of care as other patients.
4 Women with HIV should be prevented from having
children.
4 People suspected of having HIV should be required to
be tested.

27

HIV TESTING, TREATMENT AND PREVENTION: GENERIC TOOLS FOR OPERATIONAL RESEARCH

References cited

Deacon H, Stephney I, Prosalendis S (2005) Understanding HIV/AIDS
stigma: a theoretical and methdological analysis. Cape Town, South
Africa: Human Sciences Research Council.

Abdul-Quader AS, Heckathorn DD, Sabin K, et al. (2006)
Implementation and analysis of respondent driven sampling: lessons
learned from the field. Journal of Urban Health 83(6 Suppl):i1-5.

Dias SF, Matos MG, Goncalves AC (2006) AIDS-related stigma and
attitudes towards AIDS-infected people among adolescents. AIDS Care
18(3):208-214.

Aggleton P, Wood K, Malcolm A, et al. (2005) HIV-related stigma,
discrimination and human rights violations: case studies of successful
programmes. Geneva: Joint United Nations Programme on HIV/AIDS
(UNAIDS). Accessed November 2008. Available at: http://data.unaids.
org/publications/irc-pub06/JC999-HumRightsViol_en.pdf.

Ford K, Wirawan DN, Sumantera GM, et al. (2004) Voluntary HIV
testing, disclosure, and stigma among injection drug users in Bali,
Indonesia. AIDS Education and Prevention 16(6):487-498.
Foreman M, Lyra P, Breinbauer C (2003) Understanding and
responding to HIV/AIDS-related stigma and stigma and discrimination
in the health sector. Washington, DC: Pan American Health
Organization. Accessed November 2008. Available at: http://www.paho.
org/English/AD/FCH/AI/stigma.htm.

Behforouz HL, Farmer PE, Mukherjee JS (2004) From directly
observed therapy to accompagnateurs: enhancing AIDS treatment
outcomes in Haiti and in Boston. Clinical Infectious Diseases 38(Suppl
5):S429-436.
Berger BE, Ferrans CE, Lashley FR (2001) Measuring stigma in people
with HIV: psychometric assessment of the HIV stigma scale. Research
in Nursing and Health 24(6):518-529.

Fortenberry JD, McFarlane M, Bleakley A, et al. (2002) Relationships
of stigma and shame to gonorrhea and HIV screening. American
Journal of Public Health 92(3):378-381.

Bermingham S, Kippax S (1998) HIV-related discrimination: a survey
of New South Wales general practitioners. Australian and New Zealand
Journal of Public Health 22(1):92-97.

Goffman E (1963) Stigma: notes on the management of spoiled
identity. New York: Simon and Schuster.
Heijnders M, van der Meij S (2006) The fight against stigma: an
overview of stigma-reduction strategies and interventions. Psychology,
Health and Medicine 11(3):353-363.

Bharat S, Aggleton P, Tyrer P (2001) India: HIV and AIDS-related
discrimination, stigmatization and denial. Best Practice Collection.
Geneva: Joint United Nations Programme on HIV/AIDS (UNAIDS)
(UNAIDS/01.46E). Accessed November 2008. Available at: http://data.
unaids.org/Publications/IRC-pub02/JC587-India_en.pdf.

Herek GM, Capitanio JP, Widaman KF (2002) HIV-related stigma and
knowledge in the United States: prevalence and trends, 1991-1999.
American Journal of Public Health 92(3):371-377.

Brouard P, Wills C (2006) A closer look: the internalization of stigma
related to HIV. Washington, DC: USAID and the Policy Project.
Accessed November 2008. Available at: http://www.policyproject.com/
pubs/generalreport/Internal_Stigma.pdf.

Herek GM, Capitanio JP, Widaman KF (2003) Stigma, social risk, and
health policy: public attitudes toward HIV surveillance policies and the
social construction of illness. Health Psychology 22(5):533-540.

Brown L, Macintyre K, Trujillo L (2003) Interventions to reduce HIV/
AIDS stigma: what have we learned? AIDS Education and Prevention
15(1):49-69.

Heyward WL, Batter VL, Malulu M, et al. (1993) Impact of HIV
counseling and testing among child-bearing women in Kinshasa, Zaire.
AIDS 7(12):1633-1637.

Brown L, Trujillo L, Macintyre K (2001) Interventions to reduce
HIVAIDS stigma: what have we learned? New Orleans: Horizons and
Tulane University. Accessed November 2008. Available at: http://www.
popcouncil.org/pdfs/horizons/litrvwstigdisc.pdf.

Hutchinson PL, Mahlalela X (2006) Utilization of voluntary counseling
and testing services in the Eastern Cape, South Africa. AIDS Care
18(5):446-455.

Castro A, Farmer P (2005) Understanding and addressing AIDSrelated stigma: from anthropological theory to clinical practice in Haiti.
American Journal of Public Health 95(1):53-59.

ICRW (2006) HIV/AIDS stigma: finding solutions to strengthen HIV/
AIDS programs. Washington, DC: International Center for Research on
Women (ICRW). Accessed November 2008. Available at: http://www.
icrw.org/docs/2006_stigmasynthesis.pdf.

Chan KY, Yang Y, Zhang KL, et al. (2007) Disentangling the stigma
of HIV/AIDS from the stigmas of drugs use, commercial sex and
commercial blood donation - a factorial survey of medical students in
China. BMC Public Health 7(147):280.

Iyaniwura CA (2006) Adults perspective of adolescent reproductive
health behaviour in a suburban town in Nigeria. Nigerian Journal of
Medicine 15(3):255-259.

Chen J, Choe MK, Chen S, et al. (2005) Community environment and
HIV/AIDS-related stigma in China. AIDS Education and Prevention
17(1):1-11.

Jacoby A (1994) Felt versus enacted stigma: a concept revisited.
Evidence from a study of people with epilepsy in remission. Social
Science and Medicine 38(2):269-274.

Clark HJ, Lindner G, Armistead L, et al. (2003) Stigma, disclosure,
and psychological functioning among HIV-infected and non-infected
African-American women. Women and Health 38(4):57-71.

Johnston LG, Khanam R, Reza M, et al. (2008) The effectiveness of
respondent driven sampling for recruiting males who have sex with
males in Dhaka, Bangladesh. AIDS and Behavior 12(2):294-304.

Coulibaly D, Msellati P, Dedy S, et al. (1998) Attitudes et
comportements des femmes enceintes face au dépistage du VIH à
Abidjan (Côte d’Ivoire), en 1995 et 1996: raisons du refus du test et
indifférence face aux résultats [Attitudes and behaviour of pregnant
women towards HIV screening in Abidjan (the Ivory Coast) in 1995 and
1996: reasons for refusal to be tested and not returning for the results].
Sante 8(3):234-238.

Kalichman SC, Nachimson D (1999) Self-efficacy and disclosure of
HIV-positive serostatus to sex partners. Health Psychology 18(3):281287.

Deacon H, Boulle A (2007) Commentary: factors affecting HIV/
AIDS-related stigma and discrimination by medical professionals.
International Journal of Epidemiology 36(1):185-186.

Kalichman SC, Simbayi LC, Cain D, et al. (2006) Generalizing a model
of health behaviour change and AIDS stigma for use with sexually
transmitted infection clinic patients in Cape Town, South Africa. AIDS
Care 18(3):178-182.

Kalichman SC, Simbayi LC (2003) HIV testing attitudes, AIDS stigma,
and voluntary HIV counselling and testing in a black township in Cape
Town, South Africa. Sexually Transmitted Infections 79(6):442-447.

28

HIV STIGMA AND DISCRIMINATION

Kalichman SC, Simbayi LC, Jooste S, et al. (2005) Development of a
brief scale to measure AIDS-related stigma in South Africa. AIDS and
Behavior 9(2):135-143.

Nyblade LC (2006) Measuring HIV stigma: existing knowledge and
gaps. Psychology, Health and Medicine 11(3):335-345.
Oanh KTH, Ashburn K, Pulerwitz J, et al. (2008) Improving hospitalbased quality of care in Vietnam by reducing HIV-related stigma and
discrimination. Horizon Final Report. Washington, DC: Population
Council. Accessed November 2008. Available at: http://www.
popcouncil.org/horizons/projects/Vietnam_HospitalStigma.htm.

Kippax S (2006) A public health dilemma: a testing question. AIDS
Care 18(3):230-235.
Link BG, Phelan JC (2006) Stigma and its public health implications.
Lancet 367(9509):528-529.

Obermeyer CM, Osborn M (2007) The utilization of testing and
counseling for HIV: a review of the social and behavioral evidence.
American Journal of Public Health 97(10):1762-1774.

Liu H, Hu Z, Li X, et al. (2006) Understanding interrelationships among
HIV-related stigma, concern about HIV infection, and intent to disclose
HIV serostatus: a pretest-posttest study in a rural area of eastern China.
AIDS Patient Care and STDs 20(2):133-142.

Ogden J, Nyblade L (2005) Common at its core: HIV-related stigma
across contexts. Washington, DC: International Center for Research on
Women (ICRW). Accessed November 2008. Available at: http://www.
icrw.org/docs/2005_report_stigma_synthesis.pdf.

Mahendra VS, Gilborn L, Bharat S, et al. (2007) Understanding and
measuring AIDS-related stigma in health care settings: a developing
country perspective. SAHARA Journal 4(2):616-625.

Parker R, Aggleton P (2003) HIV and AIDS-related stigma and
discrimination: a conceptual framework and implications for action.
Social Science and Medicine 57(1):13-24.

Maher JE, Peterson J, Hastings K, et al. (2000) Partner violence,
partner notification, and women’s decisions to have an HIV test.
Journal of Acquired Immune Deficiency Syndromes 25(3):276-282.

Parker R, Aggleton P, Attawell K, et al. (2002) HIV/AIDS-related stigma
and discrimination: a conceptual framework and an agenda for action.
Washington, DC: Population Council, Horizons Program. Accessed
November 2008. Available at: http://www.popcouncil.org/pdfs/horizons/
sdcncptlfrmwrk.pdf.

Maman S, King E, Amin A, et al. (2006) Addressing violence against
women in HIV testing and counselling: a meeting report. Geneva:
Department of Gender, Women and Health, Department of HIV/AIDS,
World Health Organization. Accessed November 2008. Available at:
http://www.who.int/gender/documents/VCT_addressing_violence.pdf.

Peretti-Watel P, Spire B, Pierret J, et al. (2006) Management of
HIV-related stigma and adherence to HAART: evidence from a large
representative sample of outpatients attending French hospitals
(ANRS-EN12-VESPA 2003). AIDS Care 18(3):254-261.

Maman S, Mbwambo J, Hogan NM, et al. (2001) Women’s barriers
to HIV-1 testing and disclosure: challenges for HIV-1 voluntary
counselling and testing. AIDS Care 13(5):595-603.
Maman S, Mbwambo JK, Hogan NM, et al. (2003) High rates and
positive outcomes of HIV-serostatus disclosure to sexual partners:
reasons for cautious optimism from a voluntary counseling and testing
clinic in Dar es Salaam, Tanzania. AIDS and Behavior 7(4):373-382.

Policy Project (2003) Siyam’Kela: measuring HIV/AIDS related stigma.
Cape Town and Pretoria, South Africa: USAID, the POLICY Project
and the Centre for the Study of AIDS, University of Pretoria. Accessed
November 2008. Available at: http://www.policyproject.com/Special/
SAF_Siyamkela_PromisePractice.pdf.

Medley A, Garcia-Moreno C, McGill S, et al. (2004) Rates, barriers and
outcomes of HIV serostatus disclosure among women in developing
countries: implications for prevention of mother-to-child transmission
programmes. Bulletin of the World Health Organization, 82(4):299307. Accessed November 2008. Available at: http://www.who.int/
bulletin/volumes/82/4/en/299.pdf

Pulerwitz J, Michaelis AP, Lippman SA, et al. (2008) HIV-related
stigma, service utilization, and status disclosure among truck drivers
crossing the Southern borders in Brazil. AIDS Care 20(2):198-204.
Rao D, Kekwaletswe TC, Hosek S, et al. (2007) Stigma and social
barriers to medication adherence with urban youth living with HIV.
AIDS Care 19(1):28-33.

Mukherjee JS, Ivers L, Leandre F, et al. (2006) Antiretroviral therapy in
resource-poor settings. Decreasing barriers to access and promoting
adherence. Journal of Acquired Immune Deficiency Syndromes
43(Suppl 1):S123-126.

Reidpath DD, Chan KY (2005) A method for the quantitative analysis of
the layering of HIV-related stigma. AIDS Care 17(4):425-432.

Nachega JB, Knowlton AR, Deluca A, et al. (2006) Treatment
supporter to improve adherence to antiretroviral therapy in HIV-infected
South African adults. A qualitative study. Journal of Acquired Immune
Deficiency Syndromes 43(Suppl 1):S127-133.

Reidpath DD, Chan KY, Gifford SM, et al. (2005) ‘He hath the French
pox’: stigma, social value and social exclusion. Sociology of Health and
Illness 27(4):468-489.
Rintamaki LS, Davis TC, Skripkauskas S, et al. (2006) Social stigma
concerns and HIV medication adherence. AIDS Patient Care and STDs
20(5):359-368.

Nachega JB, Stein DM, Lehman DA, et al. (2004) Adherence to
antiretroviral therapy in HIV-infected adults in Soweto, South Africa.
AIDS Research and Human Retroviruses 20(10):1053-1056.

Sambisa W (2008) AIDS stigma and uptake of HIV testing in
Zambabwe. Calverton, Maryland: Macro International Inc. Accessed
November 2008. Available at: http://www.measuredhs.com/pubs/pdf/
WP49/WP49.pdf.

Nebie Y, Meda N, Leroy V, et al. (2001) Sexual and reproductive life of
women informed of their HIV seropositivity: a prospective cohort study
in Burkina Faso. Journal of Acquired Immune Deficiency Syndromes
28(4):367-372.

Schiff M, McKay M, Bell C, et al. (2003) The role of personal contact
with HIV-infected people in explaining urban, African American
preadolescents’ attitudes toward peers with HIV/AIDS. American
Journal of Orthopsychiatry 73(1):101-108.

Nyblade L, MacQuarrie K (2006) Can we measure HIV/AIDS related
stigma and discrimination? Current knowledge about quantifying
stigma in developing countries. Washington, DC: USAID, ICRW and the
POLICY Project. Accessed November 2008. Available at: http://www.
policyproject.com/pubs/generalreport/Measure%20HIV%20Stigma.pdf.

Simbayi LC, Kalichman S, Strebel A, et al. (2007a) Internalized stigma,
discrimination, and depression among men and women living with
HIV/AIDS in Cape Town, South Africa. Social Science and Medicine
64(9):1823-1831.

Nyblade L, MacQuarrie K, Phillip F, et al. (2005) Measuring HIV
stigma: results of a field test in Tanzania. Working Report. Washington,
DC: USAID. Accessed November 2008. Available at: http://www.icrw.
org/docs/2005-StigmaIndicatorsReport.pdf.

Simbayi LC, Kalichman SC, Strebel A, et al. (2007b) Disclosure of HIV
status to sex partners and sexual risk behaviours among HIV-positive

29

HIV TESTING, TREATMENT AND PREVENTION: GENERIC TOOLS FOR OPERATIONAL RESEARCH

men and women, Cape Town, South Africa. Sexually Transmitted
Infections 83(1):29-34.

Watts C, Heise L, Ellsberg M, et al. (2001) Putting women first: ethical
and safety recommendations for research on domestic violence against
women. Geneva: World Health Organization (WHO/FCH/GWH/01.1).
Accessed November 2008. Available at: http://www.who.int/gender/
violence/womenfirtseng.pdf.

Thomas BE, Rehman F, Suryanarayanan D, et al. (2005) How
stigmatizing is stigma in the life of people living with HIV: a study
on HIV positive individuals from Chennai, South India. AIDS Care
17(7):795-801.

Weiser S, Wolfe W, Bangsberg D, et al. (2003) Barriers to antiretroviral
adherence for patients living with HIV infection and AIDS in Botswana.
Journal of Acquired Immune Deficiency Syndromes 34(3):281-288.

UNAIDS (2005) Meeting on development of index on human
rights, stigma and discrimination by and for people living with HIV.
Report of the Meeting 22-23 August 2005. Geneva: Joint United
Nations Programme on HIV/AIDS (UNAIDS). Accessed November
2008. Available at: http://data.unaids.org/UNA-docs/meeting_hr_
plhivindex_23aug05_en.pdf.

Weiser SD, Heisler M, Leiter K, et al. (2006) Routine HIV testing in
Botswana: a population-based study on attitudes, practices, and
human rights concerns. PLoS Medicine 3(7):e261.
Wynia MK (2006) Routine screening: informed consent, stigma and
the waning of HIV exceptionalism. The American Journal of Bioethics
6(4):5-8.

UNAIDS (2007) Reducing HIV stigma and discrimination: a critical part
of national AIDS programmes: a resource for national stakeholders in
the HIV response. Geneva: Joint United Nations Programme on HIV/
AIDS (UNAIDS). Accessed November 2008. Available at: http://data.
unaids.org/pub/Report/2008/jc1420-stigmadiscrimi_en.pdf.

Yang Y, Zhang KL, Chan KY, et al. (2005) Institutional and structural
forms of HIV-related discrimination in health care: a study set in
Beijing. AIDS Care 17(Suppl 2):S129-140.

Van Brakel WH (2006) Measuring health-related stigma--a literature
review. Psychology Health and Medicine 11(3):307-334.
Varas-Diaz N, Serrano-Garcia I, Toro-Alfonso J (2005) AIDS-related
stigma and social interaction: Puerto Ricans living with HIV/AIDS.
Qualitative Health Research 15(2):169-187.

30

ADHERENCE TO ANTIRETROVIRAL THERAPY

CHAPTER 3
ADHERENCE TO ANTIRETROVIRAL THERAPY
1. BACKGROUND

and risks of drug interactions (Clotet 2004; Negredo et al. 2006).
Among small cohorts of patients in African populations, drugresistant strains of HIV have emerged in both treatment-naive and
treatment-experienced patients (Adje-Toure et al. 2003; Koizumi
et al. 2006). The risk of drug resistant strains as a consequence
of suboptimal adherence has also been documented in settings
such as China (Han et al. 2005) and India (Hira et al. 2004;
Balakrishnan et al. 2005).

1.1 Rationale: Why research is needed on adherence to
antiretroviral therapy
Adherence, “the extent to which a person’s behaviour – taking
medication, following a diet and/or executing lifestyle changes,
corresponds with agreed recommendations from a health care
provider” (WHO 2003), is a crucial element for scaling up HIV
treatment. Concerns about poor adherence have sometimes been
used to deny or delay access to care to those populations that
were expected to be less adherent to antiretroviral therapy, even
though it has been shown that “pre-treatment” information is less
predictive of adherence than a patient’s experience with treatment
(Spire et al. 2002). Recent evidence shows that good adherence
can be achieved in low-resource settings (Fong et al. 2003; WHO
2003; Mills et al. 2006), but it is clear that maintaining high
adherence over time requires adequate support and remains
one of the greatest challenges in both high- and low-resource
settings (Gill et al. 2005).

Many research gaps remain about the best way to monitor
patterns of adherence over time (Bangsberg 2008), the levels
and patterns of adherence in different settings, and the factors
and circumstances that lead to suboptimal adherence, including
treatment interruption. Addressing these research gaps may
contribute to improved clinical care and better informed
HIV treatment policies and programmes. Researchers may
also want to explore the links between poor adherence and
treatment abandonment, though a full exploration of treatment
discontinuation and retention issues is beyond the scope of the
instruments in this volume.

Suboptimal adherence to antiretroviral therapy has implications at
both an individual and a population level. For individual patients,
studies have demonstrated that adherence to antiretroviral therapy,
however it is measured (unannounced pill count, electronic
monitoring systems or self-reports), is a strong predictor of HIV
outcomes, as measured by virological response (Bangsberg et
al. 2000; Paterson et al. 2000; Nieuwkerk et al. 2001a), CD4
lymphocyte count (Paterson et al. 2000; Carrieri et al. 2003;
Wood et al. 2004), progression to AIDS (Bangsberg et al. 2001;
Bouhnik et al. 2005), hospitalization (Paterson et al. 2000) and
death (Hogg et al. 2000; Garcia de Olalla et al. 2002; Wood et al.
2003). The clinical implications of adherence are most evident in
the initial months of treatment (Carrieri et al. 2003), supporting an
argument that research and interventions should pay particular
attention to the factors that influence adherence in the earliest
phase of treatment.

1.2 Definitions: how researchers define adherence to
antiretroviral therapy
Nonadherence to treatment can occur when a patient takes
medication at the wrong time, skips doses, interrupts treatment
for a period of time or abandons treatment altogether (WHO
2003). It should be noted that this chapter concentrates on
medication taking — the first element of the WHO definition of
adherence. Diet and lifestyle changes, the other two elements,
are addressed to some degree in this volume (e.g. a few questions
about food security in the Client Instrument and a detailed
discussion of sexual behaviour in the Prevention chapter);
however, researchers who want to explore these elements in more
depth may need additional data collection tools, depending on
the purpose of the research.
Adherence to antiretroviral therapy has been measured in different
ways, most commonly as a percentage of prescribed pills taken or
picked up on time over a given period of time (Bangsberg 2008).
Adherence can be analysed as a continuous variable (Gross et
al. 2006) or as a categorical variable that distinguishes ‘optimal’
from ‘suboptimal’ adherence (high from moderate from low, good
from poor). While some researchers have reported adherence
as a percentage of prescribed pills taken over a given period

One of the greatest public health concerns about poor adherence
to antiretroviral therapy is that suboptimal adherence — including
taking fewer pills than prescribed, taking doses at the wrong time
and interrupting treatment — may lead to the development of
drug-resistant viral strains. Drug resistance can render first-line
drugs ineffective for patients and require second-line drugs that
are more complex, more costly and carry greater side-effects
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of time, suboptimal adherence can also be defined to include
patterns such as mistimed doses (Liu et al. 2006), treatment
interruptions (Raffa et al. 2006) and treatment discontinuation
(Bangsberg 2008).

the lack of treatment interruptions, for the successful scale-up and
sustainability of antiretroviral therapy programmes. Researchers
continue to recognize a threshold of 95% or higher as ‘optimal’
adherence, especially during the early phase of treatment. After
six months, researchers may want to measure adherence as a
continuous variable, especially for more forgiving regimens, rather
than using rigid distinctions between adherent and nonadherent
patients. Ideally, researchers will also use operational definitions
of adherence that include patterns of medication taking (e.g.
interruptions) in addition to overall averages, as well as measures
that monitor adherence levels over time.

Studies have traditionally used a threshold of 95% or more
to distinguish between optimal and suboptimal adherence
(Ammassari et al. 2001; Cederfjall et al. 2002; da Silveira et al.
2003; Weber et al. 2004; Chesney 2006; Simoni et al. 2006a).
This threshold was based on evidence that near perfect adherence
(95% or more) to existing regimens was needed to achieve
optimal patient outcomes, such as a lower risk of virological
failure, increased CD4 lymphocyte count and lower hospitalization
rates, especially during the early phase of treatment (Paterson
et al. 2000; Arnsten et al. 2001; Carrieri et al. 2003). Similarly,
several studies found a skewed bell-shaped relationship between
drug-resistance and adherence to single protease inhibitor
therapy, whereby moderate to high (80% - 90%) adherence
was associated with the greatest risk of drug-resistant mutations
(Bangsberg et al. 2004; Harrigan et al. 2005; King et al. 2005).
However, this body of research was largely based on non-boosted
protease inhibitors which are being rendered obsolete by newer
treatment regimens (Bangsberg et al. 2007).

1.3 Patterns and levels of adherence
Adherence to treatment of chronic diseases in general tends
to be around 60% (WHO 2003). Studies that have examined
adherence to antiretroviral therapy around the world have found
a wide range of levels. A meta-analysis of published studies found
that 55% of North American patients (range: 26%-86%) and
77% of African patients (range: 30%-100%) achieved ‘optimal’
adherence to antiretroviral therapy (Mills et al. 2006). These
observed proportions of patients who achieve high adherence are
similar to the findings of longitudinal studies of French patients
initiating antiretroviral therapy (Carrieri et al. 2001). Observed
adherence levels have been slightly higher in the Italian and the
Swiss cohorts (70%) (Ammassari et al. 2004; Glass et al. 2006)
and lower in the Dutch cohort (47%) (Nieuwkerk et al. 2001b).

Recent studies suggest that ritonavir-boosted protease inhibitors
(and to a lesser degree non-nucleoside reverse transcriptase
inhibitors — NNRTIs) appear to be more ‘forgiving’ than older
regimens, as they achieve viral suppression even in the face
of moderate adherence of 70% or more (Weiser et al. 2004;
Maggiolo et al. 2005; Bangsberg et al. 2007; Wainberg et
al. 2007). Evidence also suggests that the adherence level
needed to prevent drug resistance depends on the length of
time on treatment, the variant of the virus and the host genome
(Bangsberg et al. 2007). For example, near perfect adherence
(95–100%) appears to be especially important during the first
four to six months of treatment, before viral suppression has
been achieved, regardless of regimen (Wainberg et al. 2007).
Therefore, researchers agree that maximum adherence remains
a worthy goal for all regimens, though it may be difficult to attain
for many patients (Gardner et al. 2006; Wainberg et al. 2007).

Evidence indicates that high adherence to antiretroviral therapy
may be difficult to sustain over time. For example, a study
from France followed patients over three years and found that
only 26% of patients were able to maintain consistently “high”
adherence throughout the follow-up period (Carrieri et al.
2003). Similar findings have been reported from other settings
(Bangsberg 2008). As patients’ trajectories of adherence may
diminish over time, it is crucial for clinicians to monitor adherence
levels and intervene before the virus has an opportunity to
rebound (Bangsberg 2008). It is also important for researchers
to learn more about why — and to what degree — individual and
contextual factors influence adherence to antiretroviral therapy
over time. This may require two levels of information, namely:
measures to assess patients’ adherence levels at different points
in time and information about contextual and individual factors
that influence adherence. One area that remains to be fully
explored is whether there are relationships between patterns
and factors associated with missing doses and those involved in
stopping treatment altogether. For example, do most patients who
abandon treatment do so after missing more and more doses,
and are those who adhere poorly to antiretroviral therapy at risk
of abandoning treatment altogether?

It is also important to note that average adherence levels are only
one dimension of optimal adherence. Research indicates that
patterns of adherence over time, including selective drug taking,
treatment interruptions and treatment discontinuation may be just
as important as average adherence levels (Gardner et al. 2005;
Bangsberg 2008). Treatment interruption — missing pills for at least
48 consecutive hours — appears to have a considerable influence
on virological response (Raffa et al. 2006) and is a major risk factor
for resistance to nevirapine and probably to other NNRTIs (Oyugi
et al. 2007). Studies indicate that treatment modification and
discontinuation of at least part of their drug regimen occurs among
a substantial proportion of patients, with serious consequences for
health outcomes and drug resistance (Ahdieh Grant et al. 2001;
Bangsberg et al. 2007; Kiguba et al. 2007).

2. FACTORS AND PROGRAMME STRATEGIES
2.1 Factors that influence adherence to antiretroviral
therapy
Understanding the factors that influence adherence to
antiretroviral therapy is essential for designing strategies to
optimize adherence, and the evidence has been growing rapidly,

In sum, while clinical practice is changing rapidly, the evidence
underscores the importance of high levels of adherence, including
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both in high-resource settings (Chesney 2000; Ammassari et
al. 2001; Ickovics et al. 2002; Spire et al. 2002; Reynolds et al.
2004) as well as in resource-limited settings (Pinheiro et al. 2002;
Fong et al. 2003; Orrell et al. 2003; Weiser et al. 2003; Nachega
et al. 2004; Nemes et al. 2004; Stout et al. 2004; Byakika-Tusiime
et al. 2005; Safren et al. 2005). Qualitative studies carried out
in resource-limited settings provide useful insights regarding
contextual barriers to adherence and how to design programme
strategies to address them (Hardon et al. 2006).

users or those exchanging sex for survival and the degree to which
stigma discourages HIV-positive individuals from revealing their
status. This information can be collected at the aggregate level
through key informant interviews and also by asking individuals
about their experiences. Other factors, particularly those related
to patients, require individual data collection.
It is also important for researchers to examine the length of time
that patients have been taking antiretroviral therapy. Factors
associated with poor or nonadherence in the first few months
may be quite different than those factors that have the greatest
role in poor adherence over the long run. For example, those who
have just begun taking antiretroviral therapy may have to deal with
major physical and social changes, including side-effects, new
daily routines, fear of disclosing their status to others (in some
cases), uncertainty about the benefits of antiretroviral therapy
and possible modifications to their regimen. On the other hand,
after two or three years, patients may experience improvements
in their overall health, but fatigue from having to take medication
multiple times a day.

There are different ways to group the factors that influence
adherence to antiretroviral therapy, ranging from conceptual
frameworks that simply distinguish between individual and
contextual factors, to those frameworks that include more
detailed categories. Here, we adapt the framework used in the
WHO review of adherence (2003) and distinguish the following
interacting dimensions:

4 Health care and system-related factors (service delivery of
ART). These include reimbursement systems and the cost of
medications and consultations, drug distribution systems and
the availability of medicines, access to health services, levels
of confidentiality in the health care setting and the conditions
of the medical encounter.

2.2 Interventions and programming to support adherence

4 Social and demographic patient-related factors. These include

Although substantial descriptive data are now available on the
consequences and factors that influence nonadherence in
a variety of populations, until recently, much of the available
evidence on adherence interventions consisted of descriptions
of demonstration projects (Williams et al. 2006), and few studies
were able to determine whether adherence interventions are
associated with improved virological or immunological outcomes
(Pradier et al. 2003). More recently, the evidence has grown,
and a number of controlled studies have examined programme
strategies to improve antiretroviral therapy adherence. Programme
strategies to improve adherence can be categorized as follows:

socioeconomic status, food security, residence, employment
and other sociodemographic variables.

4 treatment-related, including simplification or correction of

4 Other patient factors, such as how treatment fits into patients’

regimens, management of side-effects, treatment of depression,
improved drug management and supply systems;

4 Patients’ clinical condition and therapy-related factors.
These include stage of the disease, severity of symptoms,
complexity of drug regimens, side-effects, toxicities and their
management, degree of diet restrictions and lifestyle changes
required by the regimen and the occurrence of co-morbidities,
e.g. depression or drug or alcohol abuse.

lives. These factors may include forgetfulness, schedule,
attitudes and knowledge about HIV treatment, and whether
patients feel they need to take their medications in secret (for
more detail, see the chapter on stigma and discrimination in
this volume).

4 adherence patient education and counselling, including
counselling to improve medication management skills and to
help patients overcome barriers to adherence;

4 community/peer support, including the peer support,
4 Social context and social interactions. These include factors

(accompagnateurs) programme in Haiti (see Stigma chapter),
or support groups for people living with HIV; and

such as the degree of social support (and conversely
discrimination) that patients experience from partners, families
and friends (etc.), as well as interactions with providers and
trust of health services.

4 programmes that address socioeconomic constraints, such
as free or subsidized medicines, transportation or food
supplements, or income-generating opportunities.

It is sometimes useful as a first step to conduct a situation
analysis in order to identify the general structural and social
factors that influence access to medicines and the ability to
take them. These factors may include, for example, the costs of
medications in a given country, the extent to which antiretroviral
therapy medications are regularly supplied to health facilities, the
availability of food and water in the area, the accessibility of the
health facilities where HIV treatment and care are provided, the
extent of law enforcement actions against groups such as drug

Individual level interventions
A systematic review, based on 19 relevant randomized controlled
trials from high-income countries, found that programmes that
were most successful in improving adherence were provided to
individuals over long periods of time and emphasized practical
medication management skills (Rueda et al. 2006). A metaanalysis of randomized controlled trials of clinic-based patient
education, counselling and various devices to prompt patients
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to take their medications found that participants who received
education and counselling were significantly more likely (OR=1.5)
to reach the optimal level of 95% adherence and to have an
undetectable viral load (OR=1.25) than those who were not
offered such counselling (Simoni et al. 2006b).

sites and over time. But since adherence is a dynamic process
that changes over time and is shaped by multiple factors, an
overly rigid “determinants” framework would miss important
dimensions of the process of adherence — in particular, the
patient perspective and the broader societal forces that influence
behaviours. Even within the context of operational research, it is
possible to consider some of these factors, including patients’
experiences, the strategies they use to adhere to treatment and
the wider social context of medication taking, including social
networks.

The importance of counselling, over and above external reminders
(as highlighted in the meta-analysis) was confirmed by a recent
multi-centre trial in the United States. This trial compared the
effects of an electronic medication alarm system with those of
“medication managers” — clinic staff who were given two days
of training on how to conduct adherence counselling and how
to help patients identify and overcome barriers to adherence.
Medication managers were found to significantly increase levels
of optimal adherence, which was not the case for the electronic
medication alarms (Mannheimer et al. 2006).

Recent research has begun to pay attention to such factors
and has recognized the contribution of qualitative methods in
improving explanations for adherence, particularly those that
have to do with patients’ views, what influences those views and
how those views affect behaviour (Golin et al. 2002; Nachega
et al. 2006; Sankar et al. 2006). There are calls for combining
medical and social perspectives and for using multi-disciplinary
teams (Frick et al. 2006; Friedland 2006). This chapter focuses
on ways to standardize the measurement of adherence and its
key determinants using closed-ended questions that can be
asked in all settings, but it also includes open-ended questions
that can capture the individual and context-specific dimensions
of adherence.

While randomized controlled trials are important ways to measure
the effect of individual interventions, they are limited when trying
to assess the effectiveness of community-based approaches or
programmes that aim to overcome socioeconomic constraints.
Also, trials that standardize interventions cannot assess the effect
of tailored approaches that match adherence interventions to
patient needs at different stages of treatment (Gordon 2006).
Therefore, it is necessary to complement randomized controlled
trials with other sorts of intervention studies, especially in lowresource settings.

The Adherence Module of the Client Instrument in this volume
is designed to facilitate operational research in order to inform
programmes and improve antiretroviral therapy delivery. The
instrument addresses the operational research questions listed
in the box on the next page.

Community level interventions
Evidence about the potential benefits of a variety of community
level strategies is growing. Community-based interventions
in Haiti and Rwanda, including the use of peer supporters
(accompagnateurs), have been shown to improve adherence
and outcomes (Mukherjee et al. 2006). Home-based counselling
and home-delivery of drugs appear to be effective in increasing
adherence and decreasing viral loads (Weidle et al. 2006).
Directly administered antiretroviral therapy (DAART) has been
adapted and modified from the directly observed therapy (DOT)
strategy used in the management of tuberculosis, and this
approach seems to be acceptable (Pearson et al. 2006) and
to increase optimal adherence (Luchters et al. 2008). Some
evidence suggests that strategies that alleviate the cost of
transportation and address food insecurity — which represent
major obstacles in resource-limited settings (Hardon et al. 2007)
— may improve Body Mass Index (BMI), weight and CD4 counts
(Gisha Mugisha et al. 2006; Samuels et al. 2008a; Samuels et
al. 2008b). However, confirmation of these findings will require
further studies with careful measurement of adherence levels
and the use of control groups.

The first of these three research questions (adherence levels
over time) can be answered by analysing the quantitative survey
data from the Adherence Module of the Client Instrument in this
volume. The second set of questions (about factors that influence
adherence) can be answered through regression analyses of
survey data collected using various modules in this volume. The
third set of research questions can best be answered using both
statistical analyses of quantifiable data and qualitative methods
based on responses to the open-ended questions in the Client
Instrument. Further data collection and analysis can be carried
out to explore patients’ own perspectives on the factors that
influence adherence, using qualitative methods such as narrative
techniques.
Additional research questions that may be considered in
different settings
In addition to the core research questions addressed by the
instruments in this volume, researchers may want to investigate
a host of other factors that influence adherence, as illustrated
in the box on page 35. In some cases, the Adherence Module
already includes the survey questions needed to investigate
these questions; in other cases, researchers would need to add
additional survey items.

3. RESEARCH OBJECTIVES AND QUESTIONS
In order to monitor adherence and inform interventions to support
adherence, it is essential to have standardized information across
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Key

operational research questions about adherence

1. What proportion of antiretroviral therapy patients have suboptimal adherence?
n What proportion of patients have suboptimal (or high, moderate and low) adherence after 4 months, 6 months, 1 year, 2 years (etc.)?
2. What factors are associated with optimal or suboptimal adherence?
n Health care system: Is poor adherence associated with inconsistent supply of ART, higher cost of treatment, distance from the clinic or other
facility-related barriers to access?
n Patients’ clinical condition and therapy: Is poor adherence associated with more complex treatment regimens or occurrence of side-effects or
co-morbidities?
n Social and demographic patient-related factors: Is poor adherence associated with patients’ socioeconomic status? Is it associated with food
security?
n Other patient factors: Is adherence associated with factors such as attitudes and knowledge about ART and HIV and whether patients take their
medications in secret?
n Social context: Is poor adherence associated with low levels of social support, high perceived stigma or experiences of discrimination?
3. How does the situation of patients’ lives influence sustained adherence to antiretroviral therapy?
n How do patients fit antiretroviral therapy into their daily routines?
n What are the primary reasons that nonadherent patients skip doses or interrupt their therapy? Do these patterns differ at different times of year or
over the course of treatment?
n How do factors such as patients’ socioeconomic status, food security, knowledge and attitudes and income-generating activities influence adherence?
n How do family members and other social networks support or impede patients’ adherence?

additional research questions about the influence of various factors on adherence

Health Care Delivery
ART initiation and retention criteria

Do guidelines with more stringent criteria for patients initiating and remaining in antiretroviral therapy
programmes result in better adherence?

Waiting and consultation time

Does the time patients must spend in the clinic influence their adherence?

Availability of essential medications

Does the availability and cost of drugs for AIDS-related illnesses influence adherence?

Comprehensive care

Do services that provide comprehensive care and treatment for co-morbidities (malaria, TB, substitution
treatment, hepatitis, etc.) achieve higher levels of adherence than those that do not?

Laboratory services and clinical
monitoring

Does the availability of laboratory services and regular feedback to patients on their clinical indicators
influence adherence?

Refill interval

Do patients at facilities that require patients to come for refills every month have better adherence than
patients at facilities with longer refill intervals?

Number of patients enrolled in the ART
programme

Is the size of antiretroviral therapy programmes associated with patients’ adherence?

Providers' knowledge of ART and
adherence

How well do different types of providers understand antiretroviral therapy management and the
importance of adherence?

Patients’ Health
Concurrent therapies

How do patients integrate antiretroviral therapy with other treatment modalities, including traditional and
"neo-traditional" remedies, and how does this influence adherence?

Depression

How do depression, anxiety and hopelessness influence adherence?

Alcohol and drug use

Do patients who abuse alcohol or drugs have worse adherence than those who do not? How does
substitution treatment influence adherence to ART?

Other Patient-related Factors
Economic activity

How do patients’ income-generating activities and food security influence their adherence, and how does
this change over time?

Perceptions and knowledge about ART

How do patients understand antiretroviral therapy and how does this influence adherence?

Perceptions of adherence

What meaning and importance do patients attribute to adherence, and how does this change over the
course of their treatment?

Perceptions of own health status

Do the perceptions that patients have of their own health status influence adherence?

Social Interactions
Quality of interactions with patients

What counselling skills do providers use when interacting with patients (e.g. listening, respect, time for
questions, confidentiality, non-judgemental interaction, etc.)?

Attitudes towards providing adherence
support

What are providers’ attitudes when providing adherence support to patients (disciplinary vs. patientcentred, and value vs. resent time spent on adherence counselling), and how does this influence
adherence?

Stigma

What role does stigma or discrimination play in adherence?

Perception of relationships with health
workers

How do patients perceive their relationships with health care providers, particularly with regard to trust
and honesty, and how does this influence their adherence?
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4. METHODS
4.1 Study populations and study design

by an interviewer. Most self-report measures ask patients to recall
the proportion of times that they correctly took their medications
over a defined time period.

The primary study population for operational research on
adherence is that of patients taking antiretroviral therapy,
because their perspectives and experiences are essential to
inform interventions and service delivery to improve adherence
practices. Some additional information may be elicited from key
informants, health care providers, representatives of AIDS care
organizations and family and friends (including peer supporters
or accompagnateurs) of patients taking antiretroviral therapy.

Variability in the observed levels of adherence to antiretroviral
therapy may depend on the way adherence is measured (e.g. pill
counts, MEMS, self-reports, etc.) and — in the case of face-to-face
interviews — who collects the information (e.g. a physician, social
worker or peer). It is, therefore, important to define standardized
measures, to clarify appropriate study designs and methods, and
to foster comparability across studies.

Patients can be recruited in the clinic setting, using all patients
on antiretroviral therapy as a sampling frame. Patients should
be sampled to include variability on key variables, such as
sex, time on antiretroviral therapy, etc. If possible, data should
be collected at several points in time, since adherence may
change over time. But cross-sectional data at a single point in
time can also be useful, as they can give a snapshot of patients’
experience. When designing a sampling plan, researchers should
consider the possibility that a certain proportion of patients will
abandon treatment or modify their regimens after treatment has
begun. Gathering data among this group may provide another
important perspective on the factors that influence adherence to
antiretroviral therapy.

All measures of adherence have limitations, including those
that are based on “objective” measures rather than self-reports.
For example, there are errors and biases in measures such as
electronic drug monitoring and pill counts (Berg and Arnsten
2006). Even laboratory measurements can be misleading: while
drug plasma concentration levels may offer a direct measure
of recent drug consumption in the preceding 24 hours, they
may also be biased by the possibility that patients who are not
usually adherent may take their medications appropriately the
day prior to the medical examination and hence be classified as
adherent. Thus, the decision of which method to use will depend
on the trade-offs the investigator is ready to make (see Table on
next page).

Ideally, research methods should integrate both qualitative and
quantitative data collection from multiple sources, creating
a comprehensive picture of the multi-faceted influences on
adherence. Qualitative methods are valuable because they can
elicit salient issues for a particular group and can shed light on
the social context of adherence. They can be used to explore and
explain the findings of a quantative survey, or as part of formative
research to understand adherence, to elicit the topics and to
inform the measurements to be used for a quantitative study.
Qualitative data can be collected through individual interviews,
focus group discussions and observations. They are generally
analysed through a process of coding and content analysis for
themes and patterns (Ulin et al. 2005).

Despite their potential disadvantages, self-report measures
of adherence are highly correlated with clinical measures of
viral load (Nieuwkerk and Oort 2005) and other measures
of adherence, such as pill counts and MEMS (Arnsten et al.
2001; Liu et al. 2001; Wagner 2002; Oyugi et al. 2004). In
addition, self-report measures are often chosen because they
are easier, less costly and more feasible to administer than other
measures of adherence. Appropriate selection of questions, a
non-judgemental approach that includes normalizing language
and good interviewer training can greatly improve the validity and
reliability of self-reports.
Self-report measures of adherence take many forms, and
standardization is necessary to enable comparisons across
studies. Some self-report measures involve asking patients to
recall the proportion of pills or the proportion of times that they
correctly took their medications over the previous three days, four
days, one week or one month. In shorter periods (three or four
days) patients are asked to recall which doses they took or did
not take, each day. There has not been any evidence to suggest
a difference between the validity of a 3- or 4-day measure,
suggesting that a 3-day measure may be chosen for its easier
administration (Simoni et al. 2006a). Instead of using a 1-week
measure that also includes the weekend, a question about
adherence during the weekend can be added in those settings
where weekday and weekend routines are expected to differ. A
1-month measure seeks to elicit an estimate by respondents of
their overall adherence. It may be measured using quantitative
or qualitative categories or using a visual analogue scale (VAS)
that asks respondents to indicate how high their adherence was
over the previous month. The VAS provides an ordinal measure
of adherence and allows respondents to express suboptimal

In addition to the topics and open-ended questions that are
suggested in the Adherence Module of the Client Instrument,
qualitative data collection on adherence may include narrative
techniques of asking people about their lives, events that have
occurred since being diagnosed with HIV, their daily routines and
how taking antiretroviral therapy fits into those routines. Narrative
accounts give respondents a chance to identify what factors or
circumstances they consider most relevant to their situation and
to describe social interactions that influence adherence.

4.2 Methods and measures: an overview of the literature
Adherence is frequently assessed based on some form of
observation or patient self-report. Observational methods include
medication event monitoring systems (MEMS — an electronic
pill cap that records when it is opened), pill counts (either
at pharmacy refills or unannounced visits), pharmacy refill
records and directly observed therapy. Self-reported methods use
questionnaires that are either self-administered or administered
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adherence without having to admit to missing specific doses and
may be desirable in some settings. In other settings, carefully
worded questions about different levels of adherence may
facilitate accurate responses.

always be preceded by language that normalizes suboptimal
adherence and gives respondents permission to provide an honest
response, even if it is incongruent with what they perceive as the
ideal behaviour (Simoni et al. 2006a).

Given the potential of self-report measures to overestimate
adherence as a result of desirability bias (whereby respondents
tend to give ideal rather than accurate answers), some studies
combine multiple questions into a composite measure. Scores
based on self-reports have been shown to correlate with virological
and immunological response (Carrieri et al. 2003) and with
clinical progression and mortality (Bouhnik et al. 2005), and this
approach is increasingly used to differentiate between more and
less adherent respondents (Kleeberger et al. 2001).

4.3 Recommended methods and measures

Since there is no gold standard to measure adherence, it is not
possible to recommend a single tool, and it is preferable to include
more than one measure of adherence (Berg and Arnsten 2006). In
addition, optimal measures in research settings are not necessarily
the same as those in clinical settings (Chesney 2006), and some
“tailoring” is necessary for the specific objectives of the project. A
single instrument may include multiple self-report measures, as
well as additional questions about missing pills over the weekend
or during periods of illness, and about treatment interruptions and
discontinuations. Questions on self-reported adherence should

4 Monitor adherence at several points in time. We recommend

For the purpose of the instruments in this volume, we
propose multiple measures that can be combined to provide a
comprehensive view of adherence. These measures are based
on the literature. The selection of measures and methods reflects
our efforts to take account of the situation in resource-limited
countries, where laboratory facilities to measure viral loads are
lacking and where patient outcomes are largely based on clinical
assessments. Specifically, we recommend the following:

monitoring adherence at several points in time, both because
adherence varies over the duration of treatment and because
longitudinal measures make it possible to predict the risk of
virological failure.

4 Use self-reported methods when resources are limited. Selfreports of adherence are likely to be the best option to measure
adherence in resource-limited settings, because they are
inexpensive and relatively easy to collect.

the trade-offs of different methods to measure adherence
method

MEMS (electronic pill cap)

advantages

n
n

disadvantages

Sensitive in detecting nonadherence
Useful for pharmacokinetic studies

n
n
n

Unannounced Pill count

n
n

Relatively easy
Sensitive in detecting nonadherence

n
n
n
n

Pill count at pharmacy refills

n

Relatively easy

n
n
n
n

Pharmacy refill records
(monitoring on-time pick-up)
Directly observed therapy

n

n
n

n
n

Self-report (self-administered
questionnaires or face-to-face
interview)

Relatively easy

n
n

Useful when feasible
Sensitive in detecting nonadherence
(missed visit=missed daily dose)

n

Easy
Sensitivity depends on instrument,
interviewer and general approach, but
can be quite high

n

n
n

n
n
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Costly
Relies on the assumption that pills are taken when,
and only when, the pill cap is removed
Feasible only in specific contexts
Requires accurate knowledge of the number of pills
that a patient should have at a given period
Feasible only in specific contexts
Assumes that patients keep their pills in one location
May violate patients’ privacy and result in involuntary
disclosure if conducted outside the clinic
Requires accurate knowledge of the number of pills
that a patient should have at a given period
Assumes that the patient presents all remaining pills
Not adaptable to all settings
May overestimate adherence
Relies on accurate record-keeping
May overestimate adherence
Costly and time-consuming
Time burden on patient
May violate patients’ privacy and result in involuntary
disclosure
Relies on patients both to recall the pills they have
taken and to report this truthfully
May overestimate adherence if respondent gives the
desirable response
The choice of questions, way of questioning and terms
chosen are crucial
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4 Ask about adherence in multiple ways. In order to reduce the

b. Antiretroviral therapy regimen (prescribed doses)
In order to determine patients’ adherence to their prescribed
antiretroviral therapy, it is important to establish the prescribed
regimen, including the names of the medications and the number
of pills to be taken at different times of day. Unless the interviewers
have access to patients’ medical records, interviewers will need
to ask respondents to identify their prescribed medication. If the
clinic only prescribes a small number of regimens, it may be
possible to obtain the information from a key informant prior to
the interview.

desirability bias, we recommend asking about adherence in
several different ways. A composite measure can be created
in order to differentiate between adherent and nonadherent
respondents.

4 Use a minimum set of core questions to assess adherence and
add more detailed questions if needed. In this chapter, we
propose a core set of questions that appear in the Adherence
Module of the Client Instrument. This chapter also suggests
some additional questions for researchers who need more
detailed information on adherence, for example, during in the
initial phase of treatment when adherence is crucial for the
durability of treatment response.

The following table should be completed according to the
prescribed antiretroviral therapy dosing, not the
respondents’ actual behaviour. This information may be

5. VARIABLES AND SURVEY QUESTIONS

NAME OF MEDICATION

MORNING
DOSE

MIDDAY
DOSE

EVENING
DOSE

DAILY TOTAL

# of pills

# of pills

# of pills

# of pills

1.

The Adherence Modules of the Client and Provider Instruments
in this volume are designed to gather data on the levels and
patterns of adherence to antiretroviral therapy and on factors that
may influence adherence. The rest of this section summarizes
those variables and provides recommendations for constructing
questionnaires.

2.
3.
Source of information above (patient, clinic, medical record, etc.):

obtained from the patient, the provider or the health care
facility. Cross out all non-applicable boxes.

5.1 Variables and survey questions about adherence in
the Adherence Module of the Client Instrument

c. Three-day recall of adherence
A detailed 3-day recall will elicit specific information on which pills
were not taken, as well as whether respondents ever took pills
later than the prescribed time. This exercise requires thorough
training of interviewers. To complete this set of questions, the
interviewers should reference the table that was completed
for the prescribed antiretroviral therapy regimen in order to
complete the names of all medications. They should then walk
the respondents through each of the last three days. To facilitate
recall, interviewers should use memory prompts. For example,
they may first ask respondents to think about yesterday and what
they were doing and if there was anything unique about the day,
before asking whether they took their antiretroviral therapy.

The Adherence Module of the Client Instrument contains
questions that gather data on the following types of variables:
variables in the adherence module
of the client instrument

a.
b.
c.
d.
e.
f.
g.
h.
i.
j.

Length of time on antiretroviral therapy
Antiretroviral therapy regimen (prescribed doses)
Three day recall of adherence
Circumstances of/reasons for nonadherence in the past 3
days
Adherence on weekends
One-month estimate of adherence
Circumstances of/reasons for nonadherence in the past
month
Modifying time that medications are taken
Treatment interruption
Changes in adherence over time

This set of questions should be prefaced by normalizing language
in order to reduce social desirability bias (Vinten 1998). The
normalizing language suggested here has been adapted from
language used in other studies (Simoni et al. 2006a), but should
be piloted and adapted to the study setting. When fixed dose
regimens are used, the table can be simplified by deleting the
first column and including only a single row.

a. Length of time on antiretroviral therapy
Knowing how long the respondent has been taking antiretroviral
therapy helps differentiate between the induction phase (the first
4–6 months) and the maintenance phase of treatment.

Many patients find it difficult to take all their medications as
prescribed. We would not be surprised if you have missed
taking some of your medications over the last few days. We
are trying to find out how difficult it is for patients to take
their medications, and what things make it difficult. Please
answer these questions as honestly as you can about your
own experiences.

How long ago did you first start taking antiretroviral therapy
to manage your HIV?
Number of months ago:
Number of years ago:
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Some people find it difficult to take their antiretroviral
therapy medications on the weekends. Thinking about the
past month, how many times did you miss taking a dose of
your medication on a weekend?
q never
q once
q twice
q three or more times

The following table should be completed according to the
antiretroviral medications that were actually taken over the
last three days. Use memory prompts to facilitate accurate
recall. (“What did you do yesterday morning? Did you take
any HIV medications that morning?” If yes: “Which pills?
How many of each?”) If the respondent reports missing a
pill/dose, circle the cell and assign it a number.

NAME OF MEDICATION

DAY BEFORE
YESTERDAY
YESTERDAY
3 DAYS AGO
# of pills
prescribed # of pills taken # of pills taken # of pills taken

f. One-month estimate of adherence
In order to get a 1-month estimate of adherence, we propose
three options, namely: a single question about how often patients
followed their prescribed antiretroviral therapy regimen over
the previous month, a linear visual analogue scale (VAS) and a
modified VAS. The first option — the single question — may be
preferable for ease of administration, but the VAS may be chosen
because it elicits information on a continuous scale and offers
visual, rather than verbal, response choices. In some contexts, the
linear VAS has been found to be highly correlated with viral load
(Oyugi et al. 2004). The third option, a modified VAS, uses a bead
count that was developed for use in low-resource countries, but
its association with virological outcomes has not been established.
Researchers may want to choose which measure to use for a
1-month estimate based on the results of piloting the instrument
in the particular setting.

1.
2.
3.

d. Circumstances of/reasons for nonadherence in the past 3 days
The reasons for missed doses can be investigated by using openended questions that ask respondents about the circumstances
of and reasons for not taking their medications as prescribed.
Asking about circumstances may elicit better information about
poor adherence than simply asking for the reason(s). As noted
earlier, each time a respondent reports having taken fewer pills
than prescribed, the box should be circled and numbered (e.g.
missed dose #1, missed dose #2). For each circled box, the
interviewer should ask the following questions:

In the linear VAS, interviewers show respondents a line with two
endpoints, where the left end represents “no pills taken” and the
right end represents “all pills taken”. They then ask respondents
to indicate where on the line their own performance fell regarding
pill-taking in the previous one month. The coders will later
measure the marked point in order to estimate the one-month
self-report of adherence. In the modified VAS (Hardon et al. 2006),
interviewers show respondents a jar of beads with the number of
pills they should have taken the previous month. For example,
if a respondent should have taken one pill twice a day, the jar
will include 60 beads. The respondents are asked to transfer
the beads to another jar to indicate the number of pills they
actually did take in the previous month. The proportion of beads
transferred from one jar to the other represents the estimated
1-month self-report of adherence. Visual analogue scales are
useful for obtaining an overall measure of adherence.

What circumstances led you to miss taking your medication
as recommended on (name the day and the medication
missed as identified in the previous question)? Probe for
what happened and why.
Missed Dose #1
Missed Dose #2
Missed Dose #3
(etc.)
e. Challenges adhering on weekends
Information on adherence on weekends can help differentiate
between adherent and nonadherent patients, since changes in
routine make it more difficult to keep to the prescribed regimen.
Again, the question is prefaced with normalizing language
in order to facilitate disclosure of poor adherence. Additional
information can be elicited using an open-ended question about
what happened.
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h. Modifying the time that antiretroviral therapy medications are
taken
The Adherence Module also contains detailed questions about
whether respondents have ever taken multiple doses of their
medication at one intake, for example:

Three ways to ask about 1-month estimates of adherence
Question about 1-month adherence
We know that it is difficult to take all your antiretroviral therapy just as
the doctor prescribed. Would you say that in the past month you:

q
q
q
q
q

During the past month, how often did you take a double dose
of ART medication after missing a dose?
q never
q once
q sometimes
q frequently

totally followed prescriptions
generally followed prescriptions but with some deviations
often modified timing and quantities
almost never followed prescriptions
interrupted treatment

Linear visual analogue scale

Researchers may also want to ask respondents whether they
have medications that are supposed to be taken more than once
a day. If they say yes, then the interviewer can ask: “At any point
during the past month, did you ever take all your daily doses of
this (these) medication(s) in one intake?” The survey instrument
can then ask about how often this occurred.

Now I would like to ask you to estimate how much of your prescribed
ART you took in the previous month. It is not likely that most people
would take all of their doses. A mark at the left end where there is a
number zero means you have taken no ART medications. A mark in the
middle means you have taken about half of your ART medications. A
mark on the right end where you can see the number ten means you
have taken every single dose of your ART medications. Please put a
mark on this line somewhere between zero and ten to describe your
best guess about how much of your prescribed ART you took in the
previous month.

0

i. Treatment interruption
The Adherence Module in the Client Instrument measures
treatment interruption by asking whether a respondent ever
interrupted treatment during the previous six months, and if so,
for how long. As noted earlier, evidence suggests that interrupting
treatment for at least 48 consecutive hours increases the risk of
resistance to nevirapine and probably to other NNRTIs (Oyugi
et al. 2007). These questions are followed by an open-ended
question about the circumstance that led to the respondent
interrupting treatment.

10

Modified visual analogue scale using beads
This jar of beads represents the number of pills you were supposed to
take last month. I want you to move the beads to this jar to represent
the number of pills you swallowed last month. In other words, if you
swallowed only half your pills you would move half the beads into this
jar. Or, if you swallowed all the pills you would move all the beads into
this jar. We would not be surprised if you missed some of your pills in
the previous month.

During the past six months, did you ever stop taking your
antiretroviral therapy for 48 hours or longer?
If yes: How long did you stop taking your antiretroviral
therapy?
q for more than 48 hours and less than a week
q from one to two weeks
q for more than two weeks and less than one month
q for more than one month

g. Circumstances and reasons for nonadherence in the past
month
The Adherence Module of the Client Instrument asks respondents
about the circumstances that led to missed and mistimed doses
of their antiretroviral therapy. In addition, it contains the following
three open-ended questions to gather qualitative information
on barriers to adherence and the factors that make it easier for
patients to achieve adherence:

j. Changes in adherence over time
Survey items can also be used to gauge changes in adherence
over time. For example, the linear VAS can be used to ask
respondents who have been on treatment for at least 2 months to
recall the first month when they started treatment and to estimate
their adherence level as follows:

Open-ended questions about circumstances that
influence adherence

Thinking of the first month when you started
antiretroviral therapy, please put a mark on this line to
describe your best guess about how much you followed
prescriptions.

n In general, what helps you take your medications on time?
n In the past month, what circumstances led you to miss taking your
pills on time?

n What other things make it difficult to take all your medications on
time?
0
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5.2 Variables and survey questions about factors that
influence adherence

Examples of survey questions on social support

To identify the factors that influence adherence, we suggest the
following variables to be considered in operational research.
The variables that researchers choose in a particular setting
will depend on the type of epidemic and common modes of
transmission in the study sites. For example, researchers may
want to include a module on drug use where appropriate (see the
Prevention chapter for more information). In addition, formative
research, anecdotal evidence and programme experiences
may suggest other variables for inclusion. Unless indicated,
the questions below are intended to be answered by patients
currently taking antiretroviral therapy.

n Does your partner/spouse know that you are taking antiretroviral
therapy?

n Is there any other adult in your household who does not know you
are taking antiretroviral therapy?

n Is it ever difficult for you to take your medications when someone
from your family can see you?

n Is it ever difficult for you to take your medications when someone
from your community or your workplace can see you?

n Is there anyone who regularly reminds you to take your
antiretroviral therapy?

n During the past month, have you ever not taken your antiretroviral
therapy because you did not want someone to find out?

variables related to factors that may
influence adherence in the client instrument

a.
b.
c.
d.
e.
f.
g.
h.

c. Access to the clinic
The Adherence Module of the Client Instrument contains two
core questions on access to the clinic, including a question about
whether respondents have ever been unable to get to the clinic
and a question about whether cost has ever been a barrier to
adherence. Researchers who have a particular interest in access
to care may want to gather more detailed information about how
often respondents are supposed to go to the clinic, what form of
transportation they use, how long it takes to reach the clinic and
how much it costs to get there. It may also be possible to find
out some of this information from a key informant, such as how
often most patients are supposed to come to the health facility.
Examples of more detailed questions about access that are not
included in the Adherence Module but may be useful include
the following:

Demographic variables [in the Sociodemographic Module]
Social support
Access to the clinic
Food security
Health status
Perceived side-effects
Perceived changes to the body
Additional variables, such as depression and drug use
(optional)

a. Demographic variables
Demographic variables, such as the respondent’s sex, age,
education level and marital status, are clearly important for
understanding the broader context that may influence adherence,
as are variables such as socioeconomic status, income-generating
activities and food security. Questions for gathering information on
these types of variables can be found in the Sociodemographic
Module of the Client Instrument.

Examples of survey questions about access
Survey questions on access in the Client Instrument

b. Social support
The following questions on social support appear in the Adherence
Module of the Client Instrument. Many of these close-ended
questions are followed by the question: “Please tell me about
this”. These questions are closely related to disclosure, which
is discussed at more length in the previous chapter on HIV
Stigma.

n In the past year, have you ever had problems getting your
antiretroviral therapy on time because you were not able to reach
the clinic? If yes: Please tell me about this.
n During the past year, has the cost of medications or the cost
of clinic care ever interfered with your ability to get your
antiretroviral therapy or take your medications on time? If yes:
Please tell me about this.

Researchers with a particular interest in social support may wish
to add another question about social support that is not included
in the Client Instrument: “If you were sick in bed, is there anyone
who would bring you food?” If the answer is yes, then the interview
can ask: “Please tell me about this person”.

Examples of other possible survey questions on access

n How often do you need to get to the clinic to obtain your
medications or meet with a health care worker regarding your
treatment?
n What form of transportation do you use to get from your home to
the place where you get your antiretroviral therapy? (response
options should be adapted for the setting)
n How long does it normally take you to get from your residence to
the place where you get your antiretroviral therapy?
n How much does it cost you to get from your residence to the place
where you get your antiretroviral therapy?
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d. Food security
The Adherence Module of the Client Instrument contains one
closed-ended and one open-ended question about food security,
as follows: “During the past month, have you missed a dose of
your antiretroviral therapy because you did not have enough
food?” If the respondent says yes, then the interviewer can
ask: “Please tell me about this”. Researchers who want more
information about the relationship between food security and
adherence my may use the questions about food security from
the Sociodemographic Module of the Client Instrument (noted
below) or add additional items on this topic.

Survey questions about side-effects

n Some people experience side-effects when they take antiretroviral
therapy. This varies a great deal – some people have a few, while
others have more. Have you experienced any side-effects since
you started taking ART?

n If yes, Which side-effects have been the most bothersome?
n Can you please tell me more about these side-effects?
		
n I’m going to read you a list of side-effects. Please tell me whether
you have experienced any of these side-effects in the past month.
Read list.

During the past month, how often have you had problems
getting the food you need?
q never
q sometimes
q often
q always
If yes: Please tell me about this.

n For each side-effect that the respondent reports: Has this sideeffect been very bothersome, somewhat bothersome or not at all
bothersome?

e. Health status
Questions about how respondent rate their health before and after
they began antiretroviral therapy make it possible to measure
the effect of antiretroviral therapy on patients’ lives. The two
questions below appear in the Adherence Module. They are
designed to to obtain this information efficiently. More developed
scales are available, however, for researchers who want more
detailed information on this topic, including, for example, the
SF-12v2(TM) Health Survey (Ware et al. 2002).

g. Perceived changes to the body
In addition to the side effects, it is also important to ask
respondents about changes in the appearance of the body. The
Adherence Module contains questions about body changes that
have a similar structure to the questions about side-effects. The
instrument provides a list of commonly reported body changes.
Researchers may want to modify that list based on the results of
formative research.
Survey questions about perceived changes to the body

How would you rate your health before starting antiretroviral
therapy?
q excellent
q very good
q good
q fair
q poor

n Since you started taking ART, have you experienced a change in
the way your body looks? If yes: Can you tell me what changes you
have experienced?

n In the past month, have you experienced any of the following.
Read list.

And now that you are on antiretroviral therapy, how would
you rate your health?
q excellent
q very good
q good
q fair
q poor

n For each change that the respondent reports: Has it been very
bothersome, somewhat bothersome or not at all bothersome?

n Of all the body changes that we have just discussed, please tell me
more about the changes that are the most bothersome for you?
Probe for the top 2 or 3.

f. Perceived side-effects
To understand adherence, it is important to ask about both
patients’ experienced side-effects and the influence that sideeffects have had on patients’ daily lives, as illustrated by the
questions in the next box. The Adherence Module contains a list
of symptoms to be read to respondents. This list was adapted
from the AIDS Clinical Trials Group (ACTG) baseline questionnaire
(Chesney et al. 2000), from the Justice checklist (Justice et al.
2001) and from other sources of information about side-effects
related to antiretroviral therapy such as lipodystrophies (Duran et
al. 2001). Researchers may want to modify this list of side-effects
based on the results of formative research.

h. Additional variables
Researchers may consider investigating other variables in addition
to those that are included in the Adherence Module, depending
on their particular interest and the context where their studies
are being carried out. Possible variables of interest may include
the following:

4 Depression. Depressive symptoms can be assessed by selfreport measurement tools such as the CES-D scale (Radloff
1977).
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4 Drug use. In settings where drug use represents an important

c. Frequency that patients need to come to the clinic
When antiretroviral therapy regimens are fairly standard, it may
be possible to ask a key informant in the health care facility how
frequently patients needs to come in to receive their medications.
This variable may add to an understanding of barriers to access
as a factor that may influence adherence.

route of HIV transmission, modules can be added to measure
the extent to which respondents are injecting drugs or involved
in related types of high-risk behaviours. More information on
asking about drug use can be found in the Prevention chapter
in this volume and in the Alcohol and Drug Module of the
Client Instrument.

5.4 Variables and survey questions for providers
In addition to key informant interviews, researchers may want
to interview health workers who provide services to patients
taking antiretroviral therapy. The Provider Instrument in this
volume contains an Adherence Module for that purpose. The
key variables addressed by this module are presented in the
box below:

5.3 Variables and survey questions for key informants
working in the health facility
Researchers may want to gather information on possible factors
that influence adherence by reviewing records or interviewing
key informants in health care facilities that provide HIV treatment
and related care.

key variables in the adherence module of the
provider instrument

additional variables related to adherence to
be gathered from key informants or clinical or
pharmacy records

a.
b.
c.
d.

Type of interaction with ART patients
Perceived effectiveness of adherence counselling
Provider practices related to ART service delivery
Perceptions about how well ART patients manage to take
their medication
e. Perceptions of difficulties experienced by patients in
taking pills on time

a. Reliability of the antiretroviral therapy supply
b. Cost of treatment
c. Frequency that patients need to come to the clinic for
medication and other care

a. Reliability of antiretroviral therapy supply
To investigate the reliability of antiretroviral therapy supply,
researchers can ask clinic administrators or pharmacists whether
the first-line or second-line antiretroviral therapy regimens
prescribed in the clinic have ever been out of stock or unavailable
for any reasons when patients needed them during the past year.
If respondents say yes, then researchers can follow up with a
question such as: “Please tell me about this”.

The Adherence Module of the Provider Instrument contains
some detailed questions about provider practices, including
whether the provider is involved in adherence counselling, the
type of information they give to patients and the frequency and
methods used to assess adherence. The module also contains
questions about how many of their patients report problems with
adherence (of different types), and what the providers perceive
to be the underlying reasons why their patients sometimes have
problems adhering to treatment.

b. Cost of treatment
To investigate the cost of treatment, researchers may ask clinic
administrators, providers or other key informants in the facility:
“What is the typical cost of antiretroviral therapy per month at this
clinic?” In addition, researchers may want to ask about additional
costs that antiretroviral therapy patients must incur in order to
receive treatment at the facility.
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CHAPTER 4
HIV PREVENTION IN THE CONTEXT OF
SCALED-UP ACCESS TO HIV TREATMENT
1. BACKGROUND

The primary objective of research proposed in this chapter is to
document sexual risk behaviours among HIV-positive individuals
receiving health services in order to: a) learn from comparisons
across programmes, countries, regions or time periods about
the factors that influence high- or low-risk behaviours; b)
gather information to inform behaviour change communication
strategies; and c) identify gaps in service delivery. Researchers
who want to track changes in sexual behaviours among individuals
receiving treatment or to evaluate the effectiveness of prevention
interventions may be able to use the tools in this volume for that
purpose with some adaptation.

1.1 Rationale: why research is needed on HIV prevention
among those receiving ART
As HIV treatment programmes scale up across countries, more
attention is being directed to the implications of greater access
to antiretroviral therapy for HIV prevention, and it is important to
assess the potential for both positive and negative consequences.
New antiretroviral therapy regimens improve longevity and the
quality of life of individuals with HIV, and they have the potential
to reduce HIV transmission by suppressing viral loads among
people living with HIV (Granich et al. 2008). Greater access to
treatment can also lower stigma and raise awareness of HIV,
thereby encouraging people to seek testing and adopt preventive
behaviours. But greater access to treatment may also increase
the number of sexually active individuals infected with HIV, as
antiretroviral therapy restores health and extends lifespans, leading
to a growing pool of individuals who could potentially transmit
HIV. In addition, some evidence suggests that the availability of
effective treatment in some settings has reduced concerns about
HIV transmission and contributed to an increase in high-risk sexual
practices, such as unprotected sex or multiple partners (Cohen
2005; Cassell et al. 2006). Documenting and studying the complex
links between treatment and prevention has, therefore, become a
priority issue for antiretroviral therapy programmes.

2. FACTORS AND PROGRAMME STRATEGIES
2.1 Factors that influence HIV prevention in the context of
scaling up treatment
The implications of treatment for HIV prevention is a complex
issue that involves biomedical, demographic and behavioural
factors, some of which are summarized below.
Biomedical factors that influence prevention
Antiretroviral therapy may influence sexual transmission of HIV in
a number of ways. First, treatment that suppresses viral loads to
undetectable levels may reduce but not necessarily eliminate the
risk of sexual transmission of HIV infection (Quinn et al. 2000).
Shedding of HIV continues in some patients, possibly related to
a separate reservoir of infection (Kovacs et al. 2001; Barroso et
al. 2003; Fiore et al. 2003; Zuckerman et al. 2004) or to the type
of antiretroviral therapy regimen (Neely et al. 2007), and the risk
of HIV transmission or re-infection remains.

Research on HIV prevention typically relies on behavioural
surveillance surveys, Reproductive Health Surveys and
Demographic and Health Surveys that focus on the general
population or key populations at higher risk of HIV, such as
men who have sex with men. A small but growing number
of population-based surveys have gathered data to analyse
behaviours in relation to respondents’ serostatus, such as the
2004–2005 Uganda HIV/AIDS Sero-Behavioral Survey (Bunnell et
al. 2008). Such research designs are key to monitoring trends at
the population level. By contrast, this chapter focuses on groups
whose behaviours may be influenced by the scaling up of HIV
treatment. These groups include: patients receiving antiretroviral
therapy and HIV-positive individuals who are not receiving
treatment (e.g. those who are ineligible to initiate treatment or who
are on waiting lists). Other populations of interest to operational
research projects may include partners of individuals receiving
treatment or users of testing and counselling services who test
negative.

Moreover, as discussed in the Adherence chapter, inappropriate
treatment or poor adherence may result in incomplete viral
suppression and the development and transmission of drug
resistant viral strains (Paterson et al. 2000; Bangsberg and Deeks
2002). In fact, several studies suggest a relationship between
poor adherence and higher risk sexual behaviours (Wilson et al.
2002; Flaks et al. 2003; Kozal et al. 2004), which underscores
the need to document sexual risk behaviour among HIV-positive
individuals receiving treatment.
Another biomedical factor that may influence HIV transmission is
the eligibility criteria used to determine who receives antiretroviral
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The influence of treatment availability on risk perceptions and
sexual behaviour
At the community or population level, there are various hypotheses
regarding the effects of treatment availability on risk perceptions,
attitudes and behaviours related to HIV transmission. On the one
hand, expanding treatment availability may increase knowledge
and awareness of HIV and give people a greater sense of control
over their lives, resulting in risk avoidance and reduced HIV
transmission. On the other hand, increased access to treatment
may reduce concerns about unprotected sex, if people believe
that treatment lowers the risk of transmission or the negative
consequences of HIV infection (Valdiserri 2004).

therapy. In general, while HIV infectivity in a community may
decline as antiretroviral therapy programmes scale up (Fang et al.
2004; Porco et al. 2004), some researchers argue that increased
access to treatment is unlikely to reduce HIV incidence if eligibility
criteria substantially limit the proportion of HIV-positive individuals
who can initiate treatment (Auvert et al. 2004; McClelland et al.
2006). Mathematical models suggest that universal testing could
drastically cut HIV incidence, but only if treatment were given
to all who test positive, not just those who meet strict clinical
or immunological eligibility requirements (Granich et al. 2008).
These analyses underscore the need to strengthen behaviour
change prevention efforts among individuals who are HIV-positive
but not receiving antiretroviral therapy.

While research does not support the notion of ‘behavioural
disinhibition’ among individuals receiving treatment, evidence
from high-income settings does suggest that expanded access
to treatment may be associated with increased sexual risk
taking. For example, studies among men who have sex with
men in Australia, the Netherlands, the United Kingdom and the
United States found that unprotected sex increased in those
populations after antiretroviral therapy became widely available
(CDC 1999; Dodds et al. 2000; Stolte et al. 2001; Wolitski et
al. 2001; Chen et al. 2002; Katz et al. 2002; Van de Ven et
al. 2002). High-risk sex may have increased in those settings
because treatment availability lowered concerns about the risk of
HIV transmission and the negative consequences of contracting
the virus. For example, rates of multiple partners, unprotected
sex and inconsistent condom use were found to be significantly
higher among those who believed that antiretroviral therapy
lowers infectivity (Van de Ven et al. 1999; Herlitz and Steel 2001;
Suarez et al. 2001; Wilson and Minkoff 2001; Elford et al. 2002;
Ostrow et al. 2002; Stolte et al. 2004). Similarly, a meta-analysis
by Crepaz et al. (2004) found that rates of unprotected sex
were significantly higher among respondents who believed that
treatment availability had reduced the risk of HIV transmission
or the seriousness of contracting the virus — regardless of their
treatment or serostatus.

Sexual risk behaviour among those receiving antiretroviral
therapy
Individuals receiving treatment may resume sexual activity as they
recover their health and normal functioning. Some researchers
and policy makers have raised concerns that wider access to
antiretroviral therapy might lead to increased high-risk sexual
behaviour — a phenomenon sometimes called “behavioural
disinhibition” or “risk compensation” (Cohen 2005; Cassell et
al. 2006). Many studies from Europe and the United States have
examined whether HIV treatment leads to increased sexual risk
behaviours among individuals receiving antiretroviral therapy. A
few studies have reported an association between immunological
or virological improvements and sexual risk behaviours (or proxy
measures such as STI rates) among men who have sex with
men and injecting drug users (Martin et al. 2001; Scheer et al.
2001; Tun et al. 2004). However, most research has not found
a consistent or significant association with risk behaviour, even
when patients achieve an undetectable viral load (Dukers et al.
2001; Bouhnik et al. 2002; Vanable et al. 2003; Wolf et al. 2003;
Crepaz et al. 2004; Diamond et al. 2005).
Nevertheless, studies suggest that a substantial minority of
patients receiving treatment are sexually active, and some engage
in unprotected sex. Even if receiving treatment does not increase
levels of unprotected sex, antiretroviral therapy may still increase
the risk that those patients who do engage in unprotected sex
will transmit a drug resistant strain of the virus. Surveillance data
from the United Kingdom suggest that the proportion of new
HIV infections that involve a drug resistant strain has increased
between 1994 and 2000, accounting for an estimated 27% of
new infections in 2000 (Fidler et al. 2001; Cassell et al. 2006).

Research is currently underway to examine whether treatment
availability is linked to behavioural disinhibition in low- and
middle-income countries. Little has been published at the time
this volume is going to press, but one study suggests that this is
not the case (Bunnell et al. 2006b).
Other factors that influence sexual behaviour among those living
with HIV
Based on the vast literature on sexual behaviour and its
determinants, this section summarizes other key factors that
should be considered when investigating high-risk sexual
behaviour in the context of scaling up treatment for HIV. These
include:

Only limited evidence is available from low- and middle-income
countries, but a number of studies from Côte d’Ivoire, Kenya,
South Africa and Uganda have generally failed to find significant
increases in high-risk sexual behaviour among individuals
receiving antiretroviral therapy (Moatti et al. 2003; Bateganya
et al. 2005; Bunnell et al. 2006a; Kennedy et al. 2007; Eisele et
al. 2008a; Eisele et al. 2008b; Luchters et al. 2008; Sarna et al.
2008). Thus, while existing research does not support the notion
of disinhibition, the limited evidence suggests that measuring
behaviour change and HIV prevention efforts among those
receiving treatment remains a high priority.

4 Number and type of partners. Some studies suggest that the
number of partners, the number of recent sexual encounters
and the types of sexual partners are associated with unprotected
sex (Wenger et al. 1994; Hays et al. 1997; Grulich et al. 1998;
Heckman et al. 1998; Wilson et al. 1999; Semple et al. 2000;
Crepaz and Marks 2002). Many prevention programmes
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have considered sex worker and casual partnerships to be
higher risk than regular partnerships. In the context of HIV
prevention among people living with HIV, however, regular
partnerships pose a particular risk when the regular partner is
HIV-negative and when condom use is low. Evidence from subSaharan Africa suggests that many HIV-positive individuals
are married to or living with HIV-negative partners (Dunkle et
al. 2008). In addition, unprotected sex is common in regular
partnerships, even when couples are serodiscordant or the
partner’s serostatus is unknown (Bunnell et al. 2006a).

increased the likelihood of unprotected sex among HIV-positive
women in studies from Brazil (Kerrigan et al. 2006), India
(Sri Krishnan et al. 2007), Togo (Moore and Oppong 2007),
Uganda (Nakayiwa et al. 2006) and the United States (Crepaz
and Marks 2002).
The evidence for some of these associations is somewhat circular,
in that the outcome variable — high-risk behaviour — is not
always clearly separate from independent variables, such as
number of partners or lack of control. Nevertheless, these factors
need to be taken into account in operational research on the links
between sexual behaviour and HIV treatment.

4 Concurrent partners. There is evidence that sexual concurrency
(having more than one sexual relationship at the same time)
is a more important predictor of STI transmission than the
number of partners. This has been shown in theoretical sexual
network models (Watts and May 1992; Kretzschmar 2000) and
confirmed in epidemiological studies (Morris and Kretzschmar
1997; Potterat et al. 1999; Rosenberg et al. 1999; Koumans
et al. 2001).

2.2 Programme strategies related to HIV prevention in the
context of treatment
While most HIV programmes include some information on
prevention when counselling clients who are tested for HIV or
who receive treatment, prevention is not always systematically
integrated into HIV treatment services. Messages about
prevention are typically delivered at the initiation of treatment
and infrequently thereafter; and follow-up visits typically focus on
adherence and management of side-effects with little emphasis
on preventing transmission. Some observers have noted that this
represents a missed opportunity for providers to encourage safer
behaviours and to empower people living with HIV to persuade
others to avoid risks.

4 Partner serostatus and viral load. Partner serostatus also
influences sexual risk behaviour. HIV-positive men and women
were significantly more likely to engage in unprotected sex with
seroconcordant partners in studies from both developed and
developing countries (Crepaz and Marks 2002; Hong et al.
2006; Kiene et al. 2006; Kiene et al. 2008). Similarly, research
from the United States found that HIV-negative men who have
sex with men were more likely to engage in unprotected sex
with an HIV-positive partner if that partner had an undetectable
viral load (Guzman et al. 2006). It is noteworthy, however, that
a number of recent studies from sub-Saharan Africa suggest
that a substantial proportion of patients receiving treatment
do not know the serostatus of their partner (Bunnell et al.
2006a; Simbayi et al. 2007; Luchters et al. 2008; Sarna et al.
2008).

A number of studies in the United States have found that
individual or small group counselling was associated with
reports of reduced unprotected sex among those living with HIV
(Kalichman et al. 2001; Rotheram-Borus et al. 2001; Patterson
et al. 2003; Sorensen et al. 2003; Richardson et al. 2004;
Wingood et al. 2004; Kalichman et al. 2005; Wolitski et al. 2005).
In most cases, these programmes were designed to provide
skills, to raise awareness of the risks of HIV transmission and to
address behavioural issues related to treatment and prevention.
A meta-analysis of controlled trials in the United States found
14 interventions that significantly reduced unprotected sex
(Crepaz et al. 2006). Most were based on behavioural theory
and addressed a range of issues (coping, adherence, etc.)
but focused extensively on specific skills and behaviours. In
addition, most were delivered on a one-to-one basis by health
care providers or professional counsellors and involved at least
10 sessions over three months.

4 Knowledge and attitudes about HIV and AIDS. Unprotected
sex among HIV-positive individuals has been found to be
associated with less knowledge about HIV and transmission
(Wenger et al. 1994; Muller et al. 1995; Huszti et al. 1998;
Derlega et al. 2006), with beliefs that condoms decrease
sexual pleasure (Kline and VanLandingham 1994; Hays et
al. 1997), with little commitment to self or others (Godin et
al. 1996; Kalichman et al. 1997), and with perceived lack
of control and lower confidence in one’s ability to negotiate
condom use (Crepaz and Marks 2002).

A meta-analysis of studies from developing countries between
1990 and 2005 found evidence that client-initiated testing
(commonly called VCT) may have a moderate but significant
positive effect on prevention (Denison et al. 2008). Specifically,
individuals who had received VCT were significantly less likely
to engage in unprotected sex after being tested, compared with
their behaviour before testing and compared with participants
who had not received client-initiated testing; however, the metaanalysis found no significant effect on the number of sex partners
(Denison et al. 2008). This review underscores the potential for
client-initiated testing as a prevention strategy, but also the need
for more evidence. For example, as mentioned in the chapter on

4 Disclosure. While Crepaz et al. (2002) did not find an
association between disclosing HIV status and lower condom
use, recent studies have found an association between nondisclosure and rates of multiple partners and unprotected
sex in some settings (Olley et al. 2004; Carballo-Dieguez et
al. 2006; Derlega et al. 2006; Kiene et al. 2006; Simbayi et
al. 2007). More research may be needed to sort out these
inconsistent findings.

4 Desire for children. Living with a sexual partner and a male
partner’s desire for children were found to be factors that
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Testing and Counselling in this volume, recent studies from the
United States and Zimbabwe (neither of which was included in
the meta-analysis mentioned above) reported that high-risk sex
increased following rapid HIV testing among men who tested
negative (Metcalf et al. 2005; Corbett et al. 2007).

can be successfully integrated into treatment services and which
strategies are most effective in different settings.

Since 2005, there have been a few additional studies in subSaharan Africa that have examined efforts to integrate HIV
prevention into services for people living with HIV (Kalichman
2007). For example, prevention efforts by the TASO programme
in Uganda significantly reduced levels of unprotected sex among
those living with HIV (Bunnell et al. 2006a; Were et al. 2006).
Community health workers developed individualized risk reduction
plans with goal setting, encouraged and facilitated disclosure and
partner testing, and in some places provided HIV tests at home
for family members. (These results are similar to an earlier study
in Zambia where home-based services, partner HIV testing and
couple counselling among patients receiving antiretroviral therapy
were found to reduce high-risk sexual behaviours (Allen et al.
2003).) A recent study from South Africa reported that a brief
risk reduction intervention delivered by counsellors during routine
clinical care visits led to a significant decline in unprotected
sex among those receiving the service compared with those
in the control group (Cornman et al. 2008). And, a large HIV
prevention trial has begun among discordant couples in eastern
and southern Africa (Lingappa et al. 2008). More research is
needed to examine the extent to which these prevention services

As noted earlier, the objective of the research proposed in this
chapter is to document sexual risk behaviours among specific HIVpositive populations, with the goal of identifying gaps in service
delivery, designing prevention programmes or behaviour change
communications strategies and/or comparing programmes.
Possible research questions and hypotheses relevant to sexual
risk behaviours in the context of scaling up HIV treatment are
given in the box below.

3. RESEARCH OBJECTIVES AND QUESTIONS

The first two research questions require comparisons of HIVpositive individuals who are receiving treatment with those
who are not, or before-and-after comparisons of the same
individuals over time. (Note, however, that the former design
presents a challenge, as researchers must ensure that control
and study groups are comparable and that they do not compare
healthy controls with symptomatic study group participants.) The
third research question applies to a broader study population,
including individuals who are HIV-positive but are not yet receiving
treatment. The fourth research question can be investigated by
asking health workers about their practices and by asking users
of health services about their experiences. The fifth research

operational research questions about hiv prevention
in the context of scaling up treatment

1. To what extent is receiving antiretroviral therapy associated with a change in levels of sexual activity (a resumption, an increase, an
interruption or a reduction of sexual activity)?
Hypotheses:
n Sexual activity among HIV-positive individuals increases/decreases/stays the same after initiating antiretroviral therapy.
n Sexual activity among HIV-positive individuals increases/decreases/stays the same with increased duration of antiretroviral
therapy.
2.	To what extent is receiving antiretroviral therapy associated with high-risk sexual behaviour (such as unprotected sex)?
Hypotheses:
n High-risk sexual behaviour increases/decreases/stays the same after initiating antiretroviral therapy.
n High-risk sexual behaviour increases/decreases/stays the same with increased duration of antiretroviral therapy.
3.	To what extent are knowledge, perceptions or attitudes about HIV and HIV treatment associated with high-risk sexual behaviours?
Hypotheses:
n Individuals who have limited knowledge of HIV transmission are more likely to report high-risk sexual behaviours, such as
unprotected sex.
n Individuals who believe that receiving treatment or achieving undetectable viral loads reduces or eliminates the risk of HIV
transmission are more likely to report high-risk sexual behaviours.
n Individuals who are excessively optimistic about antiretroviral therapy or who express lower concern about HIV in light of
treatment availability are more likely to report high-risk sexual behaviours.
4.	To what extent are prevention services integrated into HIV treatment services?
5.	To what extent do prevention services (delivered in the context of treatment) reduce high-risk sexual behaviours among HIV-positive
clients?
Hypotheses:
n Patients receiving prevention services in the context of HIV treatment will report fewer high-risk sexual behaviours than those who
do not receive these services.
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4.2 Measuring sexual risk behaviour

question would be relevant when seeking to evaluate the effects of
prevention strategies integrated into treatment services; however,
investigating this question may require more complex study
designs than those proposed in this volume.

Sexual risk behaviour has been documented through many
behavioural surveys conducted among general populations,
as well key populations at higher risk. Reviews of validity and
reliability of such research have found that sexual behaviour
data are fairly consistent (Aral and Peterman 1996; Crosby 1998;
Fenton et al. 2001; Wellings and Cleland 2001), and that selfreported data from partners about sexual acts and condom use
are reasonably congruent, especially for infrequent acts and short
recall periods (Ellish et al. 1996; Shew et al. 1997; Stone et al.
1999; Weir et al. 1999; Obermeyer 2005). Quantitative indicators
of risk behaviours may indicate the magnitude or direction of
changes over time, but they provide limited information on the
context of or reasons for high-risk behaviours. Qualitative data
can improve the quality of self-reports by providing information on
the context in which sexual risk behaviour takes place (Amon et
al. 2000). The variables in the box below have been used widely
to measure sexual risk behaviour in prevention studies because
they have a direct influence on sexual HIV transmission.

4. METHODS
4.1 Study populations and study design
The primary population groups to be studied for prevention
studies in the context of scaling up HIV treatment may include:

4 patients with a diagnosis of HIV who are receiving antiretroviral
therapy;

4 people living with HIV who are not on treatment but are
accessing services or are on waiting lists;

4 individuals who have used HIV testing and counselling services
may be used as a comparison group, depending on the design
of the study; and
4 health care providers and administrators working in HIV
testing, counselling and treatment programmes.

In addition, researchers may need to gather information about
knowledge of HIV infection and its transmission, attitudes about
condom use, personal risk perceptions, relationships with
partners and respondents’ ability to negotiate condom use.
For such variables, both quantitative and qualitative data are
recommended.

Ideally, prevention research should integrate both quantitative and
qualitative data collection methods in order to monitor changes
in behaviour as well as to gather an in-depth understanding
of the context in which these behaviours take place. Possible
study designs may include repeated cross-sectional surveys
among different study populations at different points in time.
For example, researchers may conduct cross-sectional surveys
among HIV-positive individuals before and after initiating
treatment and at different points in time thereafter. They may also
compare treated versus untreated HIV-positive individuals. With
some adaptation of the instrument, researchers could compare
individuals who have been tested with those who have not, or with
general population groups according to treatment availability and
coverage in different settings.

Operationalizing variables, populations of interest and recall
periods
Researchers studying HIV prevention in the context of treatment
may need to consider the following methodological points:

4 Asking respondents to categorize their sexual partners presents
important methodological challenges. Many studies have used
categories such as regular, casual and commercial sexual
partners. Regular partners are often defined as spouses or

widely used variables for measuring sexual risk behaviour
n

Multiple partners. Multiple partners can be measured by asking about the number of sexual partners during a defined reference period.

n

Concurrent partners. Concurrent partners are overlapping sexual partners. Concurrency can be measured by asking for the dates that
partnerships began and ended or, less specifically, by asking about multiple partnerships over a short but defined reference period.

n

Type of sexual partners. Partners may be categorized in different ways, such as regular, non-regular (casual) and sex workers. Categories
of male and female partners can be explored separately or together, depending on the study objectives and the extent to which men have
sex with men in the community being studied.

n

Condom use. Condom use is the key variable when studying sexual risk behaviour. Information on condom use is most often elicited with
regard to condom use during the last sexual act (for which recall is expected to be accurate for a realistic time frame) and consistent
condom use (use of condoms every time during the reference period). This information can be asked with respect to a particular partner or
all partners depending on study objectives and design.

n

Proportion of unprotected sexual acts. The proportion of penetrative sexual acts (anal and vaginal) in which neither partner used a
condom can be sought for different sexual partners and various sexual acts.
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co-habiting partners, but in some cultural contexts, researchers
may want to use a broader definition that includes long-term
partners, even if the couple is not married or cohabiting. Sex
worker partners are generally defined as sexual partners who
are paid in exchange for sex, but patterns of exchange of sex
for money or gifts are complex and the definition is not easy
to operationalize. Some researchers classify sex workers as
casual partners for convenience, however, this may lead to a
loss of information. Non-regular or casual partners are often
defined as those who are not regular partners and are not sex
workers. The categories of sexual partnerships commonly used
by researchers are complex and pose a major measurement
challenge, since they may not match local understanding and
may not translate well into different languages (UNAIDS 2007).
To avoid confusion, researchers may want to explore local
categories and terms for different types of partnerships before
finalizing the wording of their questionnaires. They will also
need to carefully explain these categories to respondents.

3 months, but researchers can modify this to 6 or 12 months,
depending on the needs of the particular study.

4 Separate research instruments or questionnaire sections may be
needed for men and women. It may sometimes be appropriate
to divide the data collection instrument into different sections
for men and women respondents to make it easier to seek
responses related to same sex sexual partners (men who have
sex with men). If the same instrument is used for both men
and women, careful skip patterns may be needed.

4 Interviewers need special training to gather data on sexual
behaviour. Training is necessary to ensure that interviewers can
build rapport with respondents, conduct interviews in a nonjudgemental manner and elicit accurate responses on sensitive
subjects. Training on other ways to collect sensitive data such
as ACASI (audio computer-assisted self-interviewing) may also
be desirable.

4 Researchers can gather information on each sexual partner

4 Studies of sexual behaviour among HIV-positive respondents

individually, or by asking about all partners of a specific type
during a certain time period. There are two approaches to
collecting data on sexual partners in prevention studies. One
approach is to collect information about each individual sexual
partner in the order that the sexual encounters occurred
during a specified reference period. Researchers can decide
how many partners are to be included depending on the study
objectives. For example, sexual network studies often focus on
the last three sexual partners (Laumann et al. 2004; Morris et
al. 2004), while studies examining the risk of HIV transmission
may focus on all sexual partners during a fixed reference
period (Bunnell et al. 2006a). The other approach is to collect
information on each category of sexual partner, for example
regular partners, casual partners and sex worker partners, in
a given reference period (Amon et al. 2000; Horizons 2006).
This method is widely used in behavioural surveillance surveys
in most countries and can allow comparisons within and
across countries and geographic regions. It is also the method
used in the Client Instrument in this volume.

may need to address slightly different variables than those
carried out among the general population. Although prevention
studies among HIV-positive populations may address many of
the same questions as those among the general population,
researchers may want to gather more detailed information
about factors that influence sexual behaviour, depending on
the scope of the study. In addition, researchers may need to
add questions pertaining to stigma or disclosure, depending
on the study population.

5. VARIABLES AND SURVEY QUESTIONS
The following section lists questions that can be used in surveys
among HIV-positive respondents or health professionals who
provide HIV-related care. Most but not all these variables are
included in the Prevention Modules of the Client and Provider
Instruments in this volume. As noted earlier, the Prevention
Module uses a reference period of 3 months, but researchers
can modify this to 6 or 12 months, depending on the study
design and the preference of the researcher. “Don’t know”,
“Don’t remember” and “No Response” categories can be added
as appropriate.

4 Recall periods may be 3, 6 or 12 months long. Different recall
periods have been used to document sexual behaviours.
Behavioral Surveillance Surveys conducted by Family Health
International (Amon et al. 2000), National Family Health
Surveys (IIPS and Macro International 2007) and monitoring
and evaluation indicators developed by the UNAIDS Monitoring
and Evaluation Reference Group (MERG) use a 12-month
reference period, while Centers for Disease Control and
Prevention studies, such as Reproductive Health Surveys,
have used a 3-month reference period (Morris et al. 2005;
Bunnell et al. 2006a). Demographic and Health Surveys
have used a 6-month reference period (Bateganya et al.
2005; Sarna et al. 2008). There are advantages and
disadvantages to each of these recall periods. Shorter recall
periods provide more reliable responses, but if few respondents
report sexual activity, researchers may need to lengthen the
recall period or increase the sample size. In this volume, the
Prevention Module of the Client Instrument uses a recall period of

key variables related to prevention among
individuals living with hiv

a. Sociodemographic variables (e.g. educational,
employment and marital status)
b. Length of time since HIV diagnosis and initiation of
antiretroviral therapy
c. Sexual activity
d. Type and number of sexual partners
e. Sexual activity and condom use with regular/casual/sex
worker partners
f. Knowledge of partner’s HIV status/disclosure of own
status to partner
g. Sexual activity and condom use among men who have sex
with men
h. Concurrent sexual partners
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respondents — the number of male partners (whether regular,
casual or sex workers). Depending on the study objectives,
researchers might want to include additional questions about
the lifetime number of sexual partners (which has been found
to be associated with an increased risk of unprotected sex), the
age at first sexual intercourse and whether sexual initiation was
forced or voluntary.

i. Knowledge and attitudes related to HIV infection and
treatment
j. Attitudes and treatment optimism related to antiretroviral
therapy
k. Fertility desires and family planning methods

5.1 Variables and survey questions related to prevention
among individuals living with HIV

e. Sexual activity and condom use with regular partners/casual
partners/sex workers
It is expected that the best recall of condom use would be
for the most recent period, so it is common to enquire about
condom use at the respondent’s most recent sexual contact.
But since successful prevention strategies require condoms
to be used consistently, surveys on prevention should also ask
about consistent condom use over a specific reference period.
Consistent condom use is typically assessed on a categorical scale
for the reference period (e.g. always, almost always, sometimes,
rarely and never). If researchers need a quantitative measure to
calculate the proportion of unprotected sexual acts, they may
want to use a shorter reference period and include more detailed
questions. Researchers may also want to ask about reasons for
using or not using condoms.

a. Sociodemographic variables
Sociodemographic variables should include age, sex, education,
employment, living conditions and socioeconomic status. Marital
status is a particularly important sociodemographic variable to
be included in sexual behaviour studies. In countries where
polygamy is common, survey instruments should ask married
individuals about more than one spouse. Researchers may also
need to disaggregate findings by sex and age in order to identify
findings that can inform the design of effective programmes for
women and men, as well as for young people (e.g. aged 15 to
24 years) versus older adults.
b. Length of time since HIV diagnosis and initiation of
antiretroviral therapy
Researchers may want to examine how sexual behaviour changes
over time among HIV-positive individuals receiving antiretroviral
therapy. Therefore, asking about the length of time that has
passed since the respondent received the HIV-positive diagnosis
or initiated antiretroviral therapy provides important information
about reference periods. Time on antiretroviral therapy is also a
key variable for comparing behaviour before and after starting
treatment and at different points in time over the course of
treatment, as well as for comparing patient groups.
c. Sexual activity and behaviours
Asking respondents whether they have had sexual intercourse
in a recent reference period allows researchers to determine the
number and proportion of patients on antiretroviral therapy who
are sexually active. This in turn provides the denominator for the
proportion of sexually active patients who engage in high-risk
sexual behaviours.

variable

variable

SUGGESTED WORDING OF SURVEY QUESTION

Penetrative sex with
each type of partner
(regular, casual, sex
worker) in the last 3
months

During the last 3 months, have you had sexual
intercourse (meaning penetrative vaginal or
anal sex) with a spouse or a live-in — what we
call a regular partner?
The same question can be posed for casual
partners, sex worker partners and male partners
(for male respondents).

Consistent condom
use with all partners
of each type (e.g.
all regular, casual,
sexual worker and
male partners)

During the last 3 months, when you had sexual
intercourse with your regular partner(s),
how often did you and your partner(s) use a
condom?
The same question can be posed for casual
partners, sex worker partners and male partners
(for male respondents).

Consistent condom
use with all partners

Thinking about all the times you had sex with
any partner during the last 3 months, would
you say that you and your partner(s) used a
condom:
q always (every time)
q almost always
q sometimes
q rarely
q never
q declined to answer

Condom use at last
sex with most recent
partner, by type

The last time that you had sexual intercourse
with your most recent regular partner, did you
and your partner use a condom?
The same question can be posed for casual
partners, sex worker partners and male partners
(for male respondents).

Reasons for not
using a condom at
last sex (optional)

Why didn’t you or your partner use a condom
the last time you had sex with a regular
partner/non-regular or casual partner/sex
worker?

SUGGESTED WORDING OF SURVEY QUESTION

Proportion of
respondents who are
sexually active

Have you had sexual intercourse (meaning
penetrative vaginal or anal sex) during the
last 3 months?

Number of sexual
partners in last 3
months

How many different partners have you had
sexual intercourse with during the last 3
months?

Reasons for sexual
inactivity in last 3
months

If sexually inactive: What are the reasons why
you have not had sex in the last 3 months?

d. Type (and number of each type) of sexual partners
The Client Instrument includes numerous variables and survey
questions related to the type and number of sexual partners,
including the total number of partners and the number of regular
partners, casual partners, sex worker partners and — for male
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f. Knowledge of regular partner’s HIV status and disclosure of
own status
Knowledge of regular partner’s HIV status and disclosure of status
to regular partner are core variables for all prevention studies,
as they can influence condom use. More details about how to
collect information on this variable are available in the Testing
and Counselling chapter.

4 Knowledge of HIV and HIV treatment. Does the respondent
believe that antiretroviral therapy can remove the virus from
the body completely? Can HIV or AIDS be completely cured?
Does the respondent think that a healthy looking person can
be infected with HIV?
j. Attitudes and treatment optimism related to antiretroviral
therapy
The items below have been adapted from questions developed
and used in studies of treatment optimism (Van de Ven et al.
1999; Elford et al. 2002; Vanable et al. 2003). These items can
be analysed individually, or they can be combined to create a
composite variable for optimism. Ideally they would be used with a
5-point scale (such as strongly agree, agree, undecided, disagree
or strongly disagree), but a 3-point scale may be preferable in
some settings.

g. Sexual activity among men who have sex with men
Depending on the research objectives and the extent of same sex
behaviour among men who have sex with men in the study sites,
researchers may want to include a section on this type of sexual
activity in the questionnaire. For studies exploring whether such
behaviour exists in the community, this line of enquiry can be
limited to a few survey questions. For more detailed information,
researchers can ask survey questions similar to those for other
types of partners. Variables may include: sexual intercourse
ever with a male partner (for male respondents), sex with a male
partner in the last 3 months, number and type of male partners
in the last 3 months and condom use with male partners in the
last 3 months.

Please indicate whether you agree, are undecided or
disagree with each of the following statements:
4 I would feel safe having intercourse with someone who
has an undetectable viral load (or who is receiving
treatment).
4 I am less worried about HIV infection now than I used
to be.
4 The new HIV treatments make me less anxious about
having unprotected sex.
4 I believe that HIV treatment makes people with HIV less
infectious.

h. Concurrent sexual partners
Researchers with a special interest in concurrent sexual
partnerships may want to ask detailed questions about the
duration of sexual relationships (including start and stop dates)
with various partners over a fixed time frame. This requires a full
set of partner related questions, however, which lengthens the
questionnaire and may not always be feasible. A simpler global
question is to ask: “During the last 3 months, did you have
sexual intercourse with any partner during the same period of
time that you were having an ongoing sexual relationship with
someone else?”

k. Fertility desires and family planning methods
Given the limited availability of assisted reproduction techniques
(such as sperm washing or in vitro fertilization) in most developing
countries, HIV-positive individuals who want children may have
no other choice but unprotected sex. Research on prevention
should, therefore, include some survey questions about number
of living children, desire for more children and use of family
planning methods, such as:

i. Knowledge and attitudes related to HIV infection and treatment
In this volume, survey questions about knowledge and attitudes
related to HIV and HIV treatment are included in the Testing and
Counselling Module of the Client Instrument. Therefore, they are
not repeated in the Prevention Module. Researchers who want
to gather information on these variables without using the whole
Client Instrument may want to extract survey questions from the
Testing and Counselling Module on the following topics:

4 Desire for children. Does the respondent want to have a
child/another child? If yes, in what timeframe? Does the
respondent’s spouse or partner want to have a child/another
child?

4 Knowledge of HIV transmission. What are some ways that

4 Current use of family planning. Does the respondent or his/

HIV can be transmitted?

her partner/spouse use any family planning method? If yes,
which one?

4 Knowledge of ways to reduce the likelihood of sexual HIV
transmission. What are some ways that an HIV-positive
person can reduce the likelihood that he or she might
transmit the virus to another person through sexual contact?

5.2 Additional variables and questions for research on
prevention
Depending on feasibility and relevance in particular settings,
researchers may consider collecting data on the following topics
in prevention studies.

4 Knowledge of people infected with HIV. Does the respondent
personally know anybody who is infected with HIV or who
has died of HIV? Or, does the respondent have a close
relative or close friend who is infected with HIV or who has
died of HIV? If yes, who was this person in relation to the
respondent?

a. Biomedical variables
If researchers can gather biomedical data, viral load and CD4
counts are key variables. Viral load may influence the risk of
transmission and should be obtained where possible. CD4 cell
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counts reflect the degree of immune suppression as a result of
HIV infection. CD4 measures can be used as surrogate markers
of improved health status, and they are more readily available
than viral load tests in most resource-limited settings. Variables
might include:

The reference period used to define active drug use varies with
surveys. The widely used Behavioral Surveillance Surveys (Amon
et al. 2000) use 6 months as the reference period. This volume
contains an optional module for the purpose of gathering data on
respondents’ use of alcohol and other types of drugs.

4 Viral load at start of treatment (if available)
4 Viral Load – most recent/current
4 CD4 at start of treatment (if available)
4 CD4 – most recent/current

5.3 Variables and survey questions related to prevention
for health care providers
There are a number of variables and survey questions related
to prevention in the Provider Instrument in this volume. Single
or composite variables on prevention services can be generated
from the following types of questions for health care providers:

b. Alcohol and Drug use
Depending upon the context, prevention strategies may need
to consider addressing alcohol and drug use, either as a mode
of HIV transmission (in the case of injecting drug users) or as
a factor that may increase the risk of sexual HIV transmission.
Alcohol use and drug use questions can be used individually
or combined to develop index scores. Drug use questions are
generally structured to ask about ever use, active drug use in
a certain reference period and high-risk behaviours related to
injecting drugs that are commonly available in the community.

4 Are clients provided information on risk reduction and
safer sex at clinics where they receive treatment?

4 Are condoms available at and distributed by the clinic?
4 Do health providers discuss disclosure of HIV status to
partners?

4 Do they recommend partner testing?
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Instructions to interviewers are in italics.

Hello, I am {NAME} working on a research project supported by {NAME OF LOCAL COLLABORATING
INSTITUTION}. We are conducting a study on HIV testing, treatment and prevention {IF NECESSARY,
ADD DETAILS}. By listening to people who may have had some experience with health services
around HIV, we hope to learn what goes right with the health services, and how to improve them.

All text that is meant to be read to the respondent is written in bold type. For example, when multiple choice
options should be read aloud, the options are in bold, like the questions themselves. When options are
intended for the interviewer only, i.e. when they should not be read aloud, they are not in bold type.

You have been selected to represent people in this area [from this clinic] and we would very much like
to hear about your opinions and experiences. Before we get started, I would like to explain to you how
the interview works.

If a respondent declines to answer a question that does not have a specific option for this response, please
write “declined to answer” in the margin of the questionnaire. Please do not read the option “declined to
answer” out loud.
Your participation in the interview and in every aspect of the study is completely voluntary.
Responses to open-ended questions should be recorded as close to verbatim as possible.
If some questions are difficult or make you uncomfortable, we can skip them. You may also ask
me to clarify any questions if you do not understand them. You may also decide to stop the interview
at any time.
All of the information that you provide for the study will be kept completely confidential. We record
your responses, but the questionnaire will not have your name on it, and your responses to our
questions are identified only by a number, never by name.
If you have questions or concerns after we are finished, you may contact {CONTACT PERSON AT
THE COMMUNITY LEVEL}.
Although there are no direct benefits to you from participating in this survey, we hope that the
survey will help to improve health services and support for people living with HIV and AIDS. The
survey will take about {ESTIMATED TIME IN MINUTES} minutes.
Do you have any questions about the survey? Would you be willing to participate in our study?

1

2

Depending on local ethical clearance, it may be necessary to fill out a signed consent form. In that case it
would be preferable to design the instrument so as to be able to separate the form from the rest of the
instrument

I have read this consent form or have had explained to me to my satisfaction the information relating
to this study. I understand what my participation will involve and agree to take part in this interview
under the terms of this agreement. I have had the opportunity to ask questions about it, and my
questions have been answered to my satisfaction.

We have a form that must be read to you before we begin, in order to confirm that we have explained
the study to you and that you have agreed to participate.
We ask you to sign the form, but we do not keep the form attached to the questionnaire, so your name
will not be linked to the information we write about you, and no one except the people responsible for
the study will have access to this information.

I consent voluntarily to participate in this study and I understand that I have the right to withdraw at
any time, without it in any way affecting my future medical care.
Participant
Name __________________________

The form just repeats what I have told you about the study, but I have to read it to you.

Date ___________________________
I understand that I have been asked by {NAME OF INSTITUTION} to participate in a research project
designed to investigate people's experiences and perspectives regarding HIV testing, counselling and
treatment.
I understand that during this study I will be asked questions about my health and health care, and
that my responses will be recorded in a questionnaire form. But my participation in the study will be
kept confidential, and my identity will be available only to those performing or supervising the
research. I understand that I would never be identified by name in any publications resulting from this
study.

Signature or thumbprint if appropriate _______________________

Witness (if appropriate)
Name ___________________________
Date ____________________________
Signature _________________________

I am aware that there may be some questions asked during the interview which may make me
uncomfortable. I realize that I do not have to answer any question that I do not want to answer. I
understand that I am free to withdraw my consent and to discontinue participation in this research
project at any time, without affecting my future care or treatment.

Investigator
Name ___________________________
Date ____________________________

I realize that I will not benefit directly from this project. However, with my participation, I hope to
help investigators understand how to improve health services.

Signature ________________________

3

4

! "#$
Interviewer can complete this section before the interview starts.
C1.1

Interview ID number in the form of 001, 002, 003...

C1.2

Date of interview DD/MM/YYYY

%
C2.1

&

Sex of the respondent? Do not read this question.
female
male

_____/_____/______
C1.3

C1.4

C2.2

How old are you? In years.

C2.3

What is your {ethnicity/religion/place of residence} {CHOOSE ONE OR SELECT ANOTHER
COUNTRY-SPECIFIC LOCAL GROUP AFFILIATION}?
{5 COUNTRY-SPECIFIC}

Interviewer name or code

Location of interview
health facility, please specify name and location: _________________________
respondent's home
other, please specify:

C1.5

Time of interview start. Use the 24:00 clock.

C1.6

Language of interview

other, please specify:
declined to answer
.............................................................

C2.4

What was the last level of schooling that you completed?
no formal education
primary incomplete
primary complete
secondary/vocational incomplete
secondary/vocational complete
post secondary or more
other, please specify:
declined to answer
.............................................................

C2.5

Are you...?
never married
married or cohabiting
divorced or separated
widowed
declined to answer

5

6

Now I have some questions about the type of work you do and your access to food.

Now I would like to ask you some question about your home and living conditions.

C2.6

C2.10

What kind of work do you do? By that I mean, what kind of activities keep you busy during
an average day, whether you earn money from them or not. Record answer as given, and then
choose an option below in C2.7.

Do you live alone?
yes

Go to C2.12

no
Go to C2.12

declined to answer
C2.7

C2.11

agriculture
fishing

With whom do you live? Mark all that apply.
with family
with friends

commerce

other, please specify:

clerical/employee

declined to answer
.............................................................

professional
skilled/semi-skilled labour
unskilled labour
C2.12

student
apprentice

yes

homemaker/housewife

no

declined to answer

vehicle/car

none (Probe: No agricultural or housework?)

bicycle

other, please specify:

scooter or motorcycle

declined to answer
.............................................................

C2.8

Do you [or any member of your household] own any of the following means of
transportation? Adjust wording if respondent lives alone.

other, please specify:
.............................................................

During the past month, how often have you had problems getting the food you need?
Go to C2.10
never

C2.13

sometimes
often

What is the main roofing / flooring / walling material {CHOOSE ONE} of the home you live
in?
{3 COUNTRY-SPECIFIC; BEST TO WORST}

always
declined to answer
C2.9

Go to C2.10

other, please specify:
declined to answer
.............................................................

Please tell me what the problems were.

7

8

C2.14

Does your home have any of the following:
yes

! "
no

!

declined to answer

1. drinking water from a tap?

$ '

2. flush toilet?
3. electricity?

%( )

*

Now I would like to ask you some questions about HIV testing and counselling. What we discuss
during the rest of this interview depends on whether or not you have ever been tested for HIV.

4. television?
5. radio?
6. electric or gas kitchen stove?
7. telephone (not including
mobile)?
C2.15

C3.1

Do you [or anyone in your household] own any of the following: Adjust wording if respondent
lives alone.
yes

no

Have you ever been tested for HIV?
yes
no

Go to C3.64 to non-user questions

don't know

Go to C3.64 to non-user questions

declined to answer

Go to C3.64 to non-user questions

declined to answer

1. land?
2. livestock / animals that are
raised?

Now I would like to ask you some questions about getting tested for HIV, how you decided to be
tested, what happened and how you felt about it.

3. a mobile phone?

C3.2

4. {3 COUNTRY-SPECIFIC}

Would you be willing to discuss these issues with me?
yes
no

5.
6.

C3.3

Go to C3.84

How many times have you been tested for HIV? Emphasize that the questions concern testing
for HIV only, and not other tests such as CD4 counts, etc. If respondent cannot remember the
precise number, a close approximation is sufficient.
number of times tested.........................................
Go to C3.11 if respondent has tested only one time

9
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$ '

+ )

&

,

The next few questions are for those who have tested more than once. Please think about when you
had your first HIV test.
C3.4

C3.7

What was the reason for your having a test? Record answer as given, and then choose option/s
below.

C3.8

Mark all that apply. Do not read the options.
respondent wanted to know serostatus

How long ago did you have your first HIV test? Record the number of months and years that
have passed. If less than a year has passed, write '0' years; similarly, if less than a month has
passed, write '0' months. Do not leave those spaces blank. Use probes and memory prompts to
help respondent calculate the number of months and years that have passed.

partner--partner's past sexual behaviour
partner--partner told you to get tested
partner--partner ill or died

number of months ago .........................................

child--child ill or died

number of years ago ............................................

exposure--your own past sexual behaviour
exposure--blood transfusion

C3.5

exposure--taking care of people with HIV or AIDS

Was the test done with blood or with a sample taken from your mouth?
blood

exposure--contaminated instrument

mouth

exposure--syringe exchange

don't remember

symptoms/health--symptoms that made you or a health provider think you might have HIV

declined to answer

symptoms/health--hospitalization for another reason
symptoms/health--giving blood

C3.6

PMTCT

Were you tested on your own initiative or because you were offered a test by a health
worker at a facility or at home?
tested on own initiative

provider said it was a routine part of care
future plans--marriage

offered test by health provider at a health facility

future plans--having children

offered test by health worker at home

future plans--planning for future

other, please specify:
.............................................................

offered test at home
other, please specify:
don't know
declined to answer
.............................................................

C3.9

Was it hard for you to be tested for the first time?
yes, hard
somewhat hard
no, not hard

11

don't remember

Go to C3.11

declined to answer

Go to C3.11

12

C3.10

Why / Why not?

+
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C3.15

Why did you go to that particular facility?

C3.16

Did anyone accompany you to the facility where you were tested?
yes
no

Note to interviewer: the following questions are for all those who have had an HIV test, whether just once or
more than once.
C3.17
For respondents who have had more than one HIV test say: We have been talking about the first time you
were tested for HIV, but now I would like you to think about your most recent HIV test.
C3.11

Go to C3.18

Who accompanied you to the facility where you were tested?
spouse/partner
parent
sibling

How long ago did you have your [most recent] HIV test? Choose question wording depending
on whether respondent has had more than one test. Record the number of months and years that
have passed. If less than a year has passed, write '0' years; similarly, if less than a month has
passed, write '0' months. Do not leave those spaces blank. Use probes and memory prompts to
help respondent calculate the number of months and years that have passed.

adult son or daughter
other family member
friend
other, please specify:

number of months ago .........................................

.............................................................................

number of years ago ............................................
C3.18
C3.12

Where were you tested?
at a health care or testing facility

mouth

at home

Go to C3.18

don't remember

other, please specify:

Go to C3.18

declined to answer

.............................................................................
C3.13

Was the test done with blood or with a sample taken from your mouth?
blood

C3.19

What was the name of the health care facility where you had this test?

Were you tested on your own initiative or because you were offered a test by a health
worker at a health facility or at home?
tested on own initiative
offered test by health provider at a health facility

C3.14

offered test at home

How long did it take you to get to the facility where you were tested? Hours, minutes

other, please specify:
.............................................................

hours ....................................................................
minutes ................................................................

13

14

C3.20

What was the reason for your having a test? Record answer as given, and then choose option/s
below.

C3.21

Mark all that apply. Do not read the options.
respondent wanted to know serostatus

C3.23

Why / why not?

partner--partner's past sexual behaviour
partner--partner told you to get tested
partner--partner ill or died
child--child ill or died
exposure--your own past sexual behaviour
exposure--blood transfusion
exposure--taking care of people with HIV or AIDS

#

.
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exposure--contaminated instrument
exposure--syringe exchange

C3.24

symptoms/health--symptoms that made you or a health provider think you might have HIV

Did you discuss getting tested with anyone before you had your HIV test?
yes

symptoms/health--hospitalization for another reason

no

Go to C3.26

symptoms/health--giving blood

don't remember

Go to C3.26

PMTCT

declined to answer

Go to C3.26

provider said it was a routine part of care
future plans--marriage

C3.25

Can you tell me more about this? Probe: for example, who did you talk to and what did you talk
about?

C3.26

Did [someone from the health facility, such as] a health care provider or counsellor meet
with you to discuss the test before you had it? Choose wording depending on whether tested at
home or at a facility.
yes

future plans--having children
future plans--planning for future
offered test at home
other, please specify:

........................................................................................

don't know
declined to answer
.............................................................

C3.22

[When you had your most recent test,] was it hard for you to be tested? Choose question
wording depending on whether respondent has had more than one test.
yes, hard

C3.27

somewhat hard
no, not hard
don't remember

Go to C3.24

declined to answer

Go to C3.24

no

Go to C3.29

don't remember

Go to C3.28

declined to answer

Go to C3.28

Was this discussion before the test with you alone, with your partner or in a group?
alone
with partner
in a group
don't remember
declined to answer

15
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C3.28

Before your blood/oral sample was taken for testing, did a health care provider or
counsellor do any of the following:
yes

no

don't
remember

C3.30

declined to
answer

explain that you had a choice to
agree to the test or refuse the
test?
tell you that your results would
not be shared with anyone
except for the clinic staff who
care for you?
explain how HIV is transmitted?
x
explain how the test works?
x
explain the meaning of positive
and negative test results?
explain that the test does not
always detect a very recent HIV
infection (this is sometimes
called a window period)?
give you advice on preventing
the spread of HIV?
give you time to ask questions?
x

Did a health worker ask you whether you agreed to be tested for HIV before your HIV test
was done?
yes
no

Go to C3.32

don't remember

Go to C3.32

declined to answer
C3.31

Did you agree to be tested?
yes

Go to C3.33

no
don't know
declined to answer
C3.32

For those who did not agree or who don't remember whether they agreed: Since you did not
agree [do not remember if you agreed] to be tested, what were the circumstances under
which you were tested?

other, please specify:
...........................................................
Go to C3.38

C3.33

Some health workers ask clients whether they agree to the test before they do it, but other health
workers just go ahead with the HIV test without asking first. I would like to ask you about your
experience when you were tested.
C3.29

For those who did agree. Did you agree in writing or by saying that you agreed? Mark all that
apply.
in writing
by saying it
other, please specify:

How important was it for you to be asked if you agreed or refused to be tested for HIV
before having the test?
very important

don't remember
declined to answer

somewhat important

.............................................................................

not important
don't know

C3.34

Did you feel that you could have said no?
yes
no
unsure
declined to answer

17

Go to C3.36

18

C3.35

Why / why not?

)

$ '

Now I would like to ask you about whether you got the results of your most recent HIV test and what
other type of services and care you received at that time. I am not going to ask you to tell me your
results now.
C3.38

Did you receive your results from your most recent HIV test?
Go to C3.42
yes
no
declined to answer

C3.36

C3.37

Go to C3.84

C3.39

Why not?

C3.40

Just to double check, have you ever received results from any previous HIV test?
yes

Was anyone else involved in getting your agreement to be tested?
yes
no

Go to C3.38

don't remember

Go to C3.38

declined to answer

Go to C3.38

Who?
C3.41

no

Go to C3.84

don't remember

Go to C3.84

declined to answer

Go to C3.84

How long ago did you have that previous test? Record the number of months and years that
have passed. If less than a year has passed, write '0' years; similarly, if less than a month has
passed, write '0' months. Do not leave those spaces blank. Use probes and memory prompts to
help respondent calculate the number of months and years that have passed.
number of months ago ... .....................................
number of years ago ............................................
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C3.42
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C3.46

) ,

yes

How long after the test did you receive your results? An approximate guess is fine.
within one hour of the test
1-3 days after the test
4-7 days after the test
more than one week after the test
don't remember

C3.47

declined to answer

C3.44

Go to C3.45

no because received test results at home

Go to C3.45

unsure

declined to
answer

How would you describe the way providers treated you after the test?
very well
well

Did anyone accompany you to the facility when you received your test results?
yes
no, no one accompanied respondent

no

was the information you were
given sufficient?
were you given the opportunity
to ask questions?
on the whole, did you find the
meeting helpful?

same day

C3.43

About your meeting with the health care provider after you got your test results:

okay
badly
very badly
)

Who accompanied you to the facility when you received your test results?
spouse/partner

Sometimes health workers do everything they can to keep clients’ HIV test results confidential so that
other people do not know about them. Other health workers sometimes say or do things that reveal
clients’ HIV status to other people without their permission. People have different feelings about how
important it is for health workers to keep HIV tests results confidential.

parent
sibling
adult son or daughter
other family member

C3.48

friend
other, please specify:
.............................................................................

somewhat important
not important

Now I would like to ask you some questions about what information or counselling you received from
the workers who gave you your test results.
C3.45

no

don't
remember

don't know
Now I would like you to think about the health workers who did your HIV test and gave you your
results.

After giving you your test results, did a health care provider do any of the following:
yes

How important is it to you that these health workers keep your HIV results confidential and
do not reveal them to anyone else without your permission?
very important

declined to
answer

C3.49

explain the meaning of the test
result?
suggest that you discuss your
status with someone?
suggest that your sexual
partner[s] be tested for HIV?
discuss how to prevent the
transmission of HIV?

Do you think that these health workers have kept your test results confidential?
yes--protected confidentiality
no--did not protect confidentiality
unsure
don't know
declined to answer
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Now, if it is okay with you, the following questions are more personal. I will begin by asking you some
questions about your HIV status and also what happened when you learned your HIV status.
Remember that the survey is confidential, and your name does not appear on the form. As we said at
the beginning of the interview, you are free to decide whether or not you want to answer any question,
and you are free to skip any questions that you would rather not answer.
C3.50

C3.55

),

When you first learned that you were HIV-positive, were you expecting this test result?
yes
no
don't know
Go to C3.57

declined to answer

Go to C3.84

C3.56

What is your HIV status?
HIV-positive

&

Now I would like to ask you to think back to the day when you first received the test results that
revealed that you were HIV-positive.

Are you willing to tell me your HIV status?
yes
no

C3.51

) +$ '0

Why / Why not?

Go to C3.55

HIV-negative
indeterminate
$ '. %
C3.52

)
Was this the result you were expecting?
yes
no
don't know
declined to answer

Go to C3.54

C3.53

Why / Why not?

C3.54

Having given you this result, what did the health worker advise you to do?

))
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&&
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The next questions are about what has happened since you received your results.
C3.57

Were you given any further medical or blood tests do see if you might need treatment or
other support?
yes
no
don't remember
declined to answer

C3.58

After giving you your test results, did any health care provider do the following:
yes

no

don't
remember

declined to
answer

refer you for medical care?
talk about getting help from a
support group for people living
with HIV or AIDS?
refer you to a support group for
people living with HIV or AIDS?

Go to C3.84
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C3.59

After giving you your test results, did any health workers talk to you about how to share
your status with people around you?
yes

.
*

no

C3.64

don't remember
declined to answer
C3.60

C3.61

,

1

) % + )

)

%

Have you ever thought about having an HIV test?
yes
no

Since you received your HIV-positive results, has a health care provider told you that you
needed any sort of care or medication in order to manage your HIV and stay healthy?
yes
no

Go to C3.84

don't remember

Go to C3.84

declined to answer

Go to C3.84

C3.65

don't know

Go to C3.67

declined to answer

Go to C3.67

Why / Why not?

What were the medications? Probe by asking to see prescription if necessary.
1...........................................................................
2...........................................................................
3...........................................................................
Go to C3.67 if respondent has not thought about having a test.

don't know and prescription unavailable
C3.62

C3.66

Since you have thought about having a test, why have you not had one?

C3.67

Do you know anyone personally who has had an HIV test?
yes

Have you been able to obtain the[se] medication[s]?
Go to C3.84
yes, all
yes, some of them
no, none of them
declined to answer

C3.63

Go to C3.84

Why not?

no

Go to C3.73

don't know

Go to C3.73

declined to answer

Go to C3.73

Go toC3.84
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C3.68

Who is this person [are these people] in relation to you? Mark all that apply.
spouse or partner

C3.72

Who and why?

C3.73

Do you know any facilities offering HIV testing and counselling to people who live around
here?
yes

friend
family member
acquaintance from community
other, please specify:
declined to answer

.............................................................

C3.69

C3.70

Do you think that getting tested was helpful for [any of] them? Phrase questions depending on
response above in C3.68.
yes
no

Go to C3.71

don't know

Go to C3.71

declined to answer

Go to C3.71

Who and why?
C3.74

no

Go to C3.79

unsure

Go to C3.79

Which facilities?

1...........................................................................
2...........................................................................
3...........................................................................
C3.75
C3.71

Do you think that getting tested caused any problems for anyone you know?
yes
no

Go to C3.73

don't know

Go to C3.73

declined to answer

Go to C3.73

If you wanted to go there, how easy or difficult would it be for you to go there from your
home?
very easy
somewhat easy
somewhat difficult
very difficult

27

don't know

Go to C3.77

declined to answer

Go to C3.77

28

C3.76

Why?

C3.82

What were the circumstances?

C3.77

How long would it take you to get to the nearest health facility that offers testing and
counselling from your home? Hours, minutes

C3.83

Why did you not accept the offer to have the test?

hours ....................................................................
minutes ................................................................
C3.78

Do you think that health workers there always keep people's HIV test results confidential
and do not reveal them to anyone outside the health clinic?
yes
no
don't know
declined to answer

C3.79

If you decided to have an HIV test, how important would it be to you that these health
workers keep your HIV results confidential and not reveal them to anyone else without your
permission?
very important
somewhat important
not important
don't know

C3.80

C3.81

Have you ever had an HIV test offered to you when you were at a health facility or in your
home?
yes
no

Go to C3.84

don't remember

Go to C3.84

declined to answer

Go to C3.84

Where was this?
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C3.87

What do you think of the practice of offering people HIV tests in their homes?

C3.88

Do you think that it is okay to require certain people to have an HIV test?
yes

Now, if you don’t mind, I would like to ask you some general questions about what you think of HIV
testing. These questions will not ask you about your personal experiences.
C3.84

Do you think it is important for people to know their HIV status?
yes
no
unsure
declined to answer

C3.85

C3.86

Go to C3.86

Why / Why not?

no

Go to C3.90

unsure

Go to C3.90

C3.89

What types of people do you think should be required to have an HIV test and why?

C3.90

If someone has HIV, do you know of anything that can be done to help them stay healthy
and live longer?
yes

What do you think about the practice of offering people HIV testing and counselling at a
health care facility, when they came for something else [For PMTCT: when they came for
ante-natal care?]

31

no

Go to C3.92

declined to answer

Go to C3.92

32

C3.91

What can be done to help them stay healthy and live longer?

C3.92

Do you know anyone personally who is living with HIV or who has died of AIDS? Mark all
that apply.
yes, know someone living with HIV

C3.94

%

yes, know someone who has died of AIDS

)) %

)

)

%

This concludes this portion of our interview. Thank you very much for your participation.

no, neither
declined to answer
Now I would like to ask you for your ideas about how to improve testing and counselling services in
your community.
C3.93

Do you have any suggestions for how to help people who are HIV-positive get the medical
care they need to stay healthy and live longer? Record answer as given.

C3.95

Time of interview or module end. Use the 24:00 clock.

C3.96

Additional interviewer notes

Do you have any suggestions for how to make it easier for women and men to find out their
HIV status? Record answer as given.
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C4.4
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no

I would like to ask you a few general questions about your opinions regarding who should be tested
and who should know about other people's test results. People have different opinions about this, and
we are interested in your honest feelings.
C4.1

Do you think that it is sometimes okay to tell other people that someone else has HIV, even
if that person doesn't want other people to know?
yes
unsure

C4.5

Why or why not?

C4.6

In general, how important do you think it is for health workers to keep their clients' HIV
results confidential and not reveal them to anyone else without the client's permission.

If someone has HIV, do you think that person should tell anyone else?
yes
it depends
no

C4.2

C4.3

don't know

Go to C4.4

declined to answer

Go to C4.4

Why / Why not?

Who should they tell? Mark all that apply.
spouse or partner
close family

Go to C4.15 if respondent is HIV-positive

other relatives
people they live with
friends
co-workers
other, please specify:
..............................................................
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C4.10

What happened?

C4.11

Do you personally know anyone who has had any of the following experiences in the past
twelve months because they had HIV or AIDS?

,

The following questions are about fear of AIDS and your feelings towards people living with HIV or
AIDS. We think that different people have different opinions about this, and we are interested in
hearing about your honest feelings and opinions.
C4.7

Please indicate whether you strongly agree, agree, are unsure, disagree or strongly
disagree with each of the following statements:
strongly
agree

agree

unsure

disagree

strongly
disagree

declined
to
answer

AIDS is a punishment for bad
behaviour.
People with AIDS deserve
blame for getting the disease.
Patients with AIDS do not have
the right to the same quality of
medical care as other patients.
Women who are HIV-positive
should be prevented from
having children.
People suspected of having HIV
should be required to be tested.
C4.8

yes

declined to answer

abandoned by spouse/partner?
abandoned by other family
members?
verbally abused or ridiculed?
physically assaulted?
fired from work or lost their
job?

Would you fear getting HIV from any of the following:
yes

no

unsure

expelled from their home?

declined to
answer

had property taken away?
denied health services?

hugging a person with HIV or
AIDS?
sitting next to a person with HIV
or AIDS?
caring for a person with HIV or
AIDS?

C4.12

This next part is about things that may happen to people when others know they have HIV.
C4.9

no

excluded from social events?

C4.13

Have you heard of people who have been badly treated because they had HIV?
yes
no

Go to C4.11

declined to answer

Go to C4.11

37

Do you know of any support groups in this area for people living with HIV or AIDS?
yes
no

Go to C4.52

don't know

Go to C4.52

declined to answer

Go to C4.52

What is the group's name?
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C4.14

Please describe the group's activities.

C4.18

C4.19
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After giving you your HIV test results, did any health care provider help you share your
status with people around you?
yes
no

Go to C4.21

declined to answer

Go to C4.21

Can you tell me what the health worker did?

),

Now if it is okay with you, I would like to ask you some questions about whether and how you have
shared your HIV status with people around you.
C4.15

Go to C4.21

Would you say you generally keep your HIV status a secret from most people?
yes
no

C4.20

For respondents who have not disclosed to anyone. Why have you chosen not to share your
HIV status with anyone?

C4.21

Do any other people in your community know that you are HIV-positive even though you
didn't tell them?
yes

unsure
declined to answer
C4.16

C4.17

Have you shared your HIV test results with anyone outside the health clinic?
yes
no

Go to C4.20

declined to answer

Go to C4.21

Who have you shared your HIV test results with? Mark all that apply.
spouse or partner
children
sibling
parent
other relative

no

friend

Go to C4.23

don't know

other, please specify:

declined to answer

.............................................................................
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C4.22

Who in your community do you think knows that you are HIV-positive even though you
didn't tell them?
health providers

Please think of one person whose reaction was the most disappointing to you. Then I will ask you
about the person whose reaction was more supportive or encouraging.

household / family members

About the person whose reaction was most disappointing:

other clients at the facility where you were tested
neighbours

C4.25

Please tell me about this person. For example, who is this person in relation to you? Probe:
friend, family, etc.

C4.26

How did they know that you are HIV positive?

C4.27

How did this person first react when they found out about your HIV status and how are they
acting now?

other, please specify:
don't know
.............................................................................
C4.23

Do you intend to tell anyone else your HIV status in the future?
yes
no
don't know
declined to answer
Go to C4.37 if no one outside the testing facility knows the respondent's HIV-positive status based on a 'no'
response to both C4.16 and C4.21.

)

$ '.&

Next, if you don't mind, I would like to ask you a couple questions about how people around you have
reacted when they found out that you have HIV.
C4.24

How did you expect your family or friends would react when they found out you are HIVpositive?

About the person whose reaction was most supportive or encouraging:
C4.28

41

Please tell me about this person. For example, who is this person in relation to you? Probe:
friend, family, etc.

42

C4.29

How did they know that you are HIV positive?

/&

%

Now, if you don't mind, I would like to ask you some other questions about your personal experiences.
C4.32

C4.30

Have you personally ever been made to feel bad because of things people did or said to you
on account of your HIV status?
yes
no

Go to C4.34

declined to answer

Go to C4.34

C4.33

Can you tell me what happened?

C4.34

Please indicate whether you agree, are unsure or disagree with the following statements:

How did this person first react when they found out about your HIV status and how is this
person acting now?

agree

What about other people who know you are HIV-positive:
C4.31

How did they first react when they learned of your HIV status and how are they acting now?

unsure

disagree

declined to
answer

Some people avoid touching me
once they know I have HIV.
Some people seem
uncomfortable being around me
once they learn I have HIV.
Some people act as though it is
my fault I have HIV, or say I
deserve it for things I have
done.
Now I would like to read you a list of things that have sometimes happened to people living with HIV
because of their HIV status and ask you whether any of these experiences have ever happened to you.
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C4.35

Have you ever experienced any of the following when you thought it was because of your
HIV status? Have you ever been:
yes

no

unsure

C4.38

Now I would like to read two statements. Please tell me whether you agree, are unsure or
disagree with each statement.

declined to
answer

agree

unsure

disagree

declined to
answer

I sometimes feel bad about
myself because I am HIVpositive.
I sometimes feel guilty because
I have HIV.

excluded from social events?
abandoned by your spouse or
partner?
abandoned by other family
members?
told that it is your fault you
have HIV?

Next I would like to ask you some questions about how you are treated when you go to health care
facilities and whether you think you have ever been treated differently than other people because of
your HIV status.

verbally abused or ridiculed?
physically assaulted by
anyone?
fired from work or lost your
job?

C4.39

When you have used health services in the past year, did any of the following happen to you
when you thought it was because of your HIV status?

expelled from home?

yes

had property taken away?
denied health services?
IF ANSWERED NO TO ALL, GO TO C4.37

C4.36

Can you tell me what happened? Record the answer as given.

C4.37

In the past twelve months, have you ever found yourself avoiding or isolating yourself from
friends or family because of your HIV status?
yes
no
declined to answer

45

no

unsure

declined to
answer

staff ignored you or avoided
taking care of you because of
your HIV status?
you were denied care that you
should have received?
you received less care or worse
care than others because of
your HIV status?
the staff seemed uncomfortable
with you because of your HIV
status Probe: for example in the
way they looked at you / talked to
you / handled themselves?
the staff seemed to use more
precautions when treating you
than when treating others
because of your HIV status?
you were treated with
disrespect or abused because
of your HIV status?
I have a few questions about other bad or good things that have happened to you since you found out
your HIV status. Please be as open as you can. We are interested in particular experiences or stories
from your life.
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C4.40

C4.41

C4.42

What have been the most difficult things that have happened in your life since you found
out your HIV status?

C4.44

Do you know of any support groups in this area for people living with HIV or AIDS?
yes
no

Go to C4.47

declined to answer

Go to C4.47

C4.45

What is the group's name?

C4.46

Please describe the group's activities.

C4.47

Since you received your HIV-positive result, have you received any financial assistance,
food assistance, or emotional and social assistance from the government or any HIV or
AIDS support organization?
yes

Have there been any good things that have happened in your life as a result of knowing
your HIV status?
yes
no

Go to C4.43

don't know

Go to C4.43

declined to answer

Go to C4.43

Please tell me what they were.

C4.48

no

Go to C4.49

don't remember

Go to C4.49

declined to answer

Go to C4.49

What sort of assistance have you received? Mark all that apply.
financial
food
emotional/social

&&
C4.43

other, please specify:
.............................................................
Since you received your HIV-positive result, have you joined an HIV or AIDS support group?
Go to C4.45
yes
no
declined to answer

C4.49

Do you think that knowing your HIV-positive status has been good for you overall?
yes
no
unsure
declined to answer
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Go to C4.51

48

C4.50

Why / Why not?

%

)

)

%

This concludes this portion of our interview. I would like to thank you very much for helping us. I
appreciate the time that you have taken to answer these questions. I realize that some of these
questions may have been difficult to answer, but it is only by hearing from women and men about
their firsthand experiences that we can understand how to improve the lives of people who are living
with HIV.
In case you or anyone else you know needs assistance, here is a list of places that provide support
groups, counselling and other services {Phrase according to the services available} for people living with
HIV.

C4.51

C4.52

Time of interview or module end. Use the 24:00 clock.

C4.53

Additional interviewer notes

Do you have any suggestions for ways that health programs can help improve the lives of
people living with HIV in this community?

49

50

C5.6

" $

What was your CD4 count at the last test?

In the next section of this interview, I would like to ask you about your experiences with taking ART.
)
Researchers should choose a term for HIV treatment that is understandable in the local context, whether that
is a complete phrase such as 'antiretroviral therapy', an acronym, such as ART, or another term.
"

)

The next questions are about those people around you who do or do not know you are taking ART,
and how these people may make it easier or harder to take your medications

&
C5.7

C5.1

Just to confirm, are you taking ART to manage your HIV? Adjust this question and the next
depending on whether this module is used alone or as part of a larger interview that has already
identified whether or not the respondent is taking ART.
yes
no

C5.2

don't know
declined to answer

Go to the end of the Adherence module

not applicable

How long ago did you first start taking antiretroviral therapy to manage your HIV? Record
the number of months and years that have passed. If less than a year has passed, write '0' years;
similarly, if less than a month has passed, write '0' months. Do not leave those spaces blank. Use
probes and memory prompts to help respondent calculate the number of months and years that
have passed.

C5.8

If respondent lives with other people: Do all the other adults living in your household know that
you are taking ART?
yes
no
don't know
no other adults live in the household

number of years ago ............................................

declined to answer

Since learning you are HIV-positive, have you had a blood test to find out your CD4 count?
Use local term if necessary.
yes

C5.9

Is it ever difficult for you to take your ART when someone from your family can see you?
yes

no

Go to C5.7

no

Go to C5.11

don't know

Go to C5.7

declined to answer

Go to C5.11

declined to answer

Go to C5.7

C5.10
C5.4

If married or cohabitating: Does your partner / spouse know that you are taking ART?
yes
no

number of months ago... ......................................

C5.3

&&

Please tell me about this.

How long ago did you have your last blood test to find out your CD4 count? Record the
number of months and years that have passed. If less than a year has passed, write '0' years;
similarly, if less than a month has passed, write '0' months. Do not leave those spaces blank. Use
probes and memory prompts to help respondent calculate the number of months and years that
have passed.
number of months ago... ......................................
number of years ago ............................................

C5.5

Do you know your latest CD4 count?
yes
no

Go to C5.7

declined to answer

Go to C5.7
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C5.11

C5.12

Is it ever difficult for you to take your ART when someone from your community or your
workplace can see you?
yes
no

Go to C5.13

declined to answer

Go to C5.13

C5.16

Please tell me about this.

C5.17

In general, do you find it easy, not very easy or difficult to take your ART?
Go to C5.19
easy

Please tell me about this.

not very easy
difficult
it depends
declined to answer
C5.13

C5.14

Is there anyone who regularly reminds you to take your ART?
yes
no

Go to C5.15

declined to answer

Go to C5.15

C5.18

Why?

Please tell me about how this person reminds you.

"
The next questions concern any possible problems you may have had getting your ART.
C5.15

During the past month, have you ever not taken your ART because you did not want
someone to find out?
yes
no

Go to C5.17

declined to answer

Go to C5.17

C5.19

53

In the past year, have you ever had problems getting your ART on time because you were
not able to reach the clinic?
yes
no

Go to C5.21

don't remember

Go to C5.21

declined to answer

Go to C5.21
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C5.20

Please tell me about this.

C5.24

C5.21

During the past year, has the cost of medication or the cost of clinic care ever interfered
with your ability to get your ART and take your medication on time?
yes

$

no

Go to C5.23

declined to answer

Go to C5.23

)

Now I would like to ask you some questions about your health before and after starting your ART, and
then I will ask about any side-effects or body changes you experienced after starting ART.
C5.25

C5.22

Please tell me about this.

Please tell me about this.

How would you rate your health before starting ART? Would you say it was:
excellent
very good
good
fair
poor

C5.26

Now that you are taking ART, how is your health? Would you say it is:
excellent
very good
good
fair
poor

C5.23

#

During the past one month, have you ever missed a dose of your ART because you did not
have enough food?
yes
no

Go to C5.25

declined to answer

Go to C5.25

.

Some people experience side-effects when they take ART. This varies a great deal. Some people have
a few, while others have more.
C5.27

55

Have you experienced any side-effects since you started taking ART?
yes
no

Go to C5.30

don't know

Go to C5.30

declined to answer

Go to C5.30

56

C5.28

Which side-effects have been the most bothersome for you?

C5.30

In the past month, have you experienced any of the following? If yes: Has this side-effect
been very bothersome, somewhat bothersome or not at all bothersome?

yes

no

1. very bot
hersome

2.
somewhat
bothersom
e

3. not at all
bothersom
e

1. fatigue or loss of energy?
2. fevers, chills or sweats?
3. feeling dizzy or light-headed?
4. pain, numbness or tingling in
the hands or feet?
5. trouble remembering?
6. nausea?
C5.29

7. vomiting?
8. diarrhoea or loose bowel
movements?
9. bloating, pain or gas in your
stomach?

Please tell me more about these side-effects.

10. heartburn?
11. persistent abdominal pain?
12. loss of appetite or a change
in the taste of food?
13. increased appetite?
14. felt sad, down or
depressed?
Next, I am going to read you a list of side-effects that some people say they feel when they are on
ART. Of course, not everyone feels these side-effects, so please tell me whether you have experienced
any of these side-effects in the past month. If you have experienced the side-effect, then I will ask you
how much it has bothered you.

15. felt nervous or anxious?
16. difficulty falling or staying
asleep?
17. nightmares or vivid dreams?
18. skin problems, such as
rash, dryness or itching?
19. cough or trouble catching
your breath?
20. headache?
21. muscle aches?
22. problems with or pain in
bones or joints?
23. problems with sex, such as
loss of interest or no
satisfaction?
24. problems with weight loss
or wasting?
25. tingling around the mouth?

57

58

Some people say they experience changes to their body while they are taking ART. I would like to ask
you some questions about this.
C5.31

C5.32

C5.34

Of all the changes that we have just discussed, please tell me more about the changes that
are the most bothersome for you? Probe the top 2 or 3.

Since you started taking ART, have you experienced a change in the way your body looks?
yes
no

Go to C5.33

don't know

Go to C5.33

Can you please tell me what changes you have experienced?

"

)

&

%

+&

,

Now I want to go over your ART medications: I will need to ask you about your prescribed doses of all
ART medications, and then I will ask you how many doses of your medication you actually took at
different time periods.
C5.35
Now I am going to read you a list of changes that some people say have happened to their body while
they are taking ART. Just like side-effects, not everyone experiences the same changes. Please tell
me whether or not you have experienced any of these changes in the past month, and if you have
experienced the change, then I will ask you how much it has bothered you.
C5.33

The following should be completed according to the prescribed ART dosing, not the respondent’s
actual behaviour. The information may be obtained from the patient, the provider or the health care
facility. Cross out all non-applicable boxes.

In the past month, have you experienced any of the following: If yes: Has this change been
very bothersome, somewhat bothersome or not at all bothersome?
yes

no

don't
know

1.
very
bothersome

2.
somewhat
bothersome

3.
not at all
bothersome

1. your cheeks thinned?
2. your belly grew?
3. your arms thinned?
4. your buttocks flattened?
5. your legs thinned?
6. the veins in your legs
increased or became more
visible?
7. your breast grew?
8. a hump appeared on the back
of your neck?
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C5.39

&

Please tell me what happened.

Many patients find it difficult to take all their ART as prescribed. We would not be surprised if you
have missed taking some of your medications over the last few days. We are trying to find out how
difficult it is for patients to take their ART, and what things make it difficult. Please answer these
questions as honestly as you can about your own experiences.
To complete the following table, the interviewer should reference the table that was completed for the
prescribed regimen in order to fill in the name of each ART medication and total daily # pills prescribed.
Interviewers should then walk the respondent through each of the last three days. In order to facilitate recall,
interviewers should use memory prompts by first asking respondents to think about yesterday and what they
were doing, and if there was anything unique about the day, before asking about specific times respondents
took their ART. For example: “What did you do yesterday morning? Did you take any ART medications that
morning?” If yes: “Which pills? How many of each?” If the respondent missed a pill/dose, circle the cell.
"
C5.36

C5.37

&

Which prescribed ART medications did you take over the last three days?

Only ask this question if respondent missed one or more doses over the last three days. What
circumstances led you to miss taking your ART medications as recommended on {name the
day and the medication missed as identified in the previous question}? Probe for what happened
and why.
Missed dose #1... .................................................

C5.40

Now I would like to ask you to estimate how much of your prescribed ART you took in the
past month. It is not likely that most people would take all of their doses. A mark at the left
end where there is a number zero means you have taken no ART medications. A mark in the
middle means you have taken about half of your ART medications. A mark on the right end
where you can see the number ten means you have taken every single dose of your ART
medications. Please put a mark on this line somewhere between zero and ten to describe
your best guess about how much of your prescribed ART you took in the previous month.
.

C5.41

In general, what helps you to take your medication on time?

Missed dose #2 ....................................................
Missed dose #3 ....................................................
"
C5.38

%

1

Some people find it difficult to take their ART medications on the weekends. Thinking about
the past month, how many times did you miss taking a dose of your medications on a
weekend:
Go to C5.40
never
once
twice
three or more times
declined to answer

Go to C5.40
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C5.42

In the past month, what circumstances led you to miss taking your pills on time?

C5.46

At any point during the past month, did you take all your daily doses of this [these]
medication[s] in one intake?
no, never
yes, once
yes, sometimes
yes, frequently
declined to answer
&

C5.47
C5.43

What other things make it difficult to take all your ART medications on time?

C5.48

During the past six months, did you ever stop taking your ART for 48 hours or longer?
yes
no

Go to C5.50

declined to answer

Go to C5.50

How long did you stop taking your antiretroviral therapy? Probe for a guess if respondent
does not remember very clearly.
for more than 48 hours and less than a week
from one to two weeks
for more than two weeks and less than one month
for more than one month
declined to answer

C5.44

C5.49

During the past month, how often did you take a double dose of ART medications after
missing a dose?
no, never

What were the reasons you stopped taking your ART?

yes, once
yes, sometimes
yes, frequently
declined to answer

C5.45

Do you have any ART medications that are supposed to be taken more than once a day?
Probe further if the answer to this question conflicts with the table in C5.35.
yes
no

Go to C5.47

don't know

Go to C5.47

declined to answer

Go to C5.47
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For HIV-positive respondents, whether or not they are receiving antiretroviral therapy.
C5.50

C5.51

We have been talking about just this past month. Now, I would like you to think back to the
first month when you started ART, I would like to ask you to estimate how of your
prescribed ART you took during that first month. Please put a mark on this line to describe
your best guess about how much of your prescribed ART you took during that first month.
.

%

"

These first three questions can be skipped if this module is used as part of a broader interview that has
already collected this information.
I would like to begin the next section by asking you how long you have known your HIV status and
whether you are receiving ART. Please excuse me if I have asked any of these questions already. I am
supposed to make sure that all the information is here.

Overall, how do you feel about being on ART?

C6.1

How long ago did you first learn you were HIV-positive? Record the number of months and
years that have passed. If less than a year has passed, write '0' years; similarly, if less than a
month has passed, write '0' months. Do not leave those spaces blank. Use probes and memory
prompts to help respondent calculate the number of months and years that have passed.
number of months ago... ......................................
number of years ago ............................................

C6.2

"

)

)

%
C6.3

This concludes this portion of our interview. Thank you very much for your participation.
C5.52

Time of interview or module end. Use the 24:00 clock.

Are you taking ART to manage your HIV?
yes
no

Go to C6.4

declined to answer

Go to C6.4

How long ago did you begin taking ART? Record the number of months and years that have
passed. If less than a year has passed, write '0' years; similarly, if less than a month has passed,
write '0' months. Do not leave those spaces blank. Use probes and memory prompts to help
respondent calculate the number of months and years that have passed.
number of months ago... ......................................

C5.53

number of years ago ............................................

Additional interviewer notes
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Now I would like to ask you think about every time you had sexual intercourse with any partner during
the past three months. I would like to ask about how frequently you and your partner[s] used
condoms.

&

This next section of the survey deals with personal matters, beginning with your sexual partners and
activities. Answers are confidential and will help us to better understand how to prevent HIV
transmission. We ask everyone the same questions, and only some of them may pertain to you.
C6.4

C6.8

Have you had sexual intercourse (meaning penetrative vaginal or anal sex) during the last
three months?
Go to C6.7
yes

Thinking about all the times you had sexual intercourse with any partner during the past
three months, would you say that you and your partner[s] used a condom:
every time
almost every time
sometimes
rarely

no

never

Go to C6.45

declined to answer

declined to answer
C6.5

C6.6

Why haven't you had sex during the last three months? Record answers exactly as given by
the respondent.

Next, I am going to read a list of reasons why some people do not have sex to see if any of
these reasons were the same as in your case. During the last three months, can you tell me
whether you did not have sex because of any of the following:
yes

no

declined to answer

poor health?
because you were afraid of
infecting your partner?
because you were afraid of reinfecting yourself?

Now I am going to ask you about different types of sexual partners. First I am going to ask you about
your spouse or any sexual partner with whom you live {FOR A BROADER DEFINITION OF REGULAR
PARTNER, INTERVIEWER COULD SAY or have been with for a while}. We call them 'regular partners'.
Then I am going to ask you about sexual partners to whom you are not married and are not living with
{IF BROAD DEFINTION USED THEN ALSO SAY: and have not been with for a while}. We call these 'non
-regular' partners.
For male respondents only: After that I will ask you about sexual partners who are paid by their
customers to have sex with them--we call these partners 'sex workers'.
% )

because you had no partner?
because you had no
desire/interest?
because you just decided to
abstain?
you don't know or don't have a
reason?

)

&

I would like to start by asking you about 'regular partners' - meaning your spouse or a live-in sexual
partner.
For male respondents: Here we are talking about female partners only.
C6.9

Go to C6.45

C6.7

&

How many different partners have you had sexual intercourse with during the last three
months? Record the total number.
C6.10

67

During the last three months, have you had sexual intercourse (meaning penetrative vaginal
or anal sex) with a spouse or a live-in partner - what we call a 'regular partner'?
yes
no

Go to C6.18

declined to answer

Go to C6.18

How many 'regular partners' have you had sexual intercourse with during the last three
months? Again by 'regular partner', I mean a spouse or live-in sexual partner? Record the
number.

68

C6.11

During the past three months, when you had sexual intercourse with your 'regular
partner[s]', how often did you and your partner[s] use a condom?
every time

C6.14

yes

almost every time
rarely
never
declined to answer

you don't like using condoms?
your partner doesn't like
condoms?
you or your partner want to
have children?

The last time that you had sexual intercourse with your most recent regular partner, did you
and your partner use a condom?
yes

you did not have condoms?
you don't know where to get
condoms?
you or your partner had
problems with condoms such
as a rash or burning?

no

C6.13

declined to answer

your partner refused?

Now I would like to ask you to think about the last time you had sexual intercourse (meaning
penetrative vaginal or anal sex) with your most recent 'regular partner'.

declined to answer

no

your partner is also HIVpositive?
your partner would become
suspicious of your HIV status if
you asked him/her to use a
condom?

sometimes

C6.12

Now I would like to read you a list of reasons why some people say they do not always use
condoms. Please tell me if any of these are reasons why you and your regular partner did
not use a condom the last time you had sex. Was it because: Mark all that apply.

Go to C6.18 (Non-regular partnerships)

Why / why not? Record the answer as given.

Now I would like to ask you a few questions about whether you and your regular partner have
discussed your HIV status. (If this module is part of a larger interview in which similar questions have
already been asked, then say: Please excuse me if I have already asked any of these questions.)
Please think about your most recent regular partner -meaning your spouse or a live-in sexual partner.
C6.15
Go to C6.15 if respondent did use a condom

C6.16

Do you know your most recent regular partner's HIV status?
yes
no

Go to C6.17

declined to answer

Go to C6.17

What is your regular partner's HIV status?
HIV-positive
HIV-negative
declined to answer

C6.17

Have you told your regular partner your own HIV status?
yes
no
declined to answer
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&

C6.22

Why / why not?

C6.23

Did you know the HIV status of all your non-regular partner(s), some or none?
all

Now I would like to ask you about 'non-regular' sexual partners you may have had during the past
three months. By 'non-regular' sexual partners I mean partners you were not married to or living with
{WHEN A BROADER DEFINTION OF REGULAR IS USED THEN SAY: and have not been with for a
while}.
For male respondents only: When we talk about 'non-regular' partners, please think about female
partners whom you did not pay to have sex.
C6.18

During the past three months, have you had sexual intercourse (meaning penetrative
vaginal or anal sex) with a 'non-regular' partner?
yes
no
declined to answer

Go to C6.25 if respondent is male, C6.39 if
respondent is female.
Go to C6.25 if respondent is male, C6.39 if
respondent is female.

C6.19

How many different 'non-regular' sexual partners have you had sexual intercourse with
during the past three months? Record the number.

C6.20

During the past three months, when you had sexual intercourse with your 'non-regular'
partners how often did you and your partner[s] use a condom?
every time

some
none
C6.24

Thinking about all the non-regular partners that you have had during the past three months,
how many have you told your HIV status?
all
some
none
declined to answer

almost every time

Go to C6.39 if respondent is female

sometimes
rarely
never
declined to answer
Now I would like to ask you to think about your most recent 'non-regular' partner. Repeat definition of
'non-regular' (partners you are not married to and have not been living with) if needed.
C6.21

The last time that you had sex (meaning penetrative vaginal or anal sex) with your most
recent non-regular or casual partner was a condom used?
yes
no
declined to answer

Go to C6.23
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I would like to ask you some questions about any female sexual partners whom you have paid to have
sex during the past three months. Specifically, I would like you to think about girls or women who
charge customers to have sex. I will call them 'sex worker' partners.
C6.25

C6.26

C6.27

no

Go to C6.30

declined to answer

Go to C6.30

C6.31

How many different female sex worker partners have you paid to have sex during the last
three months? Record number.

During the past three months, when you paid a female sex worker partner to have sexual
intercourse how often did you use a condom?
every time

)

&

,

Some men have sex with other men. We ask all men some questions about whether they have had sex
with male partners.
C6.30

Have you paid any female sex worker partners to have sexual intercourse (meaning
penetrative vaginal or anal sex) during the last three months?
yes

)

Have you ever had sexual intercourse (meaning penetrative anal sex) with a male partner?
yes
no

Go to C6.39

declined to answer

Go to C6.39

Have you had sexual intercourse (penetrative anal sex) with a male partner during the past
three months?
yes
no

Go to C6.39

declined to answer

Go to C6.39

C6.32

How many male partners have you had sex with during the past three months? Record
number.

C6.33

How many of these male partners were: Record number.

almost every time
sometimes
rarely

regular partners (meaning someone that you lived with) .............................................................

never
declined to answer
C6.28

non-regular partners (meaning someone you didn't live with and didn't pay for sex) ...............
male sex workers (someone you paid to have sex) ......................................................................

Please think about the last time you had sexual intercourse with a girl or woman you paid to
have sex. The last time that you paid a female partner to have sexual intercourse (meaning
penetrative vaginal or anal sex) did you and your partner use a condom?
yes

declined to answer

no
declined to answer
C6.29

Go to C6.30

C6.34

Why / why not?

During the past three months, when you had sex (penetrative anal sex) with any type of
male partner, how often did you or your partner[s] use a condom?
every time
almost every time
sometimes
rarely
never
declined to answer
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Please think about the last time you had sexual intercourse with a male partner.
C6.35

+

The last time that you had sex (penetrative anal sex) with a male partner, did you or your
partner use a condom?
yes

))

&

,

I am supposed to ask this next question of everyone, about whether you have ever had sexual
intercourse with someone during the same period of time that you were having an ongoing sexual
relationship with another partner.

no
declined to answer

C6.39

During the last three months did you have sexual intercourse with any partner during the
same period of time that you were having an ongoing sexual relationship with someone
else?
yes

Now I am going to ask you a few questions about whether you and your most recent male partner
have discussed your HIV status.
C6.36

no
declined to answer

Do you know your most recent male partner's HIV status?
yes

IF RESPONDENT DOES NOT REPORT A REGULAR PARTNER, GO TO C6.45

no
declined to answer

)
&

C6.37

What is your most recent male partner's HIV status?
HIV-positive

%

+ ))

&

&

% )

Now I would like to ask you about children and your plans to have any [more].

HIV-negative
declined to answer
C6.38

) &)
,

Have you told your most recent male partner your own HIV status?
yes
no

C6.40

How many living children of your own do you have? Record number.

C6.41

Do you plan to have a/another child? Adjust wording depending on whether respondent already
has a child.
yes

declined to answer

C6.42

no

Go to C6.43

unsure

Go to C6.43

declined to answer

Go to C6.43

In what time frame do you plan to have a / another child?
in the next 1 year
in 2-3 years
after more than 3 years
don't know

C6.43

Does your partner want to have a / another child?
yes
no
don't know
declined to answer
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Now I would like to talk about family planning, meaning methods that someone can use to delay or
avoid a pregnancy. The methods we will discuss may be used by either you or your regular partner.
Please listen to all the choices, even if you do not think you are using any method. At the end of the
list there is a choice for 'no method'.
C6.44

4

no

don't know

)

$ '
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Now I would like to ask you some questions about HIV transmission and other people you know who
have HIV.

Which method[s] are you or your regular partner currently using? Read out all methods and
description. Mark all that apply.
yes

) %

C6.45

What are some of the ways HIV can be transmitted? Record answer as given.

C6.46

What are some ways that an HIV-positive person can reduce the risk of transmitting the
virus to another person through sexual contact? Do not read aloud. Mark all that apply.
use condoms 100% of the time

declined to
answer

pill--women can take a pill every
day
IUD--women can have a loop or
coil inserted by a doctor or
nurse
injections--women can have
injections that prevent
pregnancy for several months
diaphragm--women can place a
diaphragm inside themselves
before intercourse
foam or jelly--women can place
foam tablets or jelly inside
themselves before intercourse
male condom--men can use a
rubber sheath on their penis
during sexual intercourse
male sterilization--men can
have an operation to avoid
having any more children
female sterilization--women can
have an operation to avoid
having any more children
natural method--every month
women can avoid having
intercourse on the days of the
month she is most likely to get
pregnant
withdrawal--men can be careful
and pull out before the fluids
come out
implants--women can have
several small rods placed in
their upper arm by a doctor or
nurse which can prevent
pregnancy for several years

use condoms more often
reduce the number of times they engage in sex
don't have sex
stay with one partner whose status one is sure of
reduce the number of partners
other, please specify:
.............................................................

C6.47

Can ART remove the virus from the body completely?
yes
no
don't know
declined to answer

C6.48

Can HIV or AIDS be completely cured?
yes
no
don't know

other, please specify:

declined to answer

no method
.............................................................
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C6.49

Do you think that a healthy-looking person can be infected with HIV?
yes

&

no

Next I will ask you about your opinions on the following statements about HIV and ART. For each
statement, please tell me whether you strongly agree, agree, are unsure, disagree or strongly
disagree. There are no right or wrong answers for this section. Please feel free to give your opinions.

don't know
declined to answer
4
C6.50

C6.51

) %

&

&)

C6.53

$ '

strongly
agree

Do you have a family member or close friend who has HIV or has died of AIDS?
yes
no

Go to C6.52

don't know

Go to C6.52

declined to answer

Go to C6.52

For each of the following statements, please indicate whether you strongly agree, agree, are
unsure, disagree or strongly disagree.

Who is this person [or are these people] in relation to you? Record answer as given. Code all
that apply. Do not read options aloud.

spouse/partner
family member
friend
other

agree

unsure

disagree

strongly
disagree

declined
to
answer

I would feel safe having
intercourse with someone who
is HIV-positive as long as they
are receiving HIV treatment.
{FIND LOCALLY APPROPRIATE
ITEM. IN HIGH LITERACY
SETTINGS, COULD ASK ABOUT
UNDETECTABLE VIRAL LOAD}
I am less worried about HIV
infection than I used to be.
The new HIV treatments make
me less anxious about having
unprotected sex.
I believe that HIV treatment
makes people with HIV less
infectious.

declined to answer
C6.52

Do you know anybody else who is infected with HIV or has died of HIV?
yes
no
declined to answer
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This concludes this portion of our interview. Thank you very much for your participation.
C6.54

Time of interview end. Use the 24:00 clock.

C6.55

Additional interviewer notes
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Now I would like to ask you two questions about drinking alcohol.
C7.1

During the past month, how often have you had a drink containing alcohol?
daily
nearly every day
3 to 4 times a week
once or twice a week
1 to 3 times a month
never

C7.2

Go to C7.3

During the past month, on the days that you drank alcohol, how many alcoholic drinks did
you usually have altogether? (one drink = 1 glass of wine, 1 glass of beer, 1 drink of hard
liquor)
1-2 drinks/day
3-5 drinks/day
6 or more drinks/day

%
Now I would like to ask you some questions about non-prescribed drugs, which include
pharmaceutical drugs that have not been prescribed for you by a doctor.
C7.3

81

Have you ever injected any non-prescribed drugs?
yes
no

Go to C7.12

declined to answer

Go to C7.12

C7.4

What non-prescribed drugs have you injected?

C7.5

Have you injected any non-prescribed drug in the past month?
yes
no

Go to C7.9

don't remember

Go to C7.9

declined to answer

Go to C7.9

82

C7.6

What non-prescribed drugs have you injected in the past month?

C7.11

Which substitution treatment are you receiving?
buprenorphine
buprenorphine/naloxone

C7.7

methadone

During the past month, how often would you say you have injected non-prescribed drugs?
daily

other, please specify:
.............................................................

nearly every day
3 to 4 times a week
once or twice a week

C7.12

1 to 3 times a month
declined to answer

During the past three months, have you ever used any of the following drugs? If yes: How
often did you use this drug?
yes

C7.8

no

declined to answer

injected with a needle or
syringe used by someone else?
passed on your used needle or
syringe to someone else?
injected with a brand new,
unused needle or syringe or
one that was exclusively used
by you?
gave, lent, sold or traded other
injecting equipment with
someone else, such as cotton,
dropper, vial or cooker?
drew up a solution from a
common container?
injected from a pre-filled
syringe?
gave, lent, sold or traded a sniff
straw or crack pipe?
C7.9

C7.10

declined
to
answer

daily

often

some
times

once

cannabis/hashish

During the past month, have you done any of the following: Mark all that apply.
yes

no

heroine
marijuana
cocaine
crack
ecstasy
amphetamines
other non-prescribed, please
specify:

.............................................................

Are you currently enrolled in a substitution program?
yes
no

Go to C7.12

declined to answer

Go to C7.12

How long ago did you first enrol in this substitution program? Record the number of months
and years that have passed. If less than a year has passed, write '0' years; similarly, if less than a
month has passed, write '0' months. Do not leave those spaces blank. Use probes and memory
prompts to help respondent calculate the number of months and years that have passed.
number of months ago... ......................................
number of years ago ............................................
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This concludes our interview. Thank you very much for your participation.
C7.13

Time of interview end. Use the 24:00 clock.

C7.14

Additional interviewer notes
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PROVIDER INSTRUMENT

Information about the study

Instructions to interviewers are in italics.

Hello, I am {NAME} working on a research project supported by {NAME OF LOCAL COLLABORATING
INSTITUTION}. We are conducting a study on HIV testing, treatment and prevention {IF NECESSARY,
ADD DETAILS}. By listening to people who may have had some experience with health services around
HIV, we hope to learn what goes right with the health services, and how to improve them.

All text that is meant to be read to the respondent is written in bold type. For example, when multiple choice
options should be read aloud, the options are in bold, like the questions themselves. When options are
intended for the interviewer only, i.e. when they should not be read aloud, they are not in bold type.

You have been selected to represent people in this area [from this clinic] and we would very much like
to hear about your opinions and experiences. Before we get started, I would like to explain to you how
the interview works.

If a respondent declines to answer a question that does not have a specific option for this response, please
write “declined to answer” in the margin of the questionnaire. Please do not read the option “declined to
answer” out loud.

Informed consent

Instructions to interviewer

 Your participation in the interview and in every aspect of the study is completely voluntary.
Responses to open-ended questions should be recorded as close to verbatim as possible.
 If some questions are difficult or make you uncomfortable, we can skip them. You may also ask me
to clarify any questions if you do not understand them. You may also decide to stop the interview at
any time.
 All of the information that you provide for the study will be kept completely confidential. We record
your responses, but the questionnaire will not have your name on it, and your responses to our
questions are identified only by a number, never by name.
 The study will not be used to evaluate this facility or to report what the providers tell us to those in
the administration.
 If you have questions or concerns after we are finished, you may contact {CONTACT PERSON AT
THE COMMUNITY LEVEL}.
 Although there are no direct benefits to you from participating in this survey, we hope that the
survey will help to improve health services and support for people living with HIV and AIDS. The
Do you have any questions about the survey? Would you be willing to participate in our study?

1

2

Depending on local ethical clearance, it may be necessary to fill out a signed consent form. In that case it
would be preferable to design the instrument so as to be able to separate the form from the rest of the
instrument

Certificate

Consent Form

I have read this consent form or have had explained to me to my satisfaction the information relating
to this study. I understand what my participation will involve and agree to take part in this interview
under the terms of this agreement. I have had the opportunity to ask questions about it, and my
questions have been answered to my satisfaction.

We have a form that must be read to you before we begin, in order to confirm that we have explained
the study to you and that you have agreed to participate.

I consent voluntarily to participate in this study and I understand that I have the right to withdraw at
any time, without it in any way affecting my future medical care.

We ask you to sign the form, but we do not keep the form attached to the questionnaire, so your name
will not be linked to the information we write about you, and no one except the people responsible for
the study will have access to this information.

Participant
Name __________________________

The form just repeats what I have told you about the study, but I have to read it to you.
Date ___________________________
 I understand that I have been asked by {NAME OF INSTITUTION} to participate in a research project
designed to investigate the experience of people who undergo HIV testing and counselling.

Signature or thumbprint if appropriate _______________________

 I understand that during this study I will be asked questions about my health and health care, and
that my responses will be recorded in a questionnaire form. But my participation in the study will be
kept confidential, and my identity will be available only to those performing or supervising the
research. I understand that I would never be identified by name in any publications resulting from this
study.

Witness (if appropriate)

 I am aware that there may be some questions asked during the interview which may make me
uncomfortable. I realise that I do not have to answer any question that I do not want to answer. I
understand that I am free to withdraw my consent and to discontinue participation in this research
project at any time, without affecting my future care or treatment.

Signature _________________________

Name ___________________________
Date ____________________________

Investigator
Name ___________________________

 I realize that I will not benefit directly from this project. However, with my participation, I hope to
help investigators understand how to improve health services.

Date ____________________________
Signature ________________________

3
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Interview information

SOCIODEMOGRAPHIC AND WORK MODULE
PR2.1

Interviewer can complete this section before the interview starts.
PR1.1

PR1.2

male

Interview ID number in the form of 001, 002, 003...

If you don’t mind, I would like to start by asking you some questions about your age, education, work
background and training. All the information you give me will be kept confidential and will not be
recorded on the same page as your name.

Date of interview DD/MM/YYYY
/

/

PR1.3

Interviewer name or code

PR1.4

Name of testing facility

Sex of the respondent. Do not read this question.
female

.

PR2.2

How old are you? In years.

PR2.3

What was the last level of schooling that you completed?
no formal education
primary incomplete
primary complete

PR1.5

secondary/vocational incomplete

Time of interview start. Use the 24:00 clock.

secondary/vocational complete
post secondary
other, please specify:

PR1.6

Language of interview

declined to answer
................................................................................................

Work background
Now I will ask you some questions about your work and training.
For the following question, if the counsellor has had training as a nurse, please mark the box nurse/midwife.
PR2.4

What is your work position?
medical doctor
nurse/midwife
counsellor
other, please specify:
................................................................................................

5
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PR2.5

What HIV or AIDS related services do you personally perform at this facility? Mark all that
apply.
clinical care

Next I am going to ask you a few questions about what type of training you have received, for example,
whether this training was formal or ‘on the job’. By formal training, I mean training that took place as
part of a class or a workshop. By ‘on-the-job’ training I mean informal learning in the course of your
work, including advice from colleagues, observation or self-study.

consultation
counselling

PR2.9

testing
dispensing drugs

Was the training formal or 'on-the-job'?
formal only
on-the-job only

support group services

Go to PR2.11

both

home visits
other, please specify:

PR2.10

................................................................................................

Thinking about the formal HIV training you received, what topics did that HIV training cover?
Mark all that apply.
HIV prevention
provider-initiated testing

In the following questions, if the provider has worked in HIV and AIDS care for less than a year then fill in the
number of months, otherwise you do not need to write out the months.

client-initiated testing
rapid testing

PR2.6

How long have you worked in HIV and AIDS care? In years and months.

HIV counselling
HIV stigma

years .......................................................................................

adherence
months ....................................................................................

PR2.7

antiretroviral therapy
prevention of mother-to-child transmission (PMTCT)

How long have you worked in this facility? In years and months.

psychosocial / general counselling or support for people living with HIV

years .......................................................................................

nutrition

months ....................................................................................

other, please specify:
................................................................................................

PR2.8

Have you had training on HIV or AIDS?
yes
no

PR2.11
Go to PR2.11

How well prepared do you feel to provide the services that you are responsible for as part of
your work? Would you say that you feel:
well prepared
somewhat prepared
not prepared enough

PR2.12

7

Why or why not?

8

PR2.19

Daily work routine

Why?

The following three questions are time consuming and are designed to be asked among a subsample of
respondents.
In the next few questions, I would like to ask about the details of your work in your own words.
PR2.13

Please describe your daily routine, on a typical day.

PR2.14

Does your work vary much from one day to the next?
yes
no

Go to PR2.16

it depends
PR2.15

In what way?

PR2.16

How many clients/patients do you personally see everyday?

PR2.17

How much time do you generally spend with each client/patient on average, in minutes?

PR2.18

On a typical day, how easy or difficult is it for you to see all of your clients/patients in the
time available? Would you say it is:
easy
manageable
difficult

9
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TESTING AND COUNSELLING (T&C) MODULE

PR3.6

What do you think hinders people in this community from being tested for HIV?

PR3.7

What could be done to improve access to testing for those who want it?

PR3.8

Do some of your clients have repeated HIV tests?
yes

For respondents who work in HIV testing and/or counselling
This next part of the interview includes questions about HIV testing and counselling. By HIV testing, I
mean testing for HIV antibodies by drawing blood or collecting oral fluids.
PR3.1

Do you personally conduct HIV testing or counselling?
yes
no

Go to the end of the T&C module at PR3.51

Sometimes clients decide on their own that they want to know their HIV status, and they come to a
health facility specifically to ask for an HIV test. In other cases, health workers are the ones who
suggest that testing is a good idea. They might offer HIV testing to clients who have come for other
kinds of health services, such as prenatal care. Or, sometimes health workers go out into the
community and offer testing in people's homes or workplaces. In the next few questions I would like to
ask about your experience with offering HIV testing, and whether offering a test is part of your job
responsibility.
PR3.2

As part of your work, do you - personally - ever offer HIV counselling and testing to clients
who have not come to the facility specifically for that purpose?
yes
no

PR3.3

PR3.9

Do you - personally - ever go out into the community to encourage people to get tested for
HIV?
yes

no

Go to PR3.10

don't know

Go to PR3.10

What do you think are the reasons that some clients have repeated HIV tests?

no
IF RESPONDENT DOES NOT EVER INITIATE TESTING (i.e. HAS SAID NO TO PREVIOUS TWO
QUESTIONS), GO TO PR3.6

PR3.4

What is the most frequent or typical way that you offer HIV testing? Probe for typical
circumstances, use of guidelines.

PR3.5

How do clients generally respond to your offer of an HIV test? Probe: do they readily accept?
Do they ever get upset?

11
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The next few questions are about counselling, meaning the discussions that health workers have with
clients about HIV tests and the meaning of test results.

Consent

Some testing facilities provide pre-test counselling, while others do not.

For the following question, please make certain that the respondent obtains consent him/herself from the
client. If he or she does not obtain consent personally then skip to the next section.

PR3.10

PR3.15

What do you think about not having pre-test HIV counselling?

Do you personally obtain consent from clients for HIV testing, or does that responsibility fall
to other staff members?
yes, obtains consent
no, doesn't obtain consent

Go to PR3.24

Only for respondents who personally obtain consent

PR3.11

How do you typically obtain a client's consent to have an HIV test?

PR3.17

Is the consent usually obtained...
in writing

As part of your work do you personally conduct pre-test counselling?
yes
no

PR3.12

PR3.16

Go to PR3.13

Do you find that the time that you can give for pre-test counselling is usually too long, about
right or too short to give clients the information they need and to answer their questions?
too long
about right
too short

verbally
PR3.13

In general, do you think that the pre-counselling information that is provided at this facility
is too much, about right, or too little?
too much

it depends; sometimes in writing, sometimes verbally
usually both
other, please specify:

about right
too little
PR3.14

................................................................................................

PR3.18

Why?

After you offer a test, how much time is the client usually given to think about the test before
deciding whether to consent?
less than 5 minutes
more than 5 minutes, but less than 15 minutes
15-30 minutes
more than 30 minutes, up to an hour
more than an hour, up to 2 hours
more than 2 hours
other, please specify:
................................................................................................
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PR3.19

PR3.20

Are there guidelines or a protocol that you are supposed to follow when obtaining consent?
yes
no

Go to PR3.22

don't know

Go to PR3.22

The next questions ask for your opinions about who should receive HIV testing. People have different
opinions about this, and we would appreciate hearing about your honest feelings.
PR3.25

Do you think that there are reasons to require somebody to have an HIV test?
yes
no

Is there a written copy of these guidelines or protocol in the health facility?
yes

Go to PR3.27

unsure

no
PR3.26

don't know
PR3.21

Who do you think should be required to have an HIV test and why?

How useful are these guidelines in practice?
very useful
somewhat useful
not very useful

PR3.22

In general, when you ask clients for their consent to have an HIV test, what proportion
agree? Would you say:
all

Privacy and confidentiality [all respondents]

almost all
Now I would like to ask you a few questions regarding how you feel about giving information to other
people about someone else’s HIV status. People have different opinions about this, and we would like
to know your honest feelings.

most
some
PR3.23

In this facility, are clients ever tested without getting their consent first?
yes, often

PR3.27

yes, sometimes

it depends

yes, but only occasionally
no, never

Do you think that it is sometimes okay to tell other people that someone else has HIV even if
that person doesn't want other people to know?
yes
no

Go to PR3.25

declined to answer
PR3.28

Why or why not?

PR3.29

In your opinion, do you think that it is ever okay for a health worker to tell someone outside
the facility that a client tested positive for HIV, even if that client did not give permission to
tell?
yes

Testing without consent [all respondents]
PR3.24

Can you describe some instances when clients were tested for HIV even when they did not
want to or were not given a chance to consent?

15

no

Go to PR3.31

unsure

Go to PR3.31
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PR3.30

Under what circumstances is it okay and why?

PR3.35

How important do you think it is to protect the confidentiality of your clients’ HIV test
results?
very important
somewhat important
not so important
it depends

PR3.36
PR3.31

What do you do to try to protect confidentiality within your HIV testing and counselling
work?

In general, would you say that staff members manage to keep clients’ information
confidential:
always
almost always
most of the time
some of the time

Many health workers try hard to protect the confidentiality of client information - including HIV test
results and medical histories. But sometimes, health workers talk about clients’ confidential
information in places where they can be overheard by other clients. For example, a receptionist may
ask a client to state the reason for the visit in front of other clients. Or, health workers sometimes
have conversations or collect medical histories in places where they can be overheard, such as
waiting areas.
PR3.32

PR3.37

What are the main challenges that staff in this facility face in protecting confidentiality?

PR3.38

Can you describe instances at this facility when it was difficult to protect confidentiality?

In your experience, do staff members in this facility ever talk about or ask patients about
confidential client information in places where they can be overheard by other clients?
Probe: this includes asking clients the reason for their visit in front of other clients.
yes
no

PR3.33

Does this facility have guidelines, rules or a protocol for protecting clients’ confidentiality?
yes
no

Go to PR3.35

don't know

Go to PR3.35

Results
PR3.39

PR3.34

In your experience, how closely do staff members follow these guidelines in practice?
Would you say they follow them:
very closely

In your experience, what proportion of clients in this facility receive their test results? Would
you say:
Go to PR3.41
all
almost all

somewhat closely

most

not very closely

some

don't know

few
don't know
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Go to PR3.41
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PR3.40

Why don't clients always receive their results?

PR3.46

How prepared do you feel to conduct post-test HIV counselling? Would you say you feel:
well prepared
somewhat prepared
not prepared enough

PR3.47
Post-test counselling

How easy or difficult do you find the work of post-test counselling? Would you say you find
it:
very easy
somewhat easy
neither easy nor difficult

Earlier, we talked about pre-test counselling. Now I would like to ask some questions about post-test
counselling.

somewhat difficult
very difficult

PR3.41

As part of your work, do you personally conduct post-test counselling?
yes
no

PR3.48

Go to PR3.49

What would make it easier for you to conduct post-test counselling?

Only for those who conduct post-test counselling
PR3.42

On average, when you conduct post-test counselling with a client, how long (in minutes) do
you typically spend?
Follow-up care and support after the test [all respondents]

PR3.43

Next, I would like to ask about follow-up care and support for those clients who test positive at this
facility.

Do you find that the duration of post-test counselling that you are able to provide is too
long, about right or too short?
too long

PR3.49

about right
too short
PR3.44

PR3.45

In your experience, how often are clients who test positive for HIV able to access follow-up
care and support?
always
almost always

In general, do you think that the post-counselling information that is provided at this facility
is too much, about right or too little?
too much

sometimes
rarely

about right

never

too little

don't know

PR3.50

Why?
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Do you have any suggestions for making it easier for HIV-positive clients to get the followup care and support they need? Probe further about both medical care and social support.
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Testing and counselling module closing statement

DISCLOSURE, SUPPORT AND STIGMA MODULE

This concludes this portion of our interview. Thank you very much for your participation.

Disclosure

PR3.51

Time of interview or module end. Use the 24:00 clock.

Now I would like to ask you about what happens when your HIV-positive clients disclose their test
results to their family, friends and people in their community.

PR3.52

Additional interviewer notes

PR4.1

If a client has HIV, do you think that client should tell anyone else?
yes
no

Go to PR4.3

it depends
PR4.2

Who do you think the client should tell? Mark all that apply.
partner
close family
other relatives
people they live with
friends
co-workers
it depends on the client
other, please specify:
...............................................................................................

PR4.3

How often do you talk to clients about how to disclose their status to friends and family?
always
frequently
sometimes
rarely
never

PR4.4

21

What challenges do your clients face in disclosing their status?
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PR4.5

Has a client ever told you that if they disclose their HIV status, they are afraid of being:
yes

Health care discrimination

no

abandoned by a
spouse/partner?
abandoned by other family
members?

The following questions are about fear of HIV and your feelings towards people living with HIV and
AIDS. People have very different feelings about this, and we are interested in hearing about your
honest opinions.

physically assaulted/beaten?

PR4.10

fired from their job?
expelled from their home?
PR4.6

Have HIV-positive clients ever told you that they experienced any of these things as a result
of being HIV-positive?
yes

Have you ever seen or heard of clients who have been badly treated at this facility because
they had HIV or AIDS?
yes
no

Go to PR4.12

declined to answer

Go to PR4.12

no

abandoned by a
spouse/partner?
abandoned by other family
members?

PR4.11

Can you tell me what happened?

PR4.12

In the past 12 months have you seen the following happen in this health facility because a
client was known to have, or was suspected of having HIV or AIDS?

physically assaulted or beaten?
fired from their job?
expelled from their home?
IF RESPONDENT SAID NO TO ALL THE SUB-ITEMS IN THE TWO QUESTIONS ABOVE, THEN GO TO
PR4.8

PR4.7

PR4.8

How did you respond when the client told you this? Probe to refer back to any affirmative
answers from the previous two questions.

yes

Do you think enough support is given to clients to help them disclose to other people?
Go to PR4.10
yes
no
don't know

PR4.9

no

declined to answer

staff seemed uncomfortable
with a client because of his or
her HIV status?
health worker gossiped about a
client's status?
client was ignored or received
less care than other clients?
client was denied care that he
or she should have received?
staff used excessive
precautions with clients
suspected of having HIV or
AIDS, for example, using latex
gloves for non-invasive
procedures?
client was treated with
disrespect or abused?

How could this be improved?
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PR4.13

Please indicate whether you agree with, are undecided or disagree with the following
statements:
agree

disagree

FEAR OF INFECTION AND WORK SAFETY MODULE

undecided

The following questions are about fear of HIV and the safety of the work environment in your health
facility.

People with AIDS deserve
blame for getting the disease.
I think patients with AIDS have
the right to the same quality of
care as other patients.
PR4.14

PR4.15

PR4.16

concerned

Aside from your pay, do you find that your work presents you with any particular rewards?
Probe: job satisfaction, not financial.
yes
no

Go to PR4.16

don't know

Go to PR4.16

How concerned are you about getting infected with HIV in the course of your work? Would
you say you are:
very concerned
slightly concerned
not very concerned
Go to PR4.18

not concerned at all
PR4.17

What types of situations at work cause you most concern?

PR4.18

How concerned would you feel about getting HIV if you had to do any of the following.
Please indicate if you would be very concerned, somewhat concerned, not sure, not very
concerned or not at all concerned.

Can you give some examples?

very
concerned

somewhat
concerned

not sure

not very
concerned

not at all
concerned

take the blood pressure of a
person with HIV or AIDS?
change the bed linens of a
person with HIV or AIDS?
change the clothes of a person
with HIV or AIDS?
give an injection to a person
with HIV or AIDS?
dress the wound of a person
with HIV or AIDS?
PR4.19

Do you estimate the risk of accidental exposure at work as low, moderate or high?
low
moderate
high
don't know
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PR4.20

Are you concerned about getting other types of infections - besides HIV - from HIV-positive
clients?
yes
no

PR4.26

What type of supplies sometimes run low?
1. .............................................................................................

Go to PR4.22

2. .............................................................................................
3. .............................................................................................

PR4.21

Which other infections are you concerned about?
PR4.27

1. .............................................................................................
2. .............................................................................................

no

3. .............................................................................................

PR4.22

Does this facility have written guidelines for implementing universal precautions?
yes
don't know

In the past year, have you been accidentally exposed to HIV?
yes

PR4.28

In your experience, would you say that staff in this health facility use universal precautions:
always

no

Go to PR4.24

almost always

don't know

Go to PR4.24

most of the time

declined to answer

Go to PR4.24

some of the time
not much at all

PR4.23

PR4.24

Please tell me what happened, and how you dealt with the situation.

don't know

In the past year, do you know of any other staff member in this health facility that has been
accidentally exposed to HIV?
yes

PR4.29

Do you have any suggestions for improving workplace safety in this health facility?

PR4.30

What are the main challenges that staff at this facility face in providing services related to
HIV and AIDS?

PR4.31

What--if anything--could be done to make your work easier?

no
Now I would like to ask you some questions about whether this health facility has enough supplies
and protocols in place to protect the health and safety of the people who work here.
PR4.25

Do you or other staff members ever run out of supplies that you need to implement
universal precautions? Probe and give examples, such as latex gloves, if needed.
yes
no

Go to PR4.27

don't know

Go to PR4.27
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PR4.32

Do you participate in any activities or groups that help you cope with the emotional
demands of your work?
yes
no

PR4.33

ADHERENCE MODULE
For health workers who care for patients living with HIV

Go to PR4.34

I would like to begin this portion of the interview by asking you more questions about the type of care
and services you personally provide as part of your work. In particular, we are interested in whether
and how you help patients who are taking antiretroviral therapy adhere to their treatment regimen. So
when I ask about adherence during this portion of the interview, I specifically mean adherence to
antiretroviral therapy.

What type of activities or groups?

PR5.1

Do you provide care for patients taking antiretroviral therapy on a regular basis as part of
your work?
yes
no

Fear of infection and work safety module closing statement

PR5.2

This concludes this portion of our interview. Thank you very much for your participation.

Do you personally provide adherence counselling to HIV-positive patients as part of your
work?
yes
no

PR4.34

Go to PR5.4

Time of interview end. Use the 24:00 clock.
PR5.3

PR4.35

Go to PR5.23

Is this adherence counselling done in the form of individual or group counselling?
individual
group

Additional interviewer notes

both
PR5.4

Do you think the adherence counselling provided at this facility is very effective, somewhat
effective or not effective?
very effective
somewhat effective
not effective
don't know

PR5.5

29

Why or why not?
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PR5.6

When you consult with a patient who is taking antiretroviral therapy, do you assess a
patient's level of adherence:
at each consultation

PR5.10

What information do you give patients to explain why all pills have to be taken?

PR5.11

What do you tell patients to do if a dose is missed?

PR5.12

What do you tell patients about side-effects and what they should do when they experience
them?

PR5.13

In your experience, how many of your patients face problems adhering well to their
antiretroviral therapy regimen?
all

most consultations
some consultations
rarely
never

Go to PR5.9

...............................................................................................

PR5.7

On average, when you assess adherence during a patient consultation, how long do you
typically spend? In minutes.
minutes....................................................................................

PR5.8

How do you assess adherence? Record answer as given, then select option below. Do not read
options. Mark all that apply.

self-recall
missed appointments

many

visual analogue scale

some

MEMS cap

few

pill counts

don't know

on-time pharmacy pick ups
other, please specify:
...............................................................................................

PR5.9

PR5.14

What are the most common problems your patients face adhering to their antiretroviral
therapy?

PR5.15

How frequently do you have patients who report interrupting their antiretroviral therapy for
more than 48 hours?
very frequently (at least one patient a
week)
somewhat frequently (at least one patient a
month)
not frequently (less than one patient a
month)
Go to PR5.18
never

What advice do you give to patients about how to take all their pills and adhere to their
antiretroviral therapy regimen?
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PR5.16

What reasons do patients give for interrupting their antiretroviral therapy?

Adherence module closing statement
This concludes this portion of our interview. Thank you very much for your participation.

PR5.17

PR5.18

PR5.23

Time of interview end. Use the 24:00 clock.

PR5.24

Additional interviewer notes

How do you deal with that situation?

In the past year, have any of the antiretroviral regimens prescribed in this clinic been out of
stock or unavailable for any reason when patients needed them?
yes
no
don't know

PR5.19

Would you say there are certain types of patients who tend to adhere better to antiretroviral
therapy than others?
yes
no

Go to PR5.23

don't know

Go to PR5.23

PR5.20

What types of patients are better adherers and why?

PR5.21

What types of patients are poor adherers and why?

PR5.22

What do you think could be done to help these patients adhere better?

33
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PREVENTION MODULE

PR6.6

In your experience, which groups of patients need special advice for prevention?

PR6.7

What specific advice/services do you give to each of these different groups?

The next portion of this interview addresses services to help patients living with HIV prevent the
transmission of HIV.
PR6.1

Do you personally provide HIV prevention information to HIV-positive patients on a regular
basis as a part of your work?
yes
no

Go to PR6.8
adolescents... ........................................................................

PR6.2

When you consult with an HIV-positive patient, what is the average amount of time (in
minutes) that you spend talking about HIV prevention with HIV-positive patients?
sex workers ...........................................................................

minutes....................................................................................

PR6.3

What type of prevention information do you discuss with them? Record answer as given, then
mark all the options that apply. Do not read the options.

breastfeeding mothers .........................................................

pregnant women ...................................................................

PR6.8

PR6.4

Do you think that people in this community think that HIV or AIDS is less dangerous than it
used to be now that antiretroviral therapy is available?
yes
no

Mark all that are mentioned.
information about HIV transmission/prevention

don't know

Go to PR6.10

how to protect themselves and their sexual partners
disclosure of HIV status

PR6.9

Why or why not?

PR6.10

Do you think that people are returning to more risky sexual behaviour now that antiretroviral
therapy is available?
yes

referral of partners for HIV test
safer sex practices
advice on condom use
provision of information on support groups
referral to support groups
discuss family planning options
discuss options for prevention of mother-to-child HIV transmission
discuss breastfeeding in relation to prevention of mother to child HIV transmission

no

discuss HIV discordance between couples

don't know
PR6.5

Do you provide HIV-positive patients with condoms?
yes

PR6.11

no
declined to answer

Do you think that receiving antiretroviral therapy encourages patients to adopt safer
behaviours?
yes
no
don't know
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Go to PR6.13
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PR6.12

Why or why not?

PR6.13

What suggestions do you have for improving HIV prevention services for patients receiving
antiretroviral therapy?

Prevention module closing statement
This concludes our interview. Thank you very much for your participation.
PR7.1

Time of interview end. Use the 24:00 clock.

PR7.2

Additional interviewer notes
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